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Sun protection education delivered by tablet personal computers: Effective with kidney trans-
plant recipients with inadequate health literacy
JK Robinson,5 M Kwasny,1 J Friedewald,2 A Desai3 and EJ Gordon4 1 Prevent Med, 
Northwestern Univ Feinberg Schl Med, Chicago, IL, 2 Transplant Ctr, Northwestern Univ 
Feinberg Schl Med, Chicago, IL, 3 Medicine, Univer of IL, Chicago, IL, 4 Healthcare Studies, 
Northwestern Univ Feinberg Schl Med, Chicago, IL and 5 Dermatology, Northwestern Univ 
Feinberg Schl Med, Chicago, IL
Objective: To assess an electronic interactive sun protection program for kidney transplant recip-
ients inclusive of users with inadequate and marginal health literacy. Methods: The program was 
delivered by tablet personal computers to Non-Hispanic White (NHW), non-Hispanic Black (NHB), 
and Hispanic/Latino (H/L) kidney transplant recipients (KTRs) in a randomized controlled trial. Skin 
cancer and sun protection knowledge were assessed at baseline and during the educational program. 
Results: Participants (n=170, 60 NHW, 48 H/L and 62 NHB) had similar baseline knowledge of 
skin cancer and sunscreen use. The mean duration of use was 27 min. Inadequate health literacy 
in 28% of KTRs was associated with H/L KTRs (45/48) (χ2, p < 0.05) and marginal health literacy 
was associated with NHB KTRs (45/62) (χ2, p <0.05). Inadequate and marginally functional health 
literate KTRs chose the audio narration in either Spanish or English with statistically significantly 
greater frequency than those with adequate functional health literacy (p <0.05). Knowledge of 
skin cancer gained by those with inadequate health literacy, mostly H/L KTRs, was greater than 
those with adequate health literacy (p <0.05). This may be attributed to those with adequate health 
literacy viewing the supplementary pictures of skin cancer without listening to the audio explana-
tions. Conclusions: Kidney transplant recipients with all levels of health literacy used the program 
to become aware of their risk of developing skin cancer and made decisions about implementing 
sun protection strategies.    
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Living with atopic dermatitis: Patient priorities and needs expressed in social media fora
KL Capozza HealthInsight, Salt Lake City, UT
With the passage of the Affordable Care Act, Congress authorized the establishment of a new 
substantial source of funding to support “patient-centered research” through the Patient Centered 
Outcomes Research Institute. This type of research aims to marry patient preferences with rigorous 
research methods. PCOR aims takes into account patients’ preferences, autonomy, and needs and 
to focus on outcomes that patients care about. Natural language processing (NLP) is a computer 
tool that can be used to better understand the patient perspective. It allows for the aggregation of 
patient comments from social media sites to gain a broad view of the topics and issues related to 
atopic dermatitis (AD) that matter to patients. Topic modeling can summarize the content of a large 
set of documents, or posts, by generating a list of main themes/topics from the aggregated content. 
This new approach to summarizing online patient information provides a valuable overview of the 
“real world” issues and needs expressed by patients. In turn, this information can be used to guide 
future areas for research. Our objective for this research is to characterize topics of interest to patients 
with AD by summarizing and quantifying the prevalence of topics articulated in online patient 
communities using two techniques: natural language processing and topic modelling.    
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Photoaging in African-American skin: A reliable photonumeric scale reveals age, male gender, 
and sun exposure as contributory factors
AL Chien, J Qi, R Grandhi, T Harris-Tryon, DM Kuhn, M Jang, N Kim, S Leung, J Esandrio, 
B Rainer, F Poon, N Cheng, GA Hinds and S Kang Department of Dermatology, Johns 
Hopkins University, Baltimore, MD
Clinical observation indicates that African-Americans are less affected by photoaging than individu-
als with lighter skin, likely due to increased photoprotection provided by melanin pigment. Although 
standardized grading scales for photoaging have been developed for Caucasians and Asians, no 
such scale has been designed for African-Americans. In this cross-sectional study, standardized 
facial photographs of 75 subjects were taken (23 males, 52 females; age range: 18 to 96). Five 
participants, who were excluded from subsequent analyses, were selected as standards to create 
a 9-point photonumeric scale (0=none, 8=most severe) for photoaging. Three dermatologists used 
the scale to independently grade the participants’ photographs. Using the intraclass correlation 
coefficient (ICC) method, the interrater reliabilities were 0.848 (95% CI: 0.778-0.894) for trial 1 and 
0.858 (0.792-0.898) for trial 2. Intrarater reliabilities, assessed over a 2 week interval, were 0.941 
(0.897-0.969), 0.942 (0.899-0.966), and 0.892 (0.827-0.930) for the three graders. Conventionally, 
ICC agreement between 0.7 and 0.8 indicates strong agreement, while ICC > 0.8 indicates almost 
perfect agreement. Photoaging scores averaged across two trials and three graders were then cor-
related with participants’ responses to a survey on lifestyle factors in univariate analyses, which 
yielded age as a significant predictor (r=0.91, p<0.001). Furthermore, an optimal multiple regression 
model to predict facial photoaging (adjusted R2 = 0.853) selected age (b1 = 0.116, p<0.001), gender 
(b2 = -0.542, p=0.016), and sun exposure (b3 = 0.176, p=0.043) as the most important variables, 
validating the utility of the scale in photoaging assessment. In summary, we developed a reliable 
photonumeric scale for photoaging in African Americans, which can serve as an objective clinical 
research tool in this population.    
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Interferon-gamma treatment for children with recurrent eczema herpeticum: a retrospective 
review
E Siegfried1 and K Darji2 1 Pediatrics, Saint Louis University School of Medicine, St. Louis, MO 
and 2 Saint Louis University School of Medicine, St. Louis, MO
Background: Eczema herpeticum is a difficult to confirm complication of severe atopic dermatitis 
(AD). Prior studies support a role for either impaired IFN-gamma protein production or IFN-gamma 
receptor polymorphisms in patients with confirmed eczema herpeticum (ADEH+) compared to 
those without evidence of prior HSV infection (ADEH-). This suggests a possible benefit from 
treatment with interferon-gamma. Objective: To retrospectively evaluate subsets of ADEH+ and 
ADEH- pediatric patients, who received treatment with interferon gamma. Methods: Eligible children 
were identified from Cardinal Glennon Children’s Hospital (CGCH) Epic electronic database. Those 
with laboratory confirmation of eczema herpeticum were included, as well as a control cohort of 
children with severe AD who had no clinical or microbiologic evidence of HSV. We collected 
demographic information, microbiologic and immune parameters, prior medications, dose and 
duration of interferon gamma treatment, and response to treatment. Results: The ADEH+ patients 
had greater elevations in serum IgE level, 90% positive IgG serology, and higher incidence of insuf-
ficient TLR responses than ADEH- patients. There was a higher incidence among ADEH+ patients 
of molluscum and skin/pharyngeal group A Strep carriage. Eight ADEH+ and 2 ADEH- patients 
received treatment with subcutaneous interferon-gamma. In all 10 patients the drug was discontin-
ued: 50% had initial control then relapse and 30% had control with interval flares. Treatment was 
also complicated by 50% poor adherence. A course of IFN-gamma was associated with total IgE 
elevations in 4 of 6 patients, as previously reported, including the greatest changes in the 2 patients 
who were ADEH-. Conclusions: Our study shows that ADEH+ patients have a higher prevalence 
of certain microbiologic markers than ADEH- patients. While treatment with interferon-gamma did 
not result in dramatic improvement, our results provide data to facilitate future clinical trial design 
for IFN-gamma treatment to in eczema herpeticum patients.    
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Levamisole-laced cocaine induced vasculitis
R Kapelow Medicine, American University of Antigua, Coolidge, Antigua and Barbuda
Levamisole-induced vasculitis in association with people who use cocaine is characterized by 
purpuric skin lesions and necrosis. Recently, there has been an increase in prevalence and it is 
important for physicians to be informed of this emergent entity in order to make it less challenging 
to diagnose. Levamisole was used as an antihelminthic medication and later withdrawn from use 
in the U.S. in 1999 due to its adverse effects. A 54-year-old woman with a past medical history of 
chronic cocaine, marijuana, opioid abuse and a ten pack-year smoking history presented to the ED 
with an increasingly painful and burning purpuric rash and skin necrosis of two days duration on 
her extremities, ear lobes, and cheeks. Additional history revealed that she had previous episodes 
of a purpuric rash, which was linked on this admission to smoking crack cocaine continuously 
for several days. A diagnosis of levamisole-induced vasculitis was suspected. A urine toxicol-
ogy screen was positive for cocaine and marijuana. Laboratory testing showed leukopenia with a 
white blood cell count (WBC) of 3,200 cells/mcL, neutropenia with an absolute neutrophil count 
(ANC) of 800 cells/mm3, positive perinuclear-antineutrophil cytoplasmic antibody (p-ANCA) and 
increased erythrocyte sedimentation rate (ESR) of 49 mm/hour. Skin biopsy of the left ear revealed 
leukocytoclastic vasculitis with acute and chronic inflammation and thrombosis of small vessels. 
Treatment of wound care was initiated with bacitracin ointment and IV methylprednisolone with 
which the patient improved tremendously. Three days later, new lesions stopped appearing and 
expanding and the patient was discharged. This case illustrates the potential adverse effects including 
skin vasculitis, agranulocytosis and even severe necrosis of soft tissue and cartilage. The value of 
a thorough history is essential to explore in patients presenting with these symptoms. Recognition 
of this syndrome is critical for symptomatic patients as discontinuation of exposure and a correct 
diagnosis prevents unnecessary, costly and potentially dangerous use of other treatment modalities.   
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Different effect of oral cyclosporin therapy and oral anti-histaminergic therapy to serum high 
sensitivity-C reactive protein level and thymus and activation regulated chemokine level in 
patients with adulthood atopic dermatitis
T Ohtsuka Department of Dermatology, International University of Health and Welfare 
Hospital, Nasushiobara, Japan
Background Many patients with atopic dermatitis (AD) are treated with oral cyclosporin or anti-his-
taminergic therapy in clinical practice. Objective To evaluate the effectiveness of oral cyclosporin 
and anti-histaminergic therapy in AD patients using laboratory findings for AD. Subjects and methods 
Twenty-five AD patients (male: female = 11: 14, age 16 - 42 years-old, mean 26.2 years-old) were 
treated with oral cyclosporine therapy. Twenty-three AD patients (male: female = 10: 13, age 15 
- 32 years-old, mean 24.2 years-old) were treated with oral anti-histaminergic therapy. Laboratory 
findings including high sensitivity-C reactive protein (CRP) and thymus and activation regulated 
chemokine (TARC) were statistically studied. Results Serum TARC level after oral cyclosporin 
therapy (1,013±883 pg/ml) was significantly decreased than that before therapy (3,8194±4,678 
pg/ml) (P<0.02). Basophil counts in peripheral blood after the therapy (49.7±26.4 x10-3/ml) was 
significantly increased than that before therapy (41.1±16.7 x10-3/ml) (P<0.05). Serum high sensi-
tivity-CRP level after anti-histaminergic therapy (0.09 ± 0.08 mg/ml) was significantly decreased 
than that before therapy (0.13 ± 0.12 mg/ml) (P<0.05). Basophil counts in peripheral blood after 
the therapy (33.4±16.2 x10-3/ml) was significantly decreased than that before therapy (41.5±23.3 
x10-3/ml) (P<0.01). Conclusion Different effects of oral cyclosporin therapy and oral anti-histami-
nergic therapy to serum high sensitivity-CRP level, TARC level and peripheral blood basophils in 
in adulthood AD patients were shown. Combination of these two therapies may be more effective 
for the treatment of adulthood AD.    
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Retrospective study comparing outcomes among patients receiving rituximab vs conventional 
adjuvant therapy for pemphigus vulgaris
A Agarwal,2 RP Hall1 and A Cardones1 1 Dermatology, Duke University School of Medicine, 
Durham, NC and 2 Duke University School of Medicine, Durham, NC
Adjuvant, steroid sparing agents are invaluable in the treatment of patients with moderate to severe 
pemphigus vulgaris (PV). Rituximab has emerged as an effective steroid sparing agent, although it 
is frequently used as second line adjuvant therapy. We performed a 7 year retrospective study to 
compare clinical outcomes among PV patients who received either rituximab or other systemic 
adjuvant therapy. Likelihood of remission (complete remission on minimal or off therapy or partial 
remission off therapy) was compared between the two groups using crude and adjusted Cox pro-
portional hazards regression controlling for age and gender. Relapse rate at 3 and 6 months after 
complete remission was evaluated using Fishers exact test. 13 (34%) patients received rituximab 
while 25 (66%) patients received other adjuvant therapy (mycophenolate mofetil, azathioprine, 
cyclophosphamide, infliximab). 10 of 13 patients who received rituximab were already on myco-
phenolate mofetil or azathioprine immediately preceding rituximab therapy, and had either active 
or relapsed disease. Median follow-up was 10 months (range 6-30). 8 (62%) patients on rituximab 
experienced remission compared to 14 (56%) patients in the control group. There was a trend for 
patients who received rituximab to have a higher likelihood of remission relative to the control 
group but this did not reach statistical significance (HR: 2.06; 95% CI: 0.79-5.37; p=0.14). Patients 
who received rituximab had a shorter median time to remission (6 months) compared to controls 
(11 months). There was no difference in the rate of 3- and 6-month relapse between the two groups. 
In conclusion, patients with moderate to severe pemphigus who received rituximab had a faster 
time to remission compared to those who received more traditional adjuvant therapy, although this 
was not statistically significant. The majority of patients who were placed on rituximab had failed 
other agents and may have had more severe disease. Prospective comparative studies are needed.   
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Early pediatric atopic dermatitis shows only a CLA+ Th2/Th1 imbalance, while adults acquire 
CLA+ Th22 activation
H Esaki1, 2, T Czarnowicki,2 J Gonzalez,2 D Malajian1, 2, S Talasila,3 A Berry,3 J Gray,3 
S Noda,2 JG Krueger,2 AS Paller3 and E Guttman-Yassky1, 2 1 Department of Dermatology, 
Icahn School of Medicine at Mount Sinai, New York, NY, 2 Laboratory for Investigative 
Dermatology, The Rockefeller University, New York, NY and 3 Department of Dermatology 
and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL
Expansion of skin homing (CLA+) T-cells in blood has been suggested as a biomarker of atopic der-
matitis (AD) activity in adults, but specific CLA+ T cell subsets have not been defined. Furthermore, 
identifying the differences and similarities between CLA+ T cell subsets in pediatric vs. adult AD 
is critical for leveraging new treatments towards children. We sought to define the role of “polar” 
CD4+ and CD8+ T-cell subsets in early pediatric AD within CLA+ vs. systemic (CLA-) T-cells using 
flow cytometry with intracellular staining for IFNg, IL-13, IL-9, IL-17, and IL-22 cytokines, defining 
Th1/Tc1, Th2/Tc2, Th9/Tc9, Th17/Tc17, and Th22/Tc22 populations, respectively. We compared 
peripheral blood from 16 children <5yo and 43 adults with well-characterized moderate to severe 
AD, as well as age-matched controls (16 children and 25 adults). CLA+ Th2 T-cells were markedly 
expanded in both AD children and adults compared with controls, but respective decreases in 
CLA+ Th1 T-cells were greater in AD children (7.5% vs. 17.2%, p<0.001). Unlike in adults, no 
imbalances were detected in pediatric AD CLA- T-cells, nor were there altered frequencies of Th22, 
Th17, or Th9 T-cells within CLA+ or CLA- compartments. Adults with AD had increased frequency 
of IL-22-producing CD4+ and CD8+ T-cells within CLA+ population (4.9% vs. 9.7%; 1.4% vs. 8.6%, 
respectively; p<0.001). These data suggest that Th2 activation within CLA+ T-cells may drive AD 
in children and that reduced counter-regulation by Th1 T-cells may contribute to this excess Th2 
activation. Th22 “spreading” of AD is not seen in young children and may be influenced by immune 
development, disease chronicity, or recurrent skin infections.    
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Immune function in children with severe inflammatory skin disease: A retrospective analysis
S Frisch1, 2 and E Siegfried3, 4 1 Dermatology, University of Illinois College of Medicine 
at Peoria, Peoria, IL, 2 Central Illinois Dermatology, Peoria, IL, 3 Pediatrics, Saint Louis 
University, Saint Louis, MO and 4 Dermatology, Saint Louis University, Saint Louis, MO
Systemic treatment with immunosuppressant medications is considered standard-of-care for severe 
atopic dermatitis. The purpose of this study was to characterize immunologic laboratory findings 
in a subset of children with severe atopic-like dermatitis and a history of skin and extracutaneous 
infections who failed treatment with oral immunosuppressants. A retrospective chart review was 
performed on 33 patients who met inclusion criteria. Fifty-five percent of patients had a history of 
recurrent otitis media and or sinusitis and 22% had pneumonia. Skin infections were most often 
due to sensitive and antimicrobial resistant Staphylococcus aureus, herpes simplex (including 4 
cases of acyclovir resistance), group B Streptococcus and molluscipox. The most common immu-
nological abnormalities were elevated total IgE (mean of 7493 and range of 3-48975), decreased 
memory and switched B cells, selective antibody deficiency, decreased toll-like receptor function 
and hypogammaglobulinemia. There was no single or constellation of identifiable immune abnor-
malities that characterized patients with a history of eczema herpeticum. Response to intravenous 
immunoglobulin (IVIG) was successful in 79% of patients with selective antibody deficiency and/
or deficient toll-like receptor response who previously failed immunosuppressants. There was a 
statistically significant relationship between the presence of selective antibody deficiency and or 
toll-like receptor deficiency and a failure to respond to immunosuppressants (P <0.0001). Treatment 
with interferon gamma was successful in 0% cases. Patients with severe atopic-like dermatitis and 
a history of frequent infections often have laboratory evidence of immune dysfunction. Screening 
immune evaluation should be considered prior to initiating systemic treatment. For patients with evi-
dence of primary immune deficiency, IVIG may be a better alternative to immunosuppressant drugs.   
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Validating the burden of disease in atopic eczema (BODE) tool as an instrument for measuring 
patient-reported quality of life in atopic dermatitis
A Wang, J Ding and AA Qureshi Dermatology, Warren Alpert Medical School of Brown 
University, Providence, RI
This is a prospective survey pilot study to validate the Burden of Disease in Atopic Eczema (BODE) 
survey as an instrument to measure the effect of atopic dermatitis in the eight health-related quality 
of life domains on a visual spectrum. The 8 specific domains include physical comfort, social 
comfort, emotional health, ability to work, volunteer or care for home, ability to care for self, 
ability to concentrate and ability to sleep. Patients over the age of 18 years seen in the dermatology 
clinic were asked to complete the BODE survey by marking their answer on a standardized 10 cm 
horizontal line ranging from 0 to 10, with 0 representing no effect from atopic dermatitis on the 
specific quality of life domain and 10 meaning maximum effect. The BODE score is calculated 
by measuring the length along the line from 0 to where the patient marks for each question. It is 
expressed as a ratio with the numerator being the length marked and the denominator being 10, 
rounded to the nearest tenth point. There are a total of 10 questions. The same patients also com-
pleted the Dermatology Life Quality Index (DLQI), Skindex16, and the Atopic Dermatitis Screening 
and Evaluation Questionnaire (ADSEQ) at the same visit. In total, 16 participants (8 males, 8 females) 
completed the surveys. The median BODE score for each participant was compared with the scores 
from the DLQI and Skindex 16. This revealed a distinct pattern amongst the participants that helped 
validate and stratify the scores of the BODE survey into four categories: “little affected” by atopic 
dermatitis represented from 0 to ≤ 0.1, “somewhat affected” from 0.1-0.3, “very affected” 0.3-0.7, 
and “extremely affected” by atopic dermatitis for all BODE scores over 0.7. The BODE tool is a 
quick and easy yet clinically relevant way for adult patients to express how atopic dermatitis affects 
their quality of life on a visual scale.    
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Oral sirolimus improves tuberous sclerosis complex skin tumors without evidence of 
resistance
N Nathan1, 2, J Wang,1 S Li,1 EW Cowen,3 M Haughey,2 J Moss2 and TN Darling1 1 
Department of Dermatology, Uniformed Services University of the Health Sciences, 
Bethesda, MD, 2 Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood 
Institute, National Institutes of Health, Bethesda, MD and 3 Dermatology Branch, Center for 
Cancer Research, National Institutes of Health, Bethesda, MD
Oral mechanistic target of rapamycin (mTOR) inhibitors have been shown to reduce visceral tumor 
volume in tuberous sclerosis complex (TSC) patients. To evaluate skin tumor response, we performed 
a retrospective analysis of 14 TSC patients prescribed sirolimus to treat lymphangioleiomyomatosis. 
Serial photographs of angiofibromas, shagreen patches and ungual fibromas taken before and after 
treatment initiation were blindly assessed using the Physician’s Global Assessment of Clinical Con-
dition (PGA), in which a score of 5 is unchanged and 4 is improved by 25-50%. Sirolimus treatment 
improved angiofibromas (median treatment duration: 12 months; median PGA: 4.5 [range 1.5-5]; 
Wilcoxon signed-rank test, p= .018) and shagreen patches (10; 4.5 [3.5-5]; p=.039) while ungual 
fibromas inconsistently improved (6.5; 4.66 [2.75-5]; p=.109). Immunohistochemistry of skin tumors 
harvested during treatment showed markedly decreased expression of phosphorylated ribosomal 
protein S6 (pS6), a marker of mTOR activation. In vitro studies of cultured cells showed that tumor 
cells were not eradicated, as indicated by the presence of cells with biallelic mutations in TSC2 
and/or constitutive activation of pS6. The development of resistance was not observed for 5 to 64 
months of treatment, assessed clinically by examining for skin tumor regrowth or biochemically by 
in vitro responsiveness to sirolimus. Fourteen months after drug cessation, angiofibromas did not 
significantly change from treated appearance (4.75 [4.5-4.75]; p=.633), while shagreen patches 
worsened (5.25 [5-5.75]; p=.020). In conclusion, oral sirolimus may improve TSC skin tumors in 
patients with indication for systemic treatment.    
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Dupilumab suppression of Th2 biomarkers correlates with reduction in transepidermal water 
loss (TEWL) and clinical improvements in adults with moderate-to-severe atopic dermatitis 
(AD)
J Hamilton,1 S Hamon,1 U Chaudhry,1 EL Simpson,2 B Swanson,3 M Liu,4 H Ren,4 
N Graham,1 G Pirozzi3 and M Ardeleanu1 1 Regeneron Pharmaceuticals, Inc., Tarrytown, 
NY, 2 Oregon Health Sciences University, Portland, OR, 3 Sanofi, Bridgewater, NJ and 4 
Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ
We evaluated whether inhibition of IL-4 and IL-13 activity with dupilumab (DPL), a fully human 
monoclonal antibody against IL-4 receptor-a (IL-4Ra), would improve skin barrier function, and 
assessed relationships of Th2 biomarkers and clinical measures, in a phase 2b trial to assess efficacy 
and safety of DPL in adults with moderate-to-severe AD (NCT01859988). After a loading dose, 
patients received placebo (PBO) or DPL (100 mg q4w, 300 mg q4w, 200 mg q2w, 300 mg q2w or 
300 mg qw) for 16 weeks (wks), with an additional 16-wk safety follow-up. Adverse events more 
frequently observed with DPL than PBO included nasopharyngitis, headache, and injection site 
reactions. A TEWL and stratum corneum hydration (SCH) substudy was conducted. At baseline 
lesional areas, DPL significantly reduced TEWL at Wk 4 (-28.8% all DPL [n=44] vs +83.8% PBO 
[n=7], p<0.0001, median % change) and further reduced or maintained TEWL through Wk 16 
(-43.8% all DPL [n=31] vs +76.2% PBO [n=3], p<0.001). There was no consistent difference in 
SCH between DPL- and PBO-treated patients. Improvement in TEWL correlated with thymus and 
activation-regulated chemokine (TARC) suppression (% change, Wk 16, Spearman r=0.47, p<0.006). 
We also assessed whether % changes in the Th2 biomarkers TARC, periostin, or eosinophils cor-
related with % changes in other clinical measures for the full study population. At Wk 16, the 
strongest correlations were % changes in TARC with clinical outcomes (n=351; including Pruritus 
5D, r=0.45; Patient Oriented Eczema Measure (POEM), r=0.40; body surface area, r=0.39; SCORing 
Atopic Dermatitis (SCORAD), r=0.36; Investigator’s Global Assessment (IGA), r=0.35; Eczema Area 
and Severity Index (EASI), r=0.33; all p<0.0001). IL-4Ra blockade with DPL may improve both 
inflammatory and barrier impairments driving AD pathogenesis.    
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Time-resolved laser induced fluorescence spectroscopy for the diagnosis of oral lichen planus
D Gorpas,1 P Davari,2 J Bec,1 D Ma,1 G Farwell,3 L Marcu1 and N Fazel2 1 Department 
of Biomedical Engineering, University of California, Davis, Davis, CA, 2 Department 
of Dermatology, University of California, Davis, Sacramento, CA and 3 Department of 
Otolaryngology, University of California, Davis, Sacramento, CA
Lichen planus (LP) is a non-infectious chronic inflammatory condition that affects the skin, oral and 
genital mucous membranes thought to be triggered by the immune system. Conventionally, oral 
lichen planus (OLP) is diagnosed through clinical assessment and histopathologic confirmation by 
oral biopsy. In this pilot study, we explore the utility of time-resolved fluorescence spectroscopy 
(TRFS) as a diagnostic tool for OLP by comparing lifetime fluorescence measurements of lesional 
vs. peri-lesional normal oral mucosa. Histopathologic confirmation was consistent with OLP in 2 
out of 4 patients biopsied. One patient was diagnosed with frictional hyperkeratosis, which was not 
considered and one patient showed sparse mucositis. Measurements on lesional and non-lesional 
buccal mucosa were conducted in vivo. Our preliminary data shows that average lifetime values 
in the range of 420-440 nm, indicate a significant differentiation between normal and diseased 
tissue. Lifetime values of non-lesional oral mucosa were equal to 4.31 ± 0.14 ns for that spectral 
range, whereas this value was 3.88 ± 0.13 ns within lesional oral mucosa. In contrast to the stan-
dard oral biopsy procedure, the TRFS laser device is non-invasive, painless with little to no risk. 
Future measurements are needed to better elucidate the discrimination efficacy of this technique 
and will provide useful information about the sources of the measured fluorescence contrast. Our 
preliminary data suggests that the TRFS technique is very promising for the development of OLP 
diagnostic methods based on average lifetime metrics.    
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Characteristics of patients with pseudocellulitis admitted to the hospital
A Raff,1 Q Weng,2 P Vedak,3 D Kroshinsky3 and A Mostaghimi2 1 Dermatology, Harvard 
Combined Residency Program, Boston, MA, 2 Dermatology, Brigham and Woman’s Hospital, 
Boston, MA and 3 Dermatology, Massachusetts General Hospital, Boston, MA
Non-infectious inflammatory dermatoses of the lower extremities are often misdiagnosed as celluli-
tis. The purpose of this study was to determine the prevalence of patients with lower limb “pseudo-
cellulitis” who were initially admitted with presumed cellulitis and to compare their characteristics 
to patients with true cellulitis. We performed a retrospective chart review at a large urban hospital 
and selected patients presenting to the emergency room who were admitted with a diagnosis of 
lower limb cellulitis. Patients who were discharged with a diagnosis of cellulitis were considered 
to have true cellulitis while patients who were discharged with an alternative diagnosis within 30 
days of discharge were considered to have pseudocellulitis. We found that 25% of patients admitted 
with cellulitis were ultimately diagnosed with pseudocellulitis. Pseudocellulitis patients were more 
likely to present with bilateral lower limb symptoms versus unilateral symptoms when compared 
to cellulitis patients. In addition, they had lower temperatures (99.3°F vs 98.3°F) and lower white 
blood cell (WBC) counts (13.15 K/ul vs 8.69 K/ul [Ref 4-10], p <0.05) on presentation to the emer-
gency room. Cellulitis patients continued to have higher WBC counts compared to pseudocellulitis 
patients throughout their hospital stay (p <0.05). Pseudocellulitis patients were twice as likely to 
receive a dermatology consult but much less likely to receive an infectious disease or surgical con-
sult as compared to cellulitis patients. While further research is needed, these preliminary results 
suggest clinical and biological differences between cellulitis and pseudocellulitis that may allow 
for improved diagnosis upon presentation.    
172
Intravenous immunoglobulin for treatment of dermatomyositis-associated calcinosis
F Galimberti and AP Fernandez Cleveland Clinic, Cleveland, OH
Dermatomyositis (DM) is an idiopathic inflammatory disorder of unknown etiology characterized 
by an inflammatory myopathy and characteristic cutaneous findings. Calcinosis is the abnormal 
deposition of calcium in skin, muscle, and subcutaneous tissue. Calcinosis is frequently observed in 
juvenile DM (JDM), but it is a rare late finding in adult DM. Cutaneous DM findings in general, and 
calcinosis in particular, are difficult to treat. Currently, there is no standard therapy for calcinosis in 
DM. We investigated calcinosis response to intravenous immunoglobulin (IVIG). A retrospective 
chart review of the Cleveland Clinic electronic medical record system (EMR) was conducted to 
identify DM patients who developed calcinosis and were treated with IVIG. Calcinosis response 
was assessed 6 to 12 months after IVIG initiation and defined as improved or stable/worse based 
on clinical documentation and, if performed, radiologic imaging. Eight patients (3 males; 5 females) 
with DM-associated calcinosis who received IVIG were identified: 5 with classic DM, 2 with JDM, 
and 1 with amyopathic DM. Mean age was 40 years old (± 25.2; range 5-74). Calcinosis developed 
on average 554 days after DM diagnosis (± 728, range: 0-1448). IVIG was initiated for treatment of 
refractory cutaneous disease with calcinosis in 5/8 patients (62.5%) and for treatment of refractory 
cutaneous disease with calcinosis and refractory myositis in 3/8 patients (37.5%). Five of 8 (62.5%) 
patients’ calcinosis improved after IVIG whereas 3 patients (37.5%) showed no improvement/wors-
ened disease. Never smokers and ANA positive patients were more likely to respond to IVIG (p = 
0.02 and p = 0.015, respectively). Two of 5 patients whose calcinosis responded to IVIG required 
fewer medications/lower dosages 3 to 6 months post-IVIG. Overall, this study suggests that IVIG 
can be an effective treatment for calcinosis in DM patients and that negative smoking history and 
positive ANA testing may be associated with better response to IVIG.    
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Identification of two salivary proteins associated with early-stage oral chronic graft-versus-
host disease
R Presland1, 2, W Alshehri,1 M Missaghi,1 M Schubert3, 4 and M Lloid3, 4 1 Oral Health 
Sciences, University of Washington, Seattle, WA, 2 Medicine (Dermatology), University of 
Washington, Seattle, WA, 3 Oral Medicine, University of Washington, Seattle, WA and 4 
Seattle Cancer Care Alliance, Seattle, WA
Chronic graft-versus-host disease (cGVHD) is a frequent and serious complication of allogeneic 
hematopoietic stem cell transplantation (allo-HSCT), affecting >50% of patients. To date, a number 
of groups have identified disease biomarkers for systemic or tissue-specific (e.g. oral) cGVHD, but 
as yet none have been validated. Previously, we carried out semi-quantitative mass spectrometry 
analysis of saliva from patients with oral cGVHD, and confirmed that the proteins IL-1 receptor 
antagonist (IL-1ra) and cystatin B were decreased in oral cGVHD patients compared to allo-HSCT 
patients without oral cGVHD. Here, we further examine expression of these markers in early-stage 
oral cGVHD patients (N=23, mean age=55 yrs), who were diagnosed with cGVHD 10-14 months 
after allo-HSCT, and compared levels of protein expression to a control allo-HSCT group with no 
oral cGVHD (N=16, mean age=51 yrs) studied 8-13 months post-allo-HSCT. The expression of 
both IL-1ra and cystatin B were significantly decreased in oral cGVHD patients compared with 
non-cGVHD controls (p<0.001). Receiver Operator Characteristic analysis gave an AUC value of 
0.90 for the 2-marker panel (95% CI, 0.79-0.97). A third marker examined, Secretory Leukocyte 
Protease Inhibitor (SLPI), was not significantly different between these two groups, but within a 
larger oral cGVHD(+) cohort, SLPI was significantly higher in patients who received a myeloablative 
transplant (N=41) compared to patients receiving a non-myeloablative transplant with low intensity 
conditioning (N=13, P=0.008). These findings identify two salivary biomarkers that are associated 
with early stage oral cGVHD, and a third marker, SLPI, an alarmin anti-protease, that is elevated in 
myeloablative allo-HSCT patients with oral cGVHD.    
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Combined treatment with arsenic trioxide and itraconazole inhibits the hedgehog pathway in 
patients with refractory metastatic basal cell carcinoma: results from a pilot trial
KJ Ransohoff,1 MS Ally,1 K Sarin,1 S Atwood,2 M Rezaee,1 I Bailey,1 P Beachy,2 AS Chang,1 
A Oro,1 D Colevas2 and JY Tang1 1 Dermatology, Stanford School of Medicine, Stanford, CA 
and 2 School of Medicine, Stanford University, Stanford, CA
Tumor resistance is an emerging problem for metastatic BCCs treated with SMO inhibitors such as 
vismodegib. 50% of resistant tumors contain mutations in SMO, the key transducer of the Hedgehog 
signaling pathway that drives BCC growth. ATO and itraconazole are 2 FDA approved drugs that 
inhibit the HH pathway at sites distinct from vismodegib, and have reduced BCC tumors in mouse 
models. Our primary goal was to assess whether combined ATO and itraconazole can reduce 
HH signaling in patients with refractory, metastatic BCCs (mBCC). The secondary objectives were 
evaluation of tumor response and tolerability during 3 months of therapy. 5 patients with mBCC 
were enrolled in this proof-of-concept phase II trial and treated with ATO (0.3 mg/kg IV for 5 days, 
every 28 days), for a total of 3 cycles. Oral itraconazole 400 mg daily was given between ATO 
cycles. We compared mRNA levels of the HH-pathway target gene, GLI1, in skin biopsies pre- and 
post-treatment. Three patients completed all 3 cycles of treatment; two discontinued early due to 
disease progression or adverse events. Side effects included grade 1/2 lymphocytopenia and trans-
aminitis, and one grade 4 AE of sepsis. Overall, ATO/itraconazole reduced GLI1 mRNA by 75% 
from baseline (P<0.0001). Four of five patients had evaluable tumor by RECIST criteria. The best 
overall response after 3 cycles was stable disease in 3 patients and progressive disease in 1 patient. 
None had tumor shrinkage. This trial demonstrates the feasibility of inhibiting the HH pathway with 
by repurposing ATO/itraconazole; our next trial will test continuous dosing schedules at to fully 
inhibit the HH pathway, which may optimize clinical response.    
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Throat infections can cause substantial aggravation of chronic plaque psoriasis
RH Thorleifsdottir1, 2, 3, JH Eysteinsdottir2, 3, JH Olafsson,2 MI Sigurdsson,4 A Johnston,5 
H Valdimarsson3 and B Sigurgeirsson2 1 Dermatology and Venereology, Akademiska 
University Hospital, Uppsala, Sweden, 2 Dermatology, University of Iceland, Reykjavik, 
Iceland, 3 Immunology, University of Iceland, Reykjavik, Iceland, 4 Medicine, University 
of Iceland, Reykjavik, Iceland and 5 Dermatology, University of Michigan, Ann Arbor, MI
The onset and exacerbation of psoriasis has been associated with environmental agents, including 
streptococcal throat infections. Chronic plaque psoriatics with sore throat-associated aggravation 
have been shown to improve with tonsillectomy. To estimate the clinical potential of tonsillectomy 
as a treatment, the number of chronic plaque psoriasis patients with sore throat-associated exacerba-
tions was assessed. 275 psoriasis patients were recruited from 4 dermatology clinics in Iceland (mean 
age 42.3±14.2yr, 127˛, 148ˇ). They answered a questionnaire on demographics, psoriasis subtype, 
age at onset, exacerbations following throat infections, other psoriasis aggravating factors and the 
effect of tonsillectomy on psoriasis. 75% of patients reported having chronic plaque psoriasis, and 
of these: 42% noted sore throat-associated psoriasis exacerbations and 72% reported streptococ-
cal-associated aggravation of psoriasis. Women more often reported psoriasis exacerbation after a 
sore throat (p<.001), as did patients with early onset psoriasis (p=.046). Aggravation due to other 
factors (general malaise, cold climate, alcohol, stress) was more common in patients with sore 
throat-associated psoriasis (p≤.01). A total of 37 (18%) of chronic plaque psoriatics had undergone 
tonsillectomy after psoriasis onset, and 49% of these noted improvement. These participants were 
more likely to report sore throat-associated aggravation of psoriasis, compared to patients that did 
not improve after tonsillectomy (p=.015). Exacerbation of chronic plaque psoriasis after a sore throat 
was found to be more common than previously noted, with streptococcal sore throat linked to not 
only guttate psoriasis but also to chronic plaque psoriasis, suggesting that tonsillectomy might be 
a useful treatment option for patients with both forms of the disease.    
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Angiogenesis in lupus vulgaris and tuberculosis verrucosa cutis lesions of cutaneous 
tuberculosis 
S Bhandarkar,1 P Lanka,4 LR Lanka,4 M Bonner,1 J Mackelfresh1 and JL Arbiser1, 2, 3 1 
Dermatology, Emory School of Medicine, Atlanta, GA, 2 Dermatology, Winship Cancer 
Institute, Atlanta, GA, 3 Dermatology, Atlanta Veteran Affairs, Atlanta, GA and 4 
Dermatology, Vinayaka Mission’s Medical College, Karaikal, India
Cutaneous tuberculosis is a common infection in the developing world. Successful treatment 
requires month long treatment with toxicity and poor compliance. Thus a better understanding 
of the host environment of tuberculosis is required for enhanced treatment of tuberculosis. We 
compared the microvessel count in the two most common forms of cutaneous tuberculosis, namely 
tuberculosis verrucosa cutis (TBVC) and lupus vulgaris (LV). The TBVC phenotype of infection is 
associated with a lower bacterial load than the LV infection phenotype. Seven lesions of each type 
(TBVC vs LV) were stained with CD31 in order to determine the microvessel density. We found 
that TBVC had a significantly elevated microvessel count compared with LV, despite LV having 
an elevated bacterial load. This suggests that therapeutic modalities that increase angiogenesis, 
such as induction of nitric oxide, may be of benefit in the treatment of tuberculosis, both in its 
cutaneous and systemic forms.    
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Decreased IL-21 expression in skin and blood contributes to progression of mycosis fungoides
M Kabasawa, M Sugaya, T Oka, N Takahashi, M Kawaguchi, H Suga, T Miyagaki, H Fujita, 
Y Asano, Y Tada, T Kadono and S Sato Department of Dermatology, Faculty of Medicine, 
University of Tokyo, Tokyo, Japan
IL-21 is a member of the common γ-chain cytokine family that is associated with immune function 
in both humoral and cell-mediated immune responses through the regulation of various immune 
cells. IL-21 is regarded as a potent anti-tumor agent, which increases the cytotoxicity of both NK 
and CD8+ T cells. Phase I and II clinical trials on the use of recombinant IL (rIL)-21 in patients 
with melanoma showed anti-tumor activity. In this study, we aimed to investigate the role of IL-21 
in mycosis fungoides (MF). We first examined messenger RNA (mRNA) expression levels in MF 
lesional skin (n = 17) and in normal skin (n = 6) by quantitative RT-PCR. IL-21 mRNA expression 
levels in patch MF and plaque MF were significantly higher than those in normal skin (P < 0.05, 
each). IL-21 mRNA expression levels in tumor MF were significantly decreased compared with 
those in patch and plaque MF (P < 0.05, each). We also found that IL-21 mRNA expression in MF 
lesional skin significantly correlated with mRNA expression levels of Th1 cytokines/chemokines 
such as CXCL10 (r = 0.49, P < 0.05), CXCL11 (r = 0.47, P < 0.05) and IFN-γ (r = 0.60, P < 0.05). 
Immunohistochemical study revealed that IL-21 was expressed by keratinocytes and endothelial 
cells in lesional skin of patch and plaque MF. Furthermore, we measured serum IL-21 levels in 
patients with MF (n = 31) and healthy controls (n = 22). Serum IL-21 levels in patch MF (n = 10) 
and plaque MF (n = 12) were comparable with those of healthy controls. By contrast, serum IL-21 
levels in patient with tumor MF (n = 10) were significantly lower than those of healthy controls (P 
< 0.01) and plaque MF patients (P < 0.05). Thus, IL-21 expression was significantly down-regulated 
in skin and blood of patients with tumor MF, which may contribute to progression of MF. Our study 
suggests that rIL-21 would be a promising therapy for MF.    
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History of severe sunburns on different body sites and risk of skin cancers in women and 
men: Two prospective cohort studies
S Wu,1 E Cho,1 W Li,1 MA Weinstock1, 2 and AA Qureshi1, 2 1 Department of Dermatology, 
Warren Alpert Medical School, Providence, RI and 2 Department of Dermatology, Rhode 
Island Hospital, Providence, RI
Severe sunburn is a strong risk factor for skin cancer. Little is known about the association of severe 
sunburns on different body sites with risk of melanoma and other skin cancers. We prospectively 
evaluated the predictive value of severe/blistering sunburns on different body sites for risk of devel-
oping different skin cancers (melanoma, squamous cell carcinoma/SCC, basal cell carcinoma/BCC) 
in 87,165 women aged 36-61 in the Nurses’ Health Study (NHS, 1982-2010) and 33,505 men 
aged 46-81 in the Health Professionals Follow-up Study (HPFS, 1992-2010). Study participants 
reported numbers of severe/blistering sunburns on different body sites (face/arms, trunk and lower 
extremity) at baseline. We documented 1177 melanomas, 2159 SCCs and 21,496 BCCs over 2.5 
million person-years of follow-up. After adjustment for other skin cancer risk factors and potential 
confounders, overall history of severe/blistering sunburn was more strongly associated with risk 
of melanoma [hazard ratios (HR)=1.49 (95% confidence interval (CI): 1.10-2.01) for women and 
2.28 (95% CI: 1.27-4.06) for men] than SCC [HRs=1.30 (1.06-1.59) for women and 1.46 (1.07-
2.01) for men] or BCC [HRs=1.31(1.24-1.39) for women and 1.16 (1.04-1.29) for men]. Sunburn 
on trunk was more strongly associated with melanoma risk [HRs=1.47 (1.12-1.92) for women and 
1.97 (1.30-2.98) for men] than sunburn on face/arms [HRs=1.08 (0.90-1.29) for women and 1.26 
(1.02-1.56) for men] or lower extremity [HRs=1.25 (1.04-1.50) for women and 1.17 (0.93-1.46) 
for men]. In conclusion, severe sunburn is more strongly associated with risk of melanoma than 
SCC or BCC, and sunburn on trunk may be a better predictor for risk of developing melanoma than 
sunburns on other body sites.    
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CD4+ histiocytosis in patients on statins for dyslipidemia mimics early mycosis fungoides
C Oh, C Torre-Cabala and M Duvic MD Anderson Cancer Center, Houston, TX
Precise histologic differentiation of neoplastic T cells from reactive histiocytes is limited because 
not only malignant cells of mycosis fungoides (MF), but also epidermal Langerhans cells and der-
mal histiocytes (dermal dendritic cells and macrophages) express CD4. In particular, it is hard to 
distinguish early MF from histiocytic proliferation which is not commonly encountered. Diagnostic 
criteria for early MF by the International Society for Cutaneous Lymphoma (2005) do not specify 
immunopathologic findings of CD4+ immune cells. Thus, high CD4 to 8 ratio > 4 might obscure 
differential diagnosis of early MF. The purpose of our study was to determine the clinical and lab-
oratory characteristics of patients with CD3-CD4+ histiocytosis within skin biopsies. Patients with 
lymphoid atypia, high CD4 to CD8 ratio, and increased histiocytic infiltration on skin biopsy (n=13) 
were selected. Clinical, laboratory, and biopsy findings were retrospectively reviewed using medical 
records. Exclusion criteria for MF included TCR monoclonality, abnormal T cell populations by 
flow cytometry, retinoid treatment, lymphadenopathy, visceral or bone marrow involvement, and 
progression of disease after treatment. All 13 patients had a history of statin medications (atorvastatin 
6/13; simvastatin 2/13; rosuvastatin 1/13; with fish oil 3/13) for dyslipidemia (hypercholesterolemia 
7/13; both hypercholesterolemia and hypertriglyceridemia 3/13). Clinical manifestations that mim-
icked early MF included pink scaly patches (9/13); pigmented purpuric dermatosis (2/13); capillaritis 
(1/13); EAC-like patches (1/13). Eleven of thirteen had an increased percentage of monocytes in the 
peripheral blood CBC analysis. We concluded that cutaneous CD4+ histiocytosis in patients on 
statins for dyslipidemia mimics early mycosis fungoides.    
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Emollient therapy alters skin barrier and microbes in infants at risk for developing atopic 
dermatitis
M Glatz,1 EC Polley,2 EL Simpson3 and HH Kong1 1 Dermatology Branch, Center for Cancer 
Research, NCI, Bethesda, MD, 2 Biometric Research Branch, Division of Cancer Treatment 
and Diagnosis, NCI, Bethesda, MD and 3 Dermatology, Oregon Health and Science 
University, Portland, OR
Atopic dermatitis (AD) begins in early childhood and is characterized by impaired skin barrier 
and shifts in the skin microbiome. Skin emollients are commonly used to protect and repair the 
defective skin barrier in AD. The goal of this study was to investigate whether long-term emollient 
therapy for AD primary prevention is associated with alterations of skin barrier function and shifts 
of the skin microbiome in infants at high risk for developing AD. As part of a larger prevention 
trial, we prospectively enrolled a substudy consisting of 19 newborns with a family history of AD 
randomized to either emollient-treatment or control group. At 6 months of age, we tested the skin 
barrier (transepidermal water loss/TEWL, water capacitance/CAP, pH) and skin microbiome (16S 
rDNA sequencing of skin swabs from cheek, dorsal and volar forearm). The emollient group (n=10) 
had significantly lower skin pH compared to controls (n=9) (p=0.02), but without a statistically sig-
nificant difference in TEWL or CAP. The emollient group had higher numbers of different bacterial 
taxa (Chao richness) at cheeks (p=0.003), dorsal forearms (p=0.008), and volar forearms (p=0.003) 
as compared to controls. Both Streptococcus pneumoniae and S. salivarius significantly contributed 
to the observed skin microbiome differences between patient groups. S. salivarius was significantly 
more abundant in emollient subjects at all sampling sites (p=0.02). We then analyzed our previous 
larger cohort of older children with AD and also observed higher S. salivarius proportions in AD 
patients with treated and less severe disease (p = 0.01). In conclusion, long-term emollient therapy 
is associated with altered skin barrier function and shifts of skin microbiome in infants at high risk 
for AD. Additional studies are needed to understand how alterations in streptococci may contribute 
to the therapeutic and preventative effects of emollients in AD.    
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Skin mapping for classification of morphea
N Teske and H Jacobe Dermatology, University of Texas Southwestern, Dallas, TX
Multicenter morphea studies are underway but are jeopardized by lack of well-defined subtypes. 
We aimed to refine the categorization of generalized morphea using computerized lesion mapping 
to determine lesion distribution patterns and whether these distributions identified clinically unique 
patient subsets. A cross-sectional study was performed of 73 generalized morphea (as defined by 
Zulian & Laxer) patients from the Morphea in Adults and Children (MAC) cohort. Graphical maps 
of each patient’s lesions were created (MATLAB matrix processing software, Mathworks, Natick, 
MA) then plotted as a heatmap (GNU Imagine Manipulation Program) representing the frequency of 
involvement of different anatomical sites. A statistical filter identified overlapping and unique regions 
of involvement to generate a map of different patterns of distribution (p<0.025). Demographic, 
clinical, and autoantibody characteristics were compared between patients with different lesion 
distributions as identified by mapping. Mapping produced two predominant patterns of distribution 
that encompassed all sampled patients: isomorphic (lesions in areas of skin friction, specifically 
the brassiere band) and symmetric (lesions symmetrically distributed on trunk and extremities, 
particularly the anterior tibia). Differences in lesion distribution were mirrored by differences in 
demographic and clinical features. Patients with isomorphic distribution (n=30) were on average 
13 years older at disease onset than those with symmetric (n=43) (p=0.0008), had more frequent 
concomitant autoimmune disorders (14/30 vs. 10/43, p=0.04), and were predominantly female 
(30/30 vs. 38/43, p=0.05). Subcutaneous/fascial involvement was more common in symmetric 
(10/43) than isomorphic patients (1/30) (p=0.02). Symmetric and isomorphic distributions of gen-
eralized morphea possess unique features that potentially identify them as more accurate and 
clinically relevant subsets than the current generalized subtype. Consideration should be given to 
the revision of current morphea subtypes.    
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A 6-year retrospective analysis of treatment patterns and outcomes of epidermal superficial 
non melanoma skin cancer at an academic dermatologic surgery center
B Drew,1 P Karia1, 2, A Mora,2 C Liang1, 2 and C Schmults1, 2 1 Harvard Medical School, 
Boston, MA and 2 Department of Dermatology, Brigham and Women’s Hospital, Boston, MA
Non melanoma skin cancer (NMSC) is predominantly comprised of basal cell carcinoma (BCC) and 
squamous cell carcinoma (SCC). Superficial BCC accounts for 30% of BCCs while SCC in situ (SCCIS) 
accounts for 12% of SCCs. Collectively, these diseases are associated with significant morbidity. 
With increasing scrutiny of the necessity and cost of dermatologic treatment modalities, further 
research is required to assess treatment efficacy. The objectives of this study were to determine 
patterns of epidermal NMSC treatment, analyze their outcomes, and identify factors associated 
with recurrence. The study consisted of a retrospective analysis of 550 patients with 678 epidermal 
NMSCs treated from Jan 2008 to Mar 2014. Baseline patient and tumor characteristics, treatment 
modality [Mohs micrographic surgery (MMS), topical medication (TM), and cryotherapy (CT)], 
and outcomes were recorded. A total of 329 tumors (49%) were treated with MMS, 292 tumors 
(43%) with TM, and 57 tumors (8%) with CT. Fluoruracil was the most commonly used TM (80%) 
followed by Ingenol mebutate (11%) and Imiquimod (9%). The median follow-up time was 24 
months (range, 2-81 months). Collectively, there were 11 recurrences (2%). Of these recurrences, 
7 (64%) had been treated with TM, only 2 with MMS (18%) and 2 with CT (18%). The difference 
in recurrence risk (3.3% non-MMS vs. 0.7% MMS) was not significant on multivariate analysis. 
Independent predictors for recurrence on multivariate analysis were tumor diameter of at least 2 
cm (HR, 5.1 [95% CI, 1.3-19.5]) and immunosuppression (3.6 [1.0-12.5]). This study indicates that 
surgical and non-surgical treatment modalities may have more equivalent efficacy than previously 
reported. High compliance with topical therapy in this cohort may account for the high cure rate of 
97%. Accurate risk estimates of outcomes from population-based data and well-controlled clinical 
trials with 2-5 year follow-up are required to further examine treatment efficacy.    
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Non-invasive imaging technologies for the delineation of basal cell carcinomas
S Que Dermatology, University of Connecticut Health Center, Farmington, CT
We examine whether non-invasive imaging modalities can help delineate tumor margins of basal 
cell carcinomas (BCCs) during dermatologic surgery. A comprehensive literature search of PubMed 
(http://www.ncbi.nim.nih.gov/pubmed) was undertaken using the following search terms: derma-
tologic surgery, confocal microscopy, dermoscopy, and optical coherence tomography. Original 
studies were included in the analysis if they met the following criteria: i) prospective study was 
written in English, ii) involved the use of dermoscopy, reflectance confocal microscopy (RCM), or 
optical coherence tomography (OCT) in dermatologic surgery, and iii) study focused on the use of 
these devices for evaluation of tumor margins. Exclusion criteria included the following: i) study 
did not contain original data, ii) study made mention of but did not focus primarily on dermoscopy, 
RCM, or OCT, and iii) study used imaging techniques for biopsy site identification or tumor diagnosis 
without overt mention of surgical margins. Information on the sensitivity and specificity of each 
device was recorded and the correlation between histopathology and non-invasive imaging was 
noted. Our search yielded 53 results, with a total of 27 publications meeting the inclusion criteria. 
Seventeen studies involved the use of RCM, 5 involved the use of dermoscopy, and 5 involved the 
use of OCT. Our review shows that dermoscopy is of limited use in delineating BCCs prior to exci-
sion and has no benefit compared to clinical inspection. In contrast, RCM has a sensitivity ranging 
from 73 to 100% and a specificity ranging from 89 to 99% for detecting and delineating BCCs. 
Values were lower for BCCs in lateral margins vs. midsections and for BCCs of the micronodular or 
infiltrative type. Results of OCT are mixed, with some studies showing a relatively low sensitivity and 
specificity for this device (sensitivity 19%, specificity 56% in one paper) and other studies reporting 
an accuracy rate as high as 84% for predicting surgical margins. Non-invasive imaging devices such 
as OCT and RCM hold some promise and can potentially help to delineate BCCs perioperatively.   
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Disease manifestations in patients with subacute cutaneous lupus erythematosus who meet 
criteria for systemic lupus
J Tiao1, 2 and V Werth1, 2 1 Dermatology, University of Pennsylvania, Philadelphia, PA and 2 
Philadelphia VAMC, Philadelphia, PA
Roughly 50% of patients with subacute cutaneous lupus erythematosus (SCLE) also meet criteria 
for systemic lupus erythematosus (SLE). However, previous studies have not characterized which 
of the SLE criteria such patients meet. This study is a case-control comparison of patients with SCLE 
who meet criteria for SLE against patients with only SCLE for the purpose of identifying which of the 
1997 American College of Rheumatology criteria SCLE/SLE patients are more likely to have. The 
information was obtained from an ongoing database of lupus patients seen at the Autoimmune Skin 
Disease clinic at the University of Pennsylvania and from their respective medical records. Thirty-two 
SCLE/SLE patients were compared with 53 SCLE-only patients. Patients were categorized into the 
following SCLE subtypes: papulosquamous (n=60), annular (n=15), mixed papulosquamous-and-an-
nular (n=9), and unspecified (n=1). Presence of the following was noted: malar rash, discoid rash, 
photosensitivity, oral ulcers, arthritis, serositis, renal disorder, neurologic disorder, hematologic 
disorder, +ANA, and positive anti-dsDNA, anti-Smith, anticardiolipin, and lupus anticoagulant tests. 
Papulosquamous SCLE/SLE patients were more likely than papulosquamous SCLE-only patients to 
exhibit oral ulcers (58% v. 8%, p<0.0001), +anti-dsDNA (50% v. 0%, p=0.0004), and +ANA (87% 
v. 13%, p<0.0001). Overall, SCLE/SLE patients were more likely than SCLE-only patients to exhibit 
photosensitivity (97% v. 67%, p<0.002), oral ulcers (59% v. 8%, p<0.0001), +anti-dsDNA (50% 
v. 3%, p<0.0001), and +ANA (87% v. 21%, p<0.0001). These findings suggest that SCLE patients 
who meet SLE criteria are no more likely than their SCLE-only counterparts to exhibit systemic 
symptoms. This is consistent with the current line of thinking that considers SCLE to be a marker 
for less severe lupus disease.    
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Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by 
healthy human volunteers
SA Reisman, C Lee, CJ Meyer, J Proksch and K Ward Reata Pharmaceuticals, Irving, TX
When applied topically to rodents, the synthetic oleanane triterpenoid RTA 408 elicits a potent der-
mal cytoprotective phenotype through activation of the transcription factor Nrf2. A series of studies 
were conducted to investigate if such cytoprotective properties translate to human dermal cells, and 
a topical lotion formulation was developed and tested clinically. In vitro, RTA 408 (3-1000 nM) was 
incubated with primary human keratinocytes for 16 hours. Ex vivo, RTA 408 (0.03, 0.3, or 3%) was 
applied to human skin explants from a healthy volunteer donor up to twice daily for 3 days. The 
Phase 1 clinical study with RTA 408 Lotion consisted of 3 parts. In Part A, healthy volunteers had 
RTA 408 Lotion (0.5%, 1%, and 3%) applied to individual 4cm2 sites twice daily for 14 days. In 
Parts B and C, separate groups of subjects had 3% RTA 408 Lotion applied twice daily to a 100-cm2 
site for 14 days (Part B) or a 500-cm2 site for 28 days (Part C). RTA 408 was well-tolerated in both 
in vitro (primary human keratinocytes) and ex vivo (human skin explants) settings up to the highest 
concentrations tested. Further, RTA 408 significantly induced a variety of Nrf2 target genes at both 
the mRNA and protein expression levels in a concentration-dependent manner. Clinically, RTA 408 
Lotion was well-tolerated in healthy volunteers, up to the highest concentration, largest surface area, 
and longest duration tested. Systemic exposure to RTA 408 was very low, with plasma concentrations 
below the lower limit of quantitation (<0.075 ng/mL) in the majority of subjects. Moreover, skin 
biopsies demonstrated significant increases in protein expression of the prototypical Nrf2 target gene 
NQO1 in the epidermis, suggesting robust activation of the pharmacological target. Overall, these 
data suggest RTA 408 Lotion is well-tolerated, activates its pharmacological target Nrf2 in human 
cells both preclinically and clinically, and appears suitable for continued clinical development.   
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Quality of life in discoid lupus patients
N Teske,1 ZE Cardon,1 X Li,2 B Huet-Adams2 and BF Chong1 1 Dermatology, University of 
Texas Southwestern, Dallas, TX and 2 Clinical Sciences, University of Texas Southwestern, 
Dallas, TX
As studies have demonstrated quality of life (QoL) impairment in a heterogeneous group of cutaneous 
lupus erythematosus (CLE) patients, this study aimed to characterize QoL in discoid lupus (DLE) 
patients specifically, given their unique clinical features. A cross-sectional study was performed of 
117 DLE patients who completed demographic, medical history, and QoL questionnaires, including 
SKINDEX-29, and underwent clinical assessments (e.g. Cutaneous Lupus Erythematosus Disease 
Severity and Area Index (CLASI)). Univariable analyses were performed to assess relationships 
between predictor variables and primary outcome measures of SKINDEX-29 scores in emotions, 
functioning, and symptoms subdomains. Predictor variables with p<0.10 in univariable analyses 
were included in multivariable logistic regression models. DLE patients had significantly higher and 
worse SKINDEX-29 symptoms scores (41±21) than other CLE patients (33±22, n=47) (p=.05), and 
particularly reported more itch than did other CLE patients (p<0.001). Univariable analyses showed 
that higher SKINDEX-29 scores correlated with higher CLASI activity (p=0.05 (emotions), p=0.002 
(functioning), p<0.0001 (symptoms)) and damage (p=0.04 (emotions), p=0.03 (functioning), p=0.02 
(symptoms)) scores, current smoking status (p<0.0001 (emotions), p=0.0003 (functioning), p=0.003 
(symptoms)), and income less than $10K/year (p=0.01 (emotions), p<0.0001 (functioning), and 
p=0.003 (symptoms)). Multivariable analyses highlighted female gender as significantly associated 
with higher SKINDEX-29 emotions (p=0.01) and symptoms scores (p=0.007), and correlated current 
smoking status with poorer QoL in the SKINDEX-29 emotions (p=0.0005), functioning (p=0.04), 
and symptoms (p=0.02) subdomains. Providers may pay greater attention to factors that lead to QoL 
impairment in DLE patients, such as itch, and consider screening for vulnerable patient subsets, 
including women and current smokers, who may benefit from counseling and referral to specialists.   
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The cerebral mechanism of scratching and its pleasurability in chronic itch
H Mochizuki,1 AD Papoiu,2 LA Nattkemper,1 A Lin,1 R Kraft,3 R Coghill4 and G Yosipovitch1 
1 Dermatology, Temple University, Philadelphia, PA, 2 Dermatology, Wake Forest University, 
Winston-Salem, NC, 3 Biomedical Engineering, Wake Forest University, Winston-Salem, NC 
and 4 Neurobiology & Anatomy, Wake Forest University, Winston-Salem, NC
Pathological scratching is one of significant problems for chronic itch patients, since it severely 
damages the skin, which, in turn, aggravates the itch symptom. Moreover, pleasurability induced by 
scratching can encourage this behavior. Thus, it is important to understand the cerebral mechanism 
of scratching and its pleasurability in chronic itch patients. In this study, we addressed this issue with 
10 chronic itch patients and 10 healthy controls using arterial spin labeling (ASL) functional mag-
netic resonance imaging. The itch sensation was evoked by applying cowhage to the right forearm. 
Scratching significantly attenuated the itch sensation, and evoked a pleasurable sensation in both 
the chronic itch and healthy control groups. Interestingly, the intense pleasurability was induced by 
scratching in the chronic itch group, regardless of whether the skin was itching. This did not occur in 
the healthy group. Analysis of ASL brain activity data have demonstrated that the reward system plays 
a crucial role in scratching-induced pleasurability. We also observed overactivity in brain regions 
related to motor control and motivation to act, including the supplementary motor area, premotor 
cortex, primary motor cortex and midcingulate cortex, as well as the caudate nucleus involved in 
the reward system in the chronic itch group compared with the healthy control group. This over-
activity may explain the pathological scratching behavior observed in chronic itch patients. These 
findings advance our understanding of pathophysiological mechanism of scratching in chronic itch.   
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VEGF-A and PlGF are involved in progression of cutaneous T-cell lymphoma
T Miyagaki, M Sugaya, T Oka, N Takahashi, M Kawaguchi, H Suga, H Fujita and S Sato 
Dermatology, The University of Tokyo, Tokyo, Japan
Angiogenesis is regarded as an important step to support primary and metastatic tumor growth. 
In cutaneous T-cell lymphoma (CTCL) such as mycosis fungoides (MF) and Sézary syndrome (SS), 
angiogenesis in lesional skin is increased, suggesting that interaction between tumor cells and their 
microvasculature occurs during the progression. Consistently, we have previously reported increased 
expression of angiogenin and angiopoietin-2, both of which are angiogenic factors, in the skin lesion 
and blood of patients with erythrodermic MF/SS. Vascular endothelial growth factor (VEGF)-A and 
placental growth factor (PlGF) are members of the VEGF family. The former binds to VEGF receptor 
(VEGFR)1 and 2, while the latter binds only to VEGFR1. In this study, we investigated expression 
of these growth factors in MF/SS patients. We first revealed that VEGF-A mRNA expression levels 
in CTCL lesional skin (plaque MF, tumor MF, or erythrodermic MF/SS) were increased compared 
to those in normal skin. Patients with erythrodermic MF/SS had significantly elevated serum levels 
of VEGF-A, which significantly correlated with those of IgE and nerve growth factor as well as itch 
intensity measured by a visual analogue scale. Next, we found that skin lesions of tumor MF and 
erythrodermic MF/SS contained increased mRNA levels of PlGF, which positively correlated with 
those of CTACK, a chemokine mediating migration of skin-homing T cells. Serum PlGF levels in 
patients with tumor MF and erythrodermic MF/SS were also significantly higher than those of con-
trols. There was a significant positive correlation between serum levels of PlGF and those of TARC 
and angiopoietin-2, which are both associated with disease severity. Moreover, local administration 
of exogenous PlGF enhanced subcutaneous EL4 lymphoma growth in C57BL/6 mice. Our study has 
suggested that VEGF-A is involved in erythrodermic MF/SS having a strong association with pruritus 
and that PlGF plays an important role in progression of MF/SS.    
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Clinical and microbiological healing of onychomycosis after three sessions of 40% urea plus 
methyl-aminolevulinate-photodynamic therapy (PDT) versus 40% urea plus placebo-PDT: 
A multicenter, randomized, controlled, phase 3 clinical trial
Y Gilaberte,1 P Robres,2 C Aspiroz,2 MP Frias,1 J Vera-Alvarez,3 I Garcia-Doval4 and 
A Rezusta5 1 Dermatology, Hospital San Jorge, Huesca, Spain, 2 Microbiology, Hospital 
Royo Villanova, Zaragoza, Spain, 3 Pathology, Hospital San Jorge, Huesca, Spain, 4 Research 
Unit of Spanish Academy of Dermatology and Venereology Foundation, Madrid, Spain and 
5 Microbiology, University Hospital Miguel Servet, Zaragoza, Spain
Onychomycosis is a fungal nail infection with poor therapeutic outcome. Different case reports 
have shown promising results using methyl-aminolevulinate photodynamic therapy (MAL-PDT) to 
treat onychomycosis. A multicentre, randomized, placebo-controlled clinical trial was performed. 
Patients both clinically and microbiologically diagnosed with onychomycosis were included in 
the study. Most of the onychomycosis were on the feet and dermatophytes, T. rubrum, were the 
fungi most frequently isolated.They were randomized to either 3 sessions, of MAL-PDT (Metvix 3 
h and irradiation with Aktilite 37 J.cm-2) or placebo PDT (pPDT) (irradiation only). Nail plates were 
softened with 40% urea ointment before PDT sessions. Clinical (evaluated by Onychomycosis 
Severity Index) and microbiological efficacy was blindly evaluated. Additionally, impact of the 
onychymycosis on quality of life (OQLI) was assessed. Forty patients were recluted, 22 received 
MAL-PDT and 18 pPDT. After 9 months of follow-up, 4 patients (18.18%) with MAL-PDT and 1 
(5.56%) with pPDT were clinically cured (p=0.23). 40.91% of patients reach OSI>75 with MAL-PDT 
and only 16.67% with pPDT (p=0.096). Seven (31.82%) and 2 patients (11.11%) respectively were 
microbiologically cured (p=0.178). Both treatments increase OQLI (9.09 with MAL-PDT and 5.53 
with pPDT, p=0.604). No significant side effects were reported. MAL-PDT was not more effective 
than placebo PDT to treat onychomycosis after 48 weeks of follow-up. However, the superior clin-
ical and microbiological results of the former support further studies to establish which subgroups 
of patients could benefit of this treatment.    
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Comparisons between ultraviolet B radiation and oral vitamin D supplementation for the 
treatment of vitamin D deficiency
D Kim1, 2, J Kim,1 JL Harden,1 M Sullivan-Whalen,1 P Gilleaudeau,1 JM Corrêa da Rosa,1 
M Suarez-Farinas,1 J Breslow,3 JG Krueger,1 M Lowes1, 4 and M Ponda3 1 Laboratory for 
Investigative Dermatology and the Center for Clinical and Translational Science, The 
Rockefeller University, New York, NY, 2 School of Medicine, Stony Brook University, 
Stony Brook, NY, 3 Laboratory of Biochemical Genetics and Metabolism, The Rockefeller 
University, New York, NY and 4 Division of Dermatology, Montefiore Medical Center, Albert 
Einstein College of Medicine, Bronx, NY
Recent clinical trial data challenge the notion that oral vitamin D supplementation mimics the ben-
efits associated with higher 25-hydroxyvitamin D levels found in observational studies, particularly 
with respect to the lipid profile and biomarkers of inflammation. Here, we compare the effects of 
narrow-band Ultraviolet B (UVB) exposure and oral vitamin D3 supplementation on immune- and 
cholesterol-related gene expression. Subjects were a sub-sample of an open-label, randomized 
trial, where vitamin D deficient participants received either UVB (n=8) or oral vitamin D3 (n=10) 
over 8 weeks. Skin biopsies and peripheral blood were obtained from each patient at baseline and 
post-repletion, and gene expression was analyzed using RT-PCR for skin biopsies and RNA sequenc-
ing for peripheral blood. RT-PCR revealed a decrease in IL-12 expression and an increase in IL-13 
expression in UVB-repleted skin compared to oral vitamin D3-repleted skin, and an upregulation of 
key lipid metabolism genes (DHCR7, APOE, LDR, CYP7A1, ABCA1, CYP51A1) in UVB-repleted skin 
compared to downregulation of these genes in oral vitamin D-repleted skin. APOE gene expression 
was significantly increased in UVB-repleted patients compared to oral vitamin D-repleted patients, 
both in skin (p = 0.025) and in blood (p = 0.003). These findings suggest that although both oral and 
UVB routes of repletion can correct vitamin D deficiency, the health benefits of vitamin D associated 
with cholesterol levels may not be obtained if repleted orally rather than through UVB exposure.   
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Granuloma annulare in patients with cutaneous B-cell lymphoma 
JM Donigan and JB Carter Dermatology, Massachusetts General Hospital, Boston, MA
Granulomatous inflammation in association with lymphoma is well-characterized; however, the 
relationship between primary cutaneous B-cell lymphoma (CBCL) and granuloma annulare (GA) 
remains unclear. We studied the features of seven patients with GA and CBCL. In this retrospective 
study, the clinical history, pathology reports, treatment, and follow-up information were reviewed. 
There were three cases of primary cutaneous follicle center lymphoma, three cases of primary 
cutaneous marginal zone lymphoma, and one case of cutaneous diffuse large B-cell lymphoma. 
The mean age at diagnosis of GA was 60 years (range 48-82). Four of the patients were male. In 
four cases, the diagnosis of lymphoma preceded that of GA (range 1-17 years). Two patients were 
diagnosed with GA and CBCL simultaneously with one of them having findings of both diagnoses 
in the same biopsy. In the final case, the diagnosis of GA preceded that of lymphoma by two years. 
Three patients had a typical clinical presentation with localized, asymptomatic, annular lesions 
responsive to treatment. One patient had localized lesions with an unknown response to treatment. 
The other three patients had atypical presentations with generalized lesions in two patients, and all 
three refractory to treatment. These findings suggest that some cases of GA in patients with CBCL 
may simply be coincidental given the extended period of time between the diagnosis of GA and 
lymphoma. Thus, the development of unusual skin findings in a patient with known CBCL may 
merit repeat biopsy given that these findings may be GA and not necessarily lymphoma. In addition, 
GA that presents with atypical clinical manifestations such as generalized lesions or resistance to 
treatment may warrant further work-up for CBCL including skin biopsy with immunohistochemical 
studies and analysis of immunoglobulin heavy chain (IgH) gene rearrangements.    
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High-throughput sequencing of T cell receptors (TCRs) in human skin shows a polyclonal T 
cell response to diphencyprone (DPCP)
N Gulati,1 D Hamm,2 JL Harden1 and JG Krueger1 1 The Rockefeller University, New York, 
NY and 2 Adaptive Biotechnologies, Seattle, WA
DPCP is a hapten that induces prototypic delayed-type hypersensitivity (DTH) reactions in human 
skin upon conjugation with endogenous proteins, and is used as a treatment for alopecia areata, 
warts, and cutaneous melanoma metastases. Yet, the antigen(s) responsible for the inflammation 
induced by DPCP are unknown. High-throughput sequencing of the TCRB CDR3 region using the 
immunoSEQ platform is a robust new tool for comprehensive evaluation of the entire repertoire 
of T cells in a specimen and quantification of T cell clonality. In this study, TCR deep sequencing 
was performed on genomic DNA derived from skin biopsies of 3 healthy volunteers (open label 
design) who were sensitized to topical DPCP. Biopsies were taken of DPCP-challenged skin at 3 
(classic DTH peak response), 14, and 120 days after challenge as well as placebo-treated skin. On 
average, the following numbers of productive unique TCR sequences were found: placebo-treated 
(309), day 3 (3,948), day 14 (2,754), and day 120 (302). All samples were diverse with a median 
clonality of 0.093 on a scale of 0 (each clone appears only once) to 1 (only one clone found). The 
numbers of productive unique sequences varied substantially among the 3 volunteers, and there 
were few sequences in common among the volunteers. Also, certain clones expanded at day 3 and 
persisted through day 120, such that day 120 samples had a distinct repertoire from placebo-treated 
skin despite the inflammation being fully resolved. This suggests that DPCP leads to formation 
of many unique antigens that are not necessarily shared between different individuals. This also 
indicates that many T cell clones not normally present in skin are recruited upon DPCP challenge 
and persist even past the peak inflammatory response as putative long-lived skin resident effector 
memory T cells. Our data may have therapeutic implications for the use of DPCP in melanoma, as 
each patient treated with DPCP could expand a unique repertoire of T cells targeted against his or 
her specific tumor-associated antigens.    
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The microbiome of patients with atopic dermatitis has deficient antimicrobial function
T Nakatsuji,1 T Hata,1 A Two,1 K Chun,1 P Kotol,1 A Bouslimani,2 H Latif,4 A Lockhart,3 
K Artis,3 G David,3 P Taylor,5 J Strieb,5 P Dorrestein,2 K Zengler,4 D Leung5 and RL Gallo1 1 
Dermatology, UC San Diego, San Diego, CA, 2 Pharmacology, UC San Diego, San Diego, 
CA, 3 Rho Federal Systems Division, Inc, Chapel Hill, NC, 4 Bioengineering, UC San Diego, 
San Diego, CA and 5 Pediatrics, NJH, Denver, CO
Patients with atopic dermatitis (AD) have recurrent skin infections by Staphylococcus aureus (SA) 
and dysbiosis of their cutaneous microbiome. The increased susceptibility to SA has been associ-
ated with diminished innate immune defense including abnormal barrier function and decreased 
induction of antimicrobial peptides (AMPs) such as cathelicidin and β-defensins. In this study, we 
hypothesized that the dysbiosis of the skin microbiome may also explain the increased susceptibility 
of AD patients to infection. We conducted high-throughput screening for antimicrobial activity on 
over 7500 individual isolates of coagulase-negative Staphylococcus (CoNS) cultured from the skin 
swabs of 30 healthy control subjects and 50 lesional and nonlesional sites of AD patients. Healthy 
subjects had a high frequency of CoNS isolates with antimicrobial activity (75.26±6.59%) but the 
bacteria isolated from AD nonlesional and lesional skin had significantly less activity [22.83±5.10%, 
15.76±4.10%, respectively (p<0.0001)]. Notably, only subjects with a low frequency of antimicro-
bial CoNS isolates were also colonized by SA. 16S rRNA sequencing revealed that antimicrobial 
activity was detected in diverse strains of CoNS, such as S. epidermidis, hominis, warneri, capitis. 
We identified two novel prokaryotic AMPs (3152.2Da and 3550.7Da), produced by one represen-
tative CoNS isolate (S. hominis) using HPLC, protein sequencing by MALDI-TOF-MS2 and genome 
sequencing. Application of this antimicrobial CoNS isolate to mouse skin colonized by SA was 
effective in reducing SA survival by >90% above that seen when AD CoNS strains were applied. 
These data show for the first time that the microbiome is the first line of defense against SA and that 
dysbiosis in AD has a major functional association to SA colonization.    
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Pembrolizumab treatment: Cutaneous adverse events and correlation with disease progression 
I Vujic1, 2, M Sanlorenzo1, 4, M Vujic,2 A Daud,3 A Algazi,3 M Gubens,3 SA Luna,1 K Lin,1 
P Quaglino,4 K Rappersberger2 and S Ortiz-Urda1 1 Dermatology, University of California, 
San Francisco, San Francisco, CA, 2 Dermatology, Rudolfstiftung Hospital, Vienna, Austria, 
3 University of California, San Francisco, San Francisco, CA and 4 Department of Medical 
Sciences, Section of Dermatology, University of Turin, Turin, Italy
We expect that more patients will receive immunomodulatory cancer treatments such as the 
anti-PD-1 drug MK-3475 (pembrolizumab) in the near future. The purpose of this study is to describe 
cutaneous adverse events (AE) and their possible correlation with treatment response. We reviewed 
charts from cancer patients who were treated with MK-3475 in two different clinical trials at Uni-
versity of California, San Francisco. We included all patients who received at least one cycle of 
MK-3475 and had at least one follow-up visit. We included 83 patients in our study. The median 
follow up was 15 weeks (range-2-105 weeks). Thirty-five patients (42.2%) developed cutaneous AE 
attributed to MK-3475. The most common cutaneous AE were maculo-papular rash (n=24), pruritus 
(n=10) and hypopigmentation (n=7). All seven patients who developed hypopigmentation were 
treated for melanoma. There were no grade 4, and two patients had grade 3 cutaneous AE. Survival 
analyses showed that patients who developed cutaneous SE had significantly longer progression free 
intervals compared with patients who did not develop cutaneous AE. MK-3475 shows a favorable 
cutaneous safety profile. The development of cutaneous AE, especially of hypopigmentation in 
melanoma patients, could be a positive prognostic sign.    
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Skin histopathology from patients with X-linked recessive ichthyosis and autosomal recessive 
congenital ichthyosis with transglutaminase 1 mutation
C Yang,1 H Pomerantz,2 J Corwin,3 MA Weinstock,2 P Fleckman,4 JJ DiGiovanna5 and 
L Robinson-Bostom1 1 Dermatology, Alpert Medical School of Brown Univ, Providence, 
RI, 2 Dermatoepidemiology, VA Medical Center, Providence, RI, 3 Dermatology, Vacaville 
Medical Center, Vacaville, CA, 4 Dermatology, Univ of Washington, Seattle, WA and 5 
Dermatology, CCR, NCI NIH, Bethesda, MD
Clinical and histologic features of X-linked recessive ichthyosis (XLRI) and autosomal recessive 
congenital ichthyosis (ARCI), especially the lamellar phenotype, overlap and their precise histologic 
characterization has been elusive. In this cross-sectional study, we sought to characterize better 
the histologic features by systematically reviewing all obtained biopsies from the National Registry 
for Ichthyosis and Related Skin Disorders, blinded to clinical information. All 117 slides from 111 
patients were evaluated for the presence of specific features in the epidermis, dermis, and adnexal 
structures, and then graded on a scale of 0 (none) to 3 (severe). Subsequently, we compared these 
observations with Registry clinical and laboratory information. We identified 8 patients with XLRI 
confirmed by elevated serum cholesterol sulfate and 9 patients with ARCI who had transglutaminase 
1 gene mutations (ARCI-TGM1). Compared to XLRI patients, ARCI-TGM1 patients had a thicker 
granular layer (3.0 vs 1.8 layers; p=0.02), more severe acanthosis (1.1 vs 0.2; p=0.05), more severe 
psoriasiform hyperplasia (0.6 vs 0; p=0.04), and more mitoses (p=0.04). The stratum corneum in 
both XLRI and ARCI-TGM1 slides were similar, with mild to moderate hyperkeratosis (1.1 and 1.8, 
p>0.05), compact orthokeratosis, and focal parakeratosis. All biopsies had mild lymphohistiocytic 
dermal infiltrate. We observed no difference in the presence or appearance of adnexal structures 
between XLRI and ARCI-TGM1. While the skin histopathology of patients with laboratory confirmed 
XLRI and ARCI-TGM1 may be similar, certain features including involvement of the granular layer, 
degree of acanthosis and psoriasiform hyperplasia, and frequency of mitoses may be useful in 
distinguishing between them.    
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Improved survival among Merkel cell carcinoma patients with either an unknown primary 
lesion or viral oncoprotein antibodies
CW Lewis,2 N Vandeven,3 KG Paulson1 and P Nghiem2, 4 1 Dept of Medicine, U of WA, 
Seattle, WA, 2 Div of Dermatology, Dept of Medicine, U of WA, Seattle, WA, 3 Dept of 
Pathology, U of WA, Seattle, WA and 4 Fred Hutchinson Cancer Research Center, Seattle, 
WA
Merkel cell carcinoma (MCC) is a rare, neuroendocrine cancer recently associated with the Merkel 
cell polyomavirus. Prior studies have shown that patients who present with a clinically apparent 
nodal metastasis (stage IIIB) and no detectable primary lesion have improved survival as compared 
to those with a primary lesion, but the basis of this association is unknown. We analyzed 103 stage 
IIIB patients (246 person-years of follow-up time; median 677 days). 89 were also tested for viral 
oncoprotein antibodies that can be used to detect MCC recurrence. Multivariate survival analyses 
were performed that controlled for immune suppression and sex, known prognostic factors. Among 
stage IIIB MCC patients, those who presented without a primary lesion (n=61) had improved recur-
rence-free survival (Haz. ratio 0.39, p<0.01) and MCC-specific survival (Haz ratio 0.41, p=0.02). 
Strikingly, 0 of 11 patients with profound immune suppression (i.e. CLL, HIV) presented without 
a primary lesion (p<0.01 when compared with immune competent patients). Unknown primary 
lesions may result from an immune response that eliminated an undetected skin lesion. Oncoprotein 
sero-positivity (present in 55% of IIIB patients) was associated with improved MCC-specific survival 
among patients with a known primary lesion (Haz. ratio 0.21, p=0.04); no effect of sero-status 
was found among those without a primary lesion. These results suggest that either an unknown 
primary lesion or oncoprotein sero-positivity indicate a “protective immune response,” not merely a 
competent immune system. An unknown primary or oncoprotein sero-positivity could also identify 
patients with a higher likelihood of a favorable response to emerging immune therapies. Patients 
with a known primary lesion who do not make oncoprotein antibodies are at higher risk and should 
be monitored particularly closely.    
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Specific quality of life questionnaires for the evaluation of cosmetic products: an essential tool
C de Belilovsky,1 N Lachmann,2 B Chadoutaud3 and C Baudouin2 1 Institut Alfred Fournier, 
Paris, France, 2 Laboratoires Expanscience, Epernon, France and 3 Clinreal, Toulouse, France
Improvement of Quality of Life (QoL) is a natural goal of cosmetic products. That is why validated 
QoL questionnaires have been included in our clinical evaluations of cosmetic products since many 
years. VQ dermato has been used in order to evaluate the contribution of a lipidic emulsion in the 
management of acne patients under isotretinoin treatment, the efficacy of a new molecule in face 
and scalp hyper-seborrhoea and the impact of rosacea on QoL. IDQOL and DFI have been used for 
two studies concerning pediatric Atopic Dermatitis (AD), MELASQOL for melasma and lentigo and 
the general MO-SF36 for post-partum overweight nutraceutical tablets. The negative impact of acne 
on QoL of young adults has been confirmed. The specific emulsion improved by 28.8% all criteria. 
For scalp and face hyper-seborrhoea, VQ dermato demonstrated the efficacy of the new molecule 
on 5 items. For rosacea, self-perception, mood and physical discomfort were mostly affected. For 
AD, the decrease of the quotations in the first study was significantly more pronounced in the groups 
with emollients + steroids (-73%) than in the groups with steroids alone (-52%). In the second 
study, the emollient applied on the entire body improved much more QoL than steroids applied 
on AD lesions. Melasma affects more deeply QoL than lentigo: 509 vs 156. QoL was statistically 
improved by the tested product: -12.3% for lentigo and -16.6% for melasma. Lastly, Mos-SF36 
could distinguish impacts on physical and mental QoL alterations of a post-partum nutraceutical 
product (-6% vs -14.6%). We have confirmed that several skin problems alter the Qol of affected 
subjects and of their family. We also showed that cosmetic products play a prominent role in the 
improvement of the QoL. Specific questionnaires may give light to a profound discrepancy between 
visible cutaneous results and consequences on the everyday life of the subjects.    
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Ethnic comparison study to understand spreading mechanism of psoriasis
J Kim,1 C Oh,2 J Jeon,2 Y Baek,2 J Ahn,2 D Kim1, 3, JM Corrêa da Rosa,4 M Suarez-Farinas,4 
M Lowes5, 1 and JG Krueger1 1 Laboratory for Investigative Dermatology, The Rockefeller 
University, New York, NY, 2 Department of Dermatology, Korea University, Seoul, Korea 
(the Republic of), 3 School of Medicine, Stony Brook University, Stony Brook, NY, 4 The 
Center for Clinical and Translational Science, The Rockefeller University, New York, NY and 
5 Division of Dermatology, Montefiore Medical Center, Albert Einstein College of Medicine, 
Bronx, NY
To understand the mechanisms of how psoriasis plaques enlarge, as well as how psoriasis progresses 
from cutaneous to systemic disease, we conducted phase V clinical research comparing small and 
large plaque psoriasis in Korean and Western populations. “Small plaque psoriasis” is the typical 
form of psoriasis that occurs in adults in Korea and other Asian countries. As more severe psoriasis is 
associated with systemic comorbidities, by comparing mild-to-moderate (mean PASI 7) versus severe 
(mean PASI 25) psoriasis groups we could study how psoriasis skin disease progresses to systemic 
disease. Lesional and non-lesional skin biopsies were collected from Korean psoriasis patients living 
in Seoul, Korea (n=59) and Western psoriasis patients living in New York, NY (n=21), and analyzed 
by immunohistochemistry, Affymetrix hgu133plus2 chips and RT-PCR. CD11c+ dendritic cells in the 
dermal papillary area were most significantly correlated with thickness of psoriatic plaque, suggest-
ing that dendritic cells may have a role in local plaque spreading. IL17A and IL17A-related pro-in-
flammatory cytokines (IL1B, IL8, IL20) appeared to drive local plaque spreading, while DEFB103B 
was increased in severe psoriasis, suggesting a role for this IL-17A-regulated keratinocyte cytokine in 
systemic disease. Furthermore, reduced expression of regulatory genes (FAS, FoxP3, CTLA4, PD-L1, 
CD69) was associated with more severe psoriasis. Gene set variation analysis revealed that psoriatic 
comorbidity pathways were enriched only in more severe psoriasis. These results emphasize the 
potential role of IL17A in the initiation and local spreading of psoriasis plaques, and the role of 
regulatory genes in systemic spreading of psoriasis.    
199
Non-melanoma skin cancers are associated with blood expansion of DC-HIL+ myeloid-derived 
suppressor cells (MDSC)
AP Word, J Chung, T Vandergriff, DB Harker, K Ariizumi and PD Cruz Dermatology, 
University of Texas-Southwestern, Dallas, TX
MDSC are the most potent suppressors of T-cell function and they proliferate exponentially during 
cancer progression. We discovered melanoma to induce MDSC expression of DC-HIL, responsible 
for these cells’ immunosuppressive function. Using the CD14+HLA-DRno/low phenotype to mark 
MDSC in humans, we showed: (1) strong positive correlation between worsening clinical stage of 
melanoma and % DC-HIL+ MDSC among peripheral blood mononuclear cells (PBMC); (2) quick 
decline in this blood level after surgical resection of early melanoma; and (3) restoration by anti-DC-
HIL mAb of reduced T-cell interferon-gamma response associated with melanoma to near-normal 
levels. To determine whether the deleterious relationship between melanoma and DC-HIL+ MDSC 
applies to non-melanoma skin cancer (NMSC), we employed flow cytometry to assay % DC-HIL+ 
MDSC in PBMC from 17 and 20 patients, respectively, with squamous cell carcinoma (SCC) and 
basal cell carcinoma (BCC) at the time of their surgical removal. Compared to 21 healthy controls 
(0.09% ± 0.02), blood DC-HIL+ MDSC were significantly higher for SCC (1.65 ± 1.28) and for 
BCC (1.71 ± 1.81) (p < 0.0001 using ANOVA). There were no significant differences in DC-HIL+ 
MDSC levels with respect to tumor surface area, depth, or body site. However, after quantifying 
the lymphohistiocytic infiltrate in SCC and BCC biopsy specimens into sparse, moderate, or dense, 
trends toward significance were documented, with higher % blood DC-HIL+ MDSC for patients 
with dense vs. sparse inflammatory infiltrate (p = 0.19 using paired T test for both SCC and BCC). 
Thus, like melanoma, NMSC is associated with proliferation of blood DC-HIL+ MDSC. Our new 
findings also suggest expansion of these immunosuppressive cells is regulated by the degree of 
inflammation triggered by the malignancy.    
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Epidermolysis bullosa acquisita (EBA) mimicking dystrophic epidermolysis bullosa (EB): 
Importance of interrogation of potential splice site
E Lilly, KA Choate and M Tomayko Dermatology, Yale University, New Haven, CT
A 55-year-old woman with pseudosyndactaly of bilateral hands, esophageal strictures requiring 
a gastric feeding tube, and continued intermittent bullae was evaluated for dystrophic EB. She 
reported onset of bullae at age 12, and denied family history (12 siblings and 5 children were 
unaffected). Whole exome sequencing did not detect any known mutations of EB, but the patient 
carried a synonymous COL7A1 c. 7191 C>A single nucleotide variation (SNV) near the 5’ end of 
exon 94, which resulted in a CAG motif. We inferred this could create a cryptic splice acceptor, 
and result in a dystrophic EB phenotype. To assess the impact of this variant on mRNA splicing, 
we generated a primary keratinocyte cell line from the patient, and isolated RNA. Alternative 
splice products were assessed by reverse transcription with oligo(dT) priming followed by PCR 
with COL7A1 specific primers. The splice site assay did not demonstrate alternative expression 
of COL7A1. H&E showed a subepidermal blister, dermal eosinophils, and dermal fibrosis. DIF 
demonstrated 3+ linear deposition of IgG and 1+ deposition of C3 along the blister floor on salt split. 
Electron microscopy (EM) found junctional separation with accumulation of amorphous material 
and decrease in anchoring fibrils. Immunomapping showed normal intensity staining of collagen 
VII. Serum levels of antibodies to BP180 and BP230 were negative, but antibodies levels to Type 
VII collagen were high (36.6 ELISA units/mL). Despite the clinical phenotype most consistent with 
severe generalized recessive dystrophic EB, whole exome sequencing did not reveal any recessive 
mutations. Interrogation of a heterozygous COL7A1 SNV confirmed it was not a splice site that 
potentially could have been a novel mutation for dominant dystrophic EB. DIF on salt split skin 
and serum anti-collagen VII levels were consistent with EBA. Thus, this represents a rare case of 
childhood EBA, which uncontrolled, led to a severe clinical phenotype. The patient was initiated 
on dapsone with improvement in pruritus.    
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Improved survival in metastatic melanoma is associated with immune genes expressed at 
the site of disease
RD Lardone, SB Plaisier, PA Sieling and DJ Lee Dirks/Dougherty Laboratory for Cancer 
Research, John Wayne Cancer Institute, Santa Monica, CA
Metastatic melanoma (MM) has a median survival rate of less than one year. Thus, a more thor-
ough knowledge of biological factors linked to MM survival should direct more effective outcome 
prediction and therapy development. To increase the sensitivity of finding conserved gene expres-
sion signatures, we used Rank-Rank Hypergeometric Overlap analysis (RRHO), a threshold-free 
algorithm that compares two independent high-throughput gene expression profiles and identifies 
an overlapping gene set with greatest statistical significance. RRHO uses genome wide compari-
sons based on ranked gene expression changes instead of raw expression values or fold-changes, 
which are more responsive to experimental differences between patient studies. We performed 
RRHO pairwise comparisons of three independent, publicly available MM gene expression profiles, 
examining common signatures in outcome/survival gene expression. Comparing groups based on 
patient outcome, pairwise RRHO comparisons showed no statistically significant overlap of genes 
overexpressed in tumors from patients with poor survival/outcome. In contrast, we found overlap 
among genes overexpressed in favorable outcome groups (number of overlapping genes/hypergeo-
metric overlap p-values: 394/10-19; 1423/10-57; 887/10-89). Pathways analysis of each overlapping 
gene list showed immune function was repeatedly the predominant functional group enriched in 
favorable outcome; 228 genes coincided on all three overlapping gene lists. In fact, the expression 
of this subset of 228 genes in an independent set of Stage III MM tumors correctly predicted clinical 
outcome in 12/14 patients. We also used Gene Enrichment Profiler to analyze the 228 genes for 
enrichment of specific cell signatures. Surprisingly, B cell-associated genes were enriched in those 
MM subjects with favorable outcomes, in addition to T and NK cell-associated genes. This cross-
study analysis suggests the power of the RRHO approach and indicates a role for anti-melanoma 
immunity in MM survival.    
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The incidence of herpes zoster in cutaneous lupus erythematosus (CLE), dermatomyositis 
(DM), pemphigus vulgaris (PV) and bullous pemphigoid (BP) 
ES Robinson1, 2, AS Payne,2 L Pappas-Taffer1, 2, R Feng,3 J Okawa1, 2 and V Werth1, 2 1 PVAMC, 
Phila, PA, 2 Dept of Derm, UPenn, Phila, PA and 3 Dept Biostatistics and Epidemiology, 
UPenn, Phila, PA
Herpes zoster (HZ) is characterized by a painful, vesicular, dermatomal rash. This study determined 
the incidence of HZ in 186 CLE, 103 DM, 84 PV and 44 BP patients seen in the practices of three 
dermatologists at the University of Pennsylvania. Patients were asked about their history of zoster 
during normal office visits. If positive, the zoster history was confirmed in the electronic medical 
record. The incidence of HZ was 29.5 in CLE (mean age±SD 46.1±14.9), 55.4 in DM (mean age±SD 
52.2±14.5), 18.6 in PV (mean age±SD 51.8±13.5) and 10.2 in BP (mean age±SD 71.4±11.8). In 
comparison, the incidence of HZ in the U.S. population is 2.1 in persons 40-49 years old, 4.2 
in 50-59 year olds and 8.6 in 70-79 years olds. Per patient report 36.1% (13/36) of CLE, 38.2% 
(13/34) of DM, 11.5% (3/26) of PV and 17.9% (5/28) of BP patients 60 years old or older had been 
vaccinated against HZ. 56.3% (9/16) of CLE, 62.5% (10/16) of DM, 100% (5/5) of PV and 100% 
(1/1) of BP patients with HZ were on immunosuppressive treatments and/or systemic steroids com-
pared to 46.5% (79/170) of CLE, 69.0% (60/87) of DM, 83.3% (65/78) of PV and 81.4% (35/43) of 
BP patients who did not have HZ. 87.5% (14/16) of both CLE and DM patients who had HZ were 
on antimalarials therapies for their disease, which was similar to the 88.2% (150/170) of CLE and 
82.8% (72/87) of DM patients without HZ on antimalarials. In the one year prior to their HZ episode 
9.1% (1/11) of CLE and 64.3% (9/14) of DM subjects were lymphopenic. Of the 62 DM patients 
with no history of HZ and a lymphocyte count in the past year, 41.9% (n=26) were lymphopenic. 
The incidence of HZ in CLE and DM is likely increased compared to the average U.S. population. 
Classic immunosuppressive medications, antimalarial therapies and lymphopenia may play a role 
in the high incidence of HZ in CLE and, particularly, in DM.    
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Psoriasis area severity index score positively associates with vascular inflammation by FDG 
PET/CT
HB Naik1, 2, B Natarajan,2 T Salahuddin,2 Q Ng,2 J Doveikis,2 M Playford,3 B Lockshin,3 
M Kaplan,4 J Gelfand5 and NN Mehta2 1 Dermatology Branch, National Cancer Institute, 
Bethesda, MD, 2 Section of Inflammation and Cardiometabolic Diseases, National Heart, 
Lung and Blood Institute, Bethesda, MD, 3 DermAssociates, Silver Spring, MD, 4 Systemic 
Autoimmunity Branch, National Institute of Arthritis, Musculoskeletal and Skin Diseases, 
Bethesda, MD and 5 Department of Dermatology, University of Pennsylvania, Philadelphia, 
PA
Psoriasis is associated with cardiovascular (CV) diseases, and severe psoriasis has been associated 
with increased risk of major cardiac events and CV death. However, data on the relationship 
between psoriasis severity and vascular disease is sparse. We hypothesize that psoriasis severity is 
directly associated with vascular inflammation measured by fluorodeoxyglucose positron emission 
tomography computed tomography (FDG PET/CT). Clinical and laboratory measures of inflammation 
were evaluated in 70 consecutive adult psoriasis patients (NCT01778569). Psoriasis severity was 
measured by psoriasis area severity index (PASI) score. Arterial inflammation was measured by 
average aortic target-to-background ratio (avTBR) using FDG PET/CT. Mean age was 52 years (SD 
13), with slight male predominance (56%). Body mass index (BMI) was consistent with overweight 
cohort population (mean 29.7, SD 5.8) and dyslipidemia was prevalent (67%). The risk for CV 
disease was low by Framingham Risk Score (FRS) estimation (median 4, IQR 3-7). PASI score was 
consistent with mild psoriasis (median 5.15, IQR 3-8.5). PASI score positively associated with aortic 
avTBR (β=0.35, p<0.01) after adjusting for demographic risk factors (RFs) (β=0.33, p<0.01) plus 
traditional CV RFs (β=0.26, p=0.01) plus BMI (β=0.19, p=0.04). PASI score added incremental value 
in predicting vascular inflammation beyond FRS (χ2 5.91, p=0.02) and high sensitivity C-reactive 
protein (χ2 4.11, p=0.04) in nested models adjusted for traditional CV RFs. In this study, we show 
that psoriasis severity was associated with vascular inflammation beyond traditional CV RFs and 
BMI, suggesting psoriatic skin inflammation may accelerate atherogenesis.    
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DERMO; An ontology for the description of dermatologic disease
HM Fisher,1 R Hoehndorf,2 SS Dadras,3 LE King,4 GV Gkoutos,5 JP Sundberg6 and 
PN Schofield1 1 Physiology Development and Neuroscience, University of Cambridge, 
Cambridge, United Kingdom, 2 Computer Science, KAUST, Thuwal, Saudi Arabia, 3 
Dermatology and Genetics/Developmental Biology, University of Connecticut, Farmington, 
CT, 4 Dept. of Medicine, Div. Dermatology, Vanderbilt University, Nashville, TN, 5 Dept. of 
Computer Science, Aberystwyth University, Aberyswyth, United Kingdom and 6 The Jackson 
Laboratory, Bar Harbor, ME
The ability to capture diagnostic information on disease using standardised terminologies has always 
been critical for integration and analysis of patient data . This need is now made greater by the new 
approaches to computing on disease information and the advent of personalised medicine. There 
have been many initiatives to generate structured terminologies to accurately capture skin disease 
diagnoses, but the available tools, such as ICD-10, remain blunt instruments in the face of the need 
for precision phenotyping, and are unsuitable for many types of computation-based research. The 
most recent terminology, DermLex, is excellent but not designed for semantic computation and is no 
longer supported. We have created an ontology, DERMO, which can be used for the coding of diag-
noses from patients and non-human model organisms. It is a simple hierarchy and currently contains 
3425 classes. These are mapped to other major terminologies, such as DermLex, UMLS, ICD9, and 
provided with synonyms and we intend to map to ICD-11. Disease entities are categorized into 18 
upper level classes which use a variety of features such as anatomical location, heritability, affected 
cell or tissue type, or etiology, as the features for classification. The ontology is available in OBO 
format from the project web site http://dermatology.googlecode.com/. The applications of DERMO 
are equally to patient care, clinical training and fundamental research. It will support automated 
inference and reasoning and can be used to support algorithms for patient stratification, genotype/
phenotype studies, and for the broader integration of skin disease information with that from other 
domains, such as model organism phenotypes and pharmacogenomics, for translational science.   
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Augmented cowhage-induced itch and altered papillary dermal peptidgeric innervation in 
uremic pruritus
T Du,1 J Bhatia2 and D Wolpowitz1 1 Dermatology, Boston University, Boston, MA and 2 
Medicine, Section of Nephrology, Boston University, Boston, MA
Uremic pruritus (UP) arises in end-stage renal disease (ESRD). While the pathogenesis of UP is not 
well understood, UP responds poorly to anti-histamines. We performed a case-control study to test 
if cutaneous protease-mediated, non-histamine itch is augmented in UP, and if UP is associated 
with altered epidermal and/or papillary dermal innervation. We recruited 12 hemodialysis subjects 
with ESRD-specific itch (UPS) (VAS-itch in the preceding week [VAS-week], 78/100), and 13 age- 
and sex-matched hemodialysis subjects without pruritus (controls) (VAS-week, 0/100; p<0.0001 
vs UPS). Cowhage spicule-induced itch was induced in the back, and the entire duration of itch 
was measured on the general Labeled Magnitude Scale. Subsequently, a punch biopsy was taken 
from this sensory-tested skin and multi-label immunohistochemistry was performed to measure 
epidermal and papillary dermal innervation. In UPS vs. controls, cowhage-induced area under 
curve (AUC) for itch was significantly larger (median, 25%-75%: 175.4, 101.0 – 252.2 vs 42.4, 
24.0-160.7; p=0.04) as was perceived peak itch intensity (53.6, 53.3-78.9 vs 34.2, 20.9-55.6; 
p=0.02). UPS showed a significant reduction in papillary dermal (pd) transient receptor potential 
V1 (TRPV1)(+)-nerve length (nl)/mm epidermis (2295, 1659 -2970 vs 2909, 2228-3523; p=0.003), 
resulting from the loss of %pd-calcitonin gene related peptide (CGRP)(+) nerves (7%, 2%-18% vs 
28%, 20%-36%; p<0.0001), with preservation of %pd-substance P(+) nerves (p=0.1) and intraepi-
dermal nerve fiber density (p=0.1). VAS-week negatively correlated with loss of pd-TRPV1-nl/
mm epidermis (correlation coefficient (CC) =-0.53, p=0.003) and %pd-CGRP nerves (CC=-0.37, 
p=0.03). Cowhage-induced AUC-itch negatively correlated with %pd-CGRP nerves only in UPS 
(CC=-0.40, p=0.02). Our data suggest augmented protease-dependent signaling contributes to UP 
and that loss of an afferent itch-inhibition signal to the spinal cord dorsal horn is one mechanism 
for how pd-CGRP nerve loss contributes to UPS and augmented cowhage-itch.    
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Detection of IFN-α response induced by infiltrated plasmacytoid dendritic cells and kerati-
nocytes via LL37 in the lesional skin of DIHS/DRESS
P Rerknimitr1, 2, 3, S Nakajima,1 A Kitoh,1 Y Miyachi1 and K Kabashima1 1 Department of 
Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2 Department of 
Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand and 3 
King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
Drug-induced hypersensitivity syndrome (DIHS)/Drug reaction with eosinophilia and systemic 
symptoms (DRESS) is characterized by extensive exfoliative dermatitis and multiorgan involve-
ment. Reactivation of latent human herpesviruses (HHVs), in particular HHV-6, is observed in the 
blood and skin. We previously demonstrated infiltration of plasmacytoid dendritic cells (pDCs) 
into the lesional skin of DIHS/DRESS. IFN-α is produced by pDCs upon TLR7- and TLR9-mediated 
recognition of viral RNA and DNA. However, whether and how infiltrated pDCs are activated to 
produce IFN-α and play some roles in DIHS/DRESS remain unclear. Initially, we performed immu-
nohistochemical staining of MxA protein that is known to be induced by IFN-α. We detected MxA 
protein in the epidermis and upper dermis of the DIHS/DRESS lesions, but not in healthy subjects. 
Next, we explored a ligand that activates pDCs and keratinocytes to produce IFN-α. We focused 
attention on LL37, an antimicrobial peptide produced mainly by keratinocytes, because LL37 is 
induced by keratinocytes upon viral infection. Immunohistochemical analysis showed a positive 
staining of LL37 in the epidermis of DIHS/DRESS. We found that LL37 directly attracted pDCs using 
chemotaxis assay, and that IFN-α induced the expression of Th1 chemokines, CXCL9 and CXCL10, 
by keratinocytes, which was further promoted by LL37. These findings are consistent with our pre-
vious report that DIHS/DRESS is a Th1-dominant condition. Take together we propose a hypothesis 
of the pathogenesis of DIHS/DRESS: LL37 is induced by keratinocytes upon viral reactivation in 
the skin at the early phase of DIHS/DRESS. LL37 directly attracts pDCs into the skin and induces 
IFN-α production, which acts on keratinocytes to produce Th1 chemokines, and subsequently to 
establish the development of DIHS/DRESS.    
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Improving pediatric acne management: A prospective multicenter study of case-based guide-
line education
S Feldstein1, 2, M Afshar1, 2, A Krakowski1, 2 and LF Eichenfield1, 2 1 Dermatology, University of 
California, San Diego, San Diego, CA and 2 Pediatric Dermatology, Rady Children’s Hospital, 
San Diego, CA
Studies have documented practice gaps in acne management between pediatricians and dermatol-
ogists. Evidence-based guidelines for acne management were published by the American Acne and 
Rosacea Society and the American Academy of Dermatology in 2013. We assess the impact of a 
case-based learning intervention on pediatrician knowledge of and treatment of acne in accordance 
with published guidelines. Participants were recruited at 4 conferences for pediatric providers. 
Knowledge of the guidelines and confidence in prescribing acne treatment were assessed, and five 
case-based questions presented, with providers choosing acne treatments before, immediately after, 
and three months after a 40 minute case-based educational presentation. Responses with selections 
consistent with the guidelines were scored as correct, and all responses evaluated for patterns of 
medication selection. 150 individuals participated, most pediatricians with over 10 years of expe-
rience. Knowledge of the guidelines and confidence in prescribing acne therapy was poor. The 
average pre-intervention management selections were 70% correct, increasing significantly to 86% 
at 3 months post-intervention time (p<0.01). The most significant improvements were demonstrated 
in provider ability to choose regimens for moderate facial and truncal acne (p <0.05). There was also 
a significant increase in the number of providers selecting a regimen that utilized retinoids for mild 
and moderate acne (p<0.05). Persisting practice gaps included a reluctance to use topical retinoids 
in pre-adolescents, and lack of initiating oral combination therapies in patients with severe acne. A 
case-based educational intervention significantly increased providers choosing acne treatments in 
accordance with evidence-based guidelines, and improved knowledge and prescribing confidence. 
Study limitations include lack of long-term follow-up and an inability to evaluate prescribing patterns 
of participating providers with clinical practices.    
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Circulating central memory T cells might be precursor of tissue resident memory T cells 
(TRM) in psoriasis
E Nishida, S Kasuya, S Muramatsu and A Morita Geriatrics and Environmental Dermatology, 
Nagoya City University, Nagoya, Japan
Psoriasis is a chronic inflammatory skin disease mediated by T helper type-17 (Th17) expressing 
IL-17A and IL-22. There are two distinct populations of memory T cells, effector memory T cells (TEM) 
which are similar to effector cells, express tissue homing receptors, and rapidly produce cytokines 
upon restimulation, and central memory T cells (TCM) which are similar to naïve T cells and express 
the lymph node homing receptor L-selectin (CD62L) and CCR7, but generally lack receptors for 
homing to peripheral tissues. In our previous study, circulating CD4+CCR7+CXCR5+ T cell levels 
were significantly higher in psoriasis patients than in healthy controls. TCM were correlated with IL-22 
producing T cells in patients with severe psoriasis. We further examined the relationship of TCM in 
the peripheral blood and the number of Foxp3+ regulatory T cells of skin lesions from 10 psoriasis 
patients. The Psoriasis Area Severity Index (PASI) score was positively correlated with the number 
of lesional Foxp3+ T cells (r=0.577). Th17 population among CD4 cells in the peripheral blood 
did not correlate with the number of lesional Foxp3+ T cells (r=0.305) nor PASI scores (r=0.166). 
However, circulating CD4+CCR7+CXCR5+ T cells are negatively correlated with PASI scores and 
the number of lesional Foxp3+ T cells (r=-0646,-0.601), but not correlated with circulating Th17 
(r=0.267). In the current study, we examined whether the existence of tissue resident memory T cell 
(TRM) was concerned with the psoriasis lesion. We obtained the lesional samples from patients. The 
specimens were stained with anti -CD69 and anti-CD4/8 antibodies. We found obvious number of 
CD8+CD69+cells in all the lesional skins. TRM might persist in clinically resolved psoriatic lesions. 
Some triggers including environmental insults might give the effects on TRM to produce the cytokines 
related to psoriasis pathogenesis. Taken together, TCM might be precursors of TRM which can be 
suppressed by Foxp3+ regulatory T cells in psoriasis.    
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Two dimensional imaging of basal cell carcinoma using desorption electrospray ionization 
mass spectrometry (DESI-MS)
AS Chiou,1 LS Eberlin,2 I Planell-Mendez,2 KJ Ransohoff,1 JY Tang,1 SZ Aasi1 and RN Zare2 
1 Dermatology, Stanford University, Stanford, CA and 2 Chemistry, Stanford University, 
Stanford, CA
Cutaneous neoplasms often demonstrate aberrant metabolic processes, resulting in different expres-
sion patterns of lipids and other metabolites compared to normal skin. As such, areas of tumor 
involvement often have unique “lipidomic” signatures, a rich source of diagnostic information based 
on lipid expression patterns that has become more accessible through technological advances in 
mass spectrometry imaging (MSI). MSI has recently been used to discern areas of head and neck 
squamous cell cancers from stroma and to distinguish Spitz nevi from Spitzoid melanoma. This pilot 
study demonstrates use of MSI to image human basal cell carcinoma (BCC), the most common type 
of skin cancer, to differentiate areas of tumor from uninvolved skin. We employ a non-destructive 
MSI technique called desorption electrospray ionization mass spectrometry (DESI-MS) to spatially 
map the molecular information of 24 de-identified frozen tissue sections from 12 patients who 
underwent Mohs surgery for BCC. All major histologic types were represented including nodular, 
superficial, and infiltrative. H&E specimens were created from the same sections imaged by MSI, 
and areas of tumor were marked out using imaging software. Direct comparison between H&E and 
MS images enabled identification of metabolic signatures overrepresented in areas of tumor, and 
2-D images were generated based on signal intensities of selected mass spectrometry species. For 
example, the lipids glycerophosphoglycerol(36:4) and glycerophosphoserines(34:1) were observed 
in higher relative intensities in the region of BCC compared to adjacent normal tissue. This initial 
study suggests lipid expression profiles can differentiate areas of involvement of cutaneous tumors 
such as BCC from uninvolved skin and benign structures.    
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Photodynamic therapy using a white-light LED source is as effective and well-tolerated as 
daylight photodynamic therapy for the treatment of actinic keratoses, a randomised, sin-
gle-blinded, prospective study
SM O’Gorman,1 J Clowry,1 M Manley,2 J McCavana,2 L Gray,2 A Kavanagh,1 A Lally1 and 
P Collins1 1 The Charles Centre, Department of Dermatology, Saint Vincent’s University 
Hospital, Dublin, Ireland and 2 Medical Physics, Saint Vincent’s University Hospital, Dublin, 
Ireland
Daylight photodynamic therapy (dlPDT) using topical 5-methyl aminolaevulinic acid (MAL) is 
equally effective for treatment of diffuse actinic keratoses (AKs) compared with conventional (cPDT). 
Pain, the limiting factor with cPDT, is significantly reduced with dlPDT. Our aim was to determine if 
PDT using a white light LED source (wlPDT) could match the efficacy and pain scores of dlPDT. We 
recruited 22 consecutive patients, with AKs on the scalp or forehead, to give the study a power of 
0.80 at a significance level of 0.05. Two symmetrical treatment fields were defined and AKs counted, 
mapped and photographed at baseline, day 28 and 3 months. MAL was applied. Treatment com-
menced 30 minutes later and lasted two hours. Between April and July 2014 patients had half of their 
scalp treated with dlPDT and the other half treated with wlPDT (500 LED theatre-light), one week 
apart, and randomly allocated. Pain scores were assessed using a visual analogue scale at 30-minute 
intervals. Irradiance, illuminance, and light spectra measurements were performed. The integrated 
dose in Jcm-2 was measured. The effective light dose (Jeff), weighted to the absorption spectrum for 
protoporphyrin IX, was calculated. All patients were male. Median age was 72 years. There was 
no significant difference in AK count at baseline between treatment groups (median (IQR) of 20.5 
(8.5) in dlPDT and 20.5 (12.5) in wlPDT fields, p = 0.3469). There was no significant difference in 
efficacy between groups at 28 days (p= 0.135), with a median reduction in AK number of 62.32% 
with dlPDT and 67.65% with wlPDT. Efficacy was equally maintained at 3 months for dl and wl 
PDT (p= 0.2971). The median pain score(IQR) was 0/100 (4) for dlPDT and 2/100 (5) for wlPDT (p= 
0.2887). WlPDT is non-inferior to dlPDT and is an effective weather-independent treatment option.   
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The association between aspirin and NSAIDs with the risk of psoriasis in a population-based 
cohort
B Cohen, KJ Martires and R Ho The Ronald O. Perelman Department of Dermatology, New 
York University Langone Medical Center, New York, NY
The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been reported to trigger or exacer-
bate psoriasis. A recent study reported an association between NSAIDs and psoriatic arthritis in a 
large cohort of US women. We sought to further investigate the link between psoriasis, aspirin, and 
specific NSAIDs, including naproxen, ibuprofen, indomethacin and selective COX-2 inhibitors in 
a population-based cohort. We analyzed publicly available survey data from the National Health 
and Nutrition Examination Study (NHANES) collected from 2009-2012, which included specific 
questions regarding the use of aspirin, NSAIDs, and psoriasis history. We validated questionnaire 
responses using medication data provided. We used Fisher’s exact test for univariate analyses and 
constructed multivariable logistic regression models. Our dataset included 12,382 adult patients. 
We identified 351 cases (2.8%) of psoriasis. 13.6% and 11.6% of patients endorsed regular aspirin 
and NSAID use, respectively. Univariate analysis revealed a significant association between a history 
of psoriasis and the use of NSAIDs (p<0.001) and aspirin (p=0.001). After adjusting for age, gender, 
race, obesity (defined by BMI>30), arthritis (including psoriatic, rheumatoid, and osteoarthritis), 
gout, ankylosing spondylitis, alcohol use, and participation in vigorous recreational exercise, the 
association between NSAIDs and psoriasis persisted (OR=2.92, p=0.042). Of the NSAIDs examined 
individually, naproxen had a particularly strong association with psoriasis univariately (p=0.017). 
For aspirin, however, after adjusting for age, gender, race, arthritis, gout, ankylosing spondylitis, 
alcohol use, exercise, as well as the traditional cardiovascular risk factors, namely hypertension, 
hyperlipidemia, obesity, diabetes, and smoking, the association between psoriasis and aspirin was 
no longer significant (OR=1.69, p=0.454). Therefore, caution should be taken when considering 
anti-inflammatory medications in patients with psoriasis who may also demonstrate symptoms 
of arthritis.    
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The effects of antibiotic use on Staphylococcus aureus carriage rates and resistance patterns 
in patients with acne vulgaris in a dermatology setting
GR Delost,2 ME Delost,1 JA Armile,1 N Carty,2 CC Keller2 and JR Lloyd3 1 Youngstown 
State University, Youngstown, OH, 2 Laboratory of Human Pathogens, Lake Erie College 
of Osteopathic Medicine, Erie, PA and 3 Dermatology, University Hospitals Case Medical 
Center, Cleveland, OH
Overuse of antibiotics has led to the development of antibiotic resistant strains of Staphylococcus 
aureus, which are occurring more frequently within the community. In the dermatology setting, 
antibiotics are a mainstay in the treatment of acne vulgaris. The objective of this study is to ascertain 
if long-term antibiotic therapy for acne alters the carriage rate and/or antibiotics resistance profiles of 
S. aureus. Nasal swab samples were obtained from dermatology patients who were diagnosed with 
acne vulgaris (n=254) that were either being treated with oral and topical antibiotics (n=184) or no 
antibiotic treatment (n=70). Samples were tested for the presence of S. aureus by growth on mannitol 
salts agar. Confirmed isolates were subcultured into Trypticase Soy broth and subsequently grown 
on Mueller-Hinton agar. Susceptibility to selected antibiotics was determined using disk diffusion 
methods according to CLSI guidelines. The S. aureus carriage rate was significantly lower in acne 
patients treated with antibiotics (4.9%), compared to acne patients not treated with antibiotics 
(27.1%)(p<0.0001). The percentage of S. aureus isolates resistant to one or more antibiotics did not 
significantly differ between the two groups (p=0.4348). These results demonstrate that treatment of 
acne patients with antibiotics decreases the S. aureus carriage rate, but does not significantly alter 
the antibiotic resistance rates.    
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Bleach baths significantly reduce itch and severity of atopic dermatitis with no significant 
change in S. aureus colonization and only modest effects on skin barrier function
N Perez-Nazario, T Yoshida, S Fridy, A De Benedetto and LA Beck Dermatology, University 
of Rochester Medical Center, Rochester, NY
Studies have shown that bleach baths improve disease severity in subjects with atopic dermatitis 
(AD). This open label study was designed to test whether bleach normalizes skin barrier function 
and/or reduces itch in adults with AD who are colonized with S. aureus. AD and nonatopic, healthy 
controls (NA) subjects were instructed to take two bleach baths (0.005% NaClO; 5-10min duration) 
per week for a total of 12 wks as add-on therapy. Skin barrier assessments included pH, stratum 
corneum (SC) hydration, transepidermal water loss (TEWL), SC cohesion as well as transepithelial 
electrical resistance (TEER), which was measured in epidermal samples isolated from biopsies of 
nonlesional skin. Efficacy measures included EASI, 5D pruritus, and Itchy QoL. Interim analysis of 
the results from 6 AD (4M/2F; 38±9 yrs [Mean±SEM]) with equal representation of mild, moderate 
and severe disease, and 5 NA (2M/3F; 46±1 yr) was performed. A decrease in EASI score of 47±12% 
(P=0.03) was observed with 67% of subjects achieving an EASI50 at 12 wks. There was no difference 
in SC hydration, pH, SC cohesion or TEER between NA and AD subjects upon enrollment and only 
TEER changed with bleach treatment. TEWL was greater in AD subjects compared to NA (P=0.02) 
at baseline and TEWL decreased by18±6% in AD subjects after 6 wks of treatment (P=0.06). TEER 
decreased by a mean of 38% (P=0.04) with bleach treatment suggesting a worsening of barrier 
function. Itch was significantly reduced as measured by ItchyQoL (20±6%; P=0.03) and 5-D Pru-
ritus (23±4%; P=0.001) after 12 wks of treatment. Five out of 6 AD subjects remained S. aureus 
culture positive after bleach treatment. In summary, adjunct treatment with bleach baths improved 
disease severity and pruritus in adult AD subjects and had a modest effect on skin barrier function. 
Additional analysis will be performed when enrollment is completed (n=15 AD) and will include 
serum biomarkers, skin microbiome and transcriptome.    
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Does nutrition affect psoriasis severity?
S Churton1, 2, H Barkoukis,2 S Debanne,2 T McCormick1, 2, KD Cooper1, 2 and N Korman1, 
2 1 Dermatology, Murdough Family Center for Psoriasis, Univ Hospitals Case Medical Ctr, 
Cleveland, OH and 2 Case Western Reserve University, Cleveland, OH
Psoriasis is a systemic inflammatory disorder affected by lifestyle choices such as diet. Dietary anti-
oxidants including vitamins, whole grains, fruits, and vegetables have anti-inflammatory effects that 
may improve psoriasis and cardiovascular disease (CVD) risk. In this cross-sectional, observational 
study, 83 adults with psoriasis completed a 24-hour dietary recall on a day representative of their 
average diet. Those with nutrient absorption disorders or previous bariatric surgery were excluded. 
Mean age was 51; mean duration of psoriasis was 19 years; mean PASI was 8.7 (range 0-46); mean 
BMI was 30.7; and mean blood pressure (BP) was 132/81. Weight and systolic BP positively asso-
ciated with PASI (p=0.012 and p=0.027, respectively). Average kilocalorie (kcal) intake was 1270 
kcal, which positively associated with PASI (p=0.036). Higher total fat and sodium intakes trended 
toward higher PASI (p=0.058 and p=0.066, respectively). A greater amount of discretionary fat 
from oil associated with higher PASI (p=0.04); higher monounsaturated fat intake associated with 
PASI (p=0.044) but not saturated or polyunsaturated fat. Because high glycemic index (GI) diets 
contribute to increased oxidative stress, acute and chronic inflammation, and increased CVD risk, 
we evaluated the GI and glycemic load (GL). Mean GI was 51.7 and mean GL was 125.9, neither of 
which correlated with PASI nor are the values significantly higher than the US population. A majority 
of patients exceeded fat, saturated fat, calories, and sodium recommended dietary allowance (RDA) 
and did not meet RDAs for whole grains, vegetables, fruits, and vitamins A, C, D, E, and K, none 
of which had an association with PASI. Failing to meet RDAs of these important, anti-inflammatory 
foods and vitamins may contribute to increased BMI, inflammation and co-morbidities associated 
with psoriasis such as CVD. Patients with psoriasis may be able to change their CVD risk by restrict-
ing fats and sodium, and adding vitamin-containing vegetables.    
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Disease–specific changes in skin bacteriome and mycobiome in Atopic Dermatitis (AD) 
patients
PK Mukherjee, J Chandra, M Hammond, M Retuerto, M Ghannoum and S Nedorost 
Dermatology, University Hospitals Case Medical Center, Cleveland, OH
AD is a pruritic, inflammatory skin condition that flares periodically with significant social/financial 
burden. Cause of AD is unknown, but is associated with changes in skin microbes, barrier defects 
and immune dysregulation. While the skin microbiome has been characterized, its role in AD is 
not well understood.Here we used Ion-Torrent sequencing to identify AD-associated changes in 
the skin bacterial microbiome (Bacteriome, BM) and fungal microbiome (Mycobiome, FM), com-
pared to allergic contact dermatitis (ACD). Swabs of affected (AFF) and unaffected (UAFF) skin in 
post-pubertal patients (n = 13) with AD or ACD were obtained after informed consent, following an 
IRB-approved protocol. DNA was extracted from the swabs, PCR-amplified (for bacteria and fungi), 
and sequenced. Operational taxonomic units were obtained from sequencing data using QIIME. 
Principal components analysis (PCA) was conducted to assess overall variance in the datasets. 
Richness (number of taxa), Shannon diversity index (DI), abundance and frequency of BM and 
FM were generated using R software package. Sequencing results showed similar numbers of raw 
sequences for both BM and FM (1.59 and 1.77 M, respectively). Both BM and FM clustered closely 
in AFF skin samples of AD but were diffuse in UAFF samples. Richness of BM and FM in AD was 
higher in UAFF sites (324 and 65, respectively) compared to AFF sites (294 and 42, respectively). 
Similar patterns were noted for ACD patients. Unlike in ACD, diversity of BM and FM in AD was 
reduced in AFF (2.37 and 2.26, respectively) compared to UAFF (2.73 and 2.63, respectively) skin. 
221 bacterial and 77 fungal genera were noted in AFF and UAFF skin sites of AD patients. Majority 
(213/221) of BM were present in both AFF and UAFF sites; Sphingobacetrium was unique to AFF 
sites and 7 genera were unique to UAFF sites. 12 FM genera were unique to AFF sites, 35 were 
unique to UAFF sites, and 30 were differentially present. These results demonstrated that AD was 
associated with specific changes in diversity and abundance of BM and FM.    
216
Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis
S Muramatsu, E Nishida, R Kubo, Y Shintani and A Morita Nagoya City University, Nagoya, 
Japan
Psoriasis is a chronic autoimmune disease involving a complex network of cytokines, such as 
tumor necrosis factor (TNF)-α, and interleukin (IL)-6. In recent years, biologic therapies, including 
TNF-α inhibitor and IL-12/IL-23p40 inhibitor, have demonstrated therapeutic efficacy in patients 
with psoriasis. Previous research suggested that IL-6 is a marker of pathologic activity processes in 
psoriasis. There are few reports, however, of the response of serum IL-6 levels in psoriatic patients 
treated with biologics. The aim of the present study was to evaluate changes in serum IL-6 levels 
during biologic treatment. We analyzed 182 psoriasis patients treated with biologics (99 treated 
with infliximab [IFX], 52 with adalimumab [ADA], 31 with ustekinumab [UST]) in our hospital. 
Disease severity was assessed based on the Psoriasis Area and Severity Index (PASI) score. Patients 
were classified into two groups by the improvement ratio (high: ≥75%, low: <75%) in the PASI score 
at the endpoint (IFX: 22 weeks, ADA: 24 weeks, UST: 28 weeks). Serum IL-6 levels significantly 
correlated with PASI scores. PASI scores significantly decreased with all three treatments. IFX and 
ADA therapy led to significant decreases in serum IL-6 levels. High responders showed more 
remarkable decreases in serum IL-6. On the other hand, serum IL-6 levels remained unchanged 
by UST therapy. Baseline levels of serum IL-6 did not differ significantly between the two groups. 
Serum IL-6 levels serve as biomarkers, but are not good predictors of the therapeutic response to 
biologics in patients with psoriasis. Differences in the response of serum IL-6 levels to IFX, ADA, 
and UST may be due to the action mechanisms of these drugs.    
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Beneficial effects of blood group antigen synthesis-increasing molecules on skin moisture and 
recovery of transepidermal water loss 
S Kim1, 2, 3, S Jin1, 2, 3, J Oh1, 2, 3, M Shin1, 2, 3, S Lee1, 2, 3, D Lee1, 2, 3, M Choi1, 2, 3, S Cho4, 2, 3 and 
J Chung1, 2, 3 1 Department of Dermatology, Seoul National University College of Medicine, 
Seoul, Korea (the Republic of), 2 Laboratory of Cutaneous Aging Research, Biomedical 
Research Institute, Seoul National University Hospital, Seoul, Korea (the Republic of), 3 
Institute of Human-Environment Interface Biology, Medical Research Center, Seoul National 
University, Seoul, Korea (the Republic of) and 4 Department of Dermatology, Seoul National 
University Boramae Hospital, Seoul, Korea (the Republic of)
Recently, we have reported the decrease in A or B antigens along the granular layer in acute 
UV-irradiated or chronically sun-exposed skin. Since UV gives detrimental effects on skin barrier 
function, we investigated whether induced ABH antigen expression help skin barrier function. Five 
natural plant extracts (Camellia sinensis leaf extract, Polygonum cuspidatum root extract, Ginkgo 
biloba leaf extract, Cynara scolymus leaf extract, Selaginella tamariscina extract) and 5 monosac-
charides (D-Glucose, D-Galactose, L-fucose, N-acetyl-D-glucosamine, N-acetyl-D-galactosamine) 
were found to increase B antigen expression in HaCaT cells. Then, three types of composition in 
the vehicle cream were topically applied to the healthy human skin (n=20): composition TYPE I 
contained 5 natural plant extracts, composition TYPE II contained 5 monosaccharides, and com-
position TYPE III contained all of them. After one-time topical application, skin hydration and 
transepidermal water loss (TEWL) were measured at various time points. For the recovery of TEWL, 
tape stripping was performed before application. All three types of compositions increased skin 
hydration and recovery of TEWL until 6 h after application, except that the recovery of TEWL by 
TYPE I was observed only until 15 min, compared to the vehicle cream. ABH blood group antigen 
staining showed increase in 6 of 6 individuals in TYPE II-applied skin samples, and 4 of 6 6 indi-
viduals in TYPE I or III-applied samples. In conclusion, although the ABH blood group antigen is 
still not proven to have roles in skin barrier function, molecules that can increase them may have 
beneficial effects on human skin hydration and the recovery of barrier function.    
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Anti-desmocollin IgG reactivity appears early in pemphigus vulgaris and is associated with 
milder disease
S Geller,1 T Schmidt,2 R Eming,2 T Zeeli,1 O Sarig,1 M Hertl2 and E Sprecher1 1 Tel Aviv 
Sourasky Medical Center, Tel Aviv, Israel and 2 Philipps University, Marburg, Germany
Desmosomal cadherins including desmogleins (Dsg) and desmocollins (Dsc), are critical for cell-cell 
adhesion within the epidermis. IgG autoantibodies against Dsg3 and Dsg1 are thought to play an 
important role in the pathogenesis of PV. However, more recent studies suggest that Dsc may also 
be targeted by autoAbs in PV. We aimed to determine the prevalence of anti-Dsc2 and -Dsc3 IgG in 
newly diagnosed PV patients and to investigate the association between anti-Dsc IgG reactivity and 
disease phenotype and severity. Serum IgG reactivity against human Dsc2, Dsc3 and Dsg3 recombi-
nant proteins was analyzed by immunoblotting. Included were the sera of 26 PV patients with active 
blistering disease: 19 with new onset disease and 7 with exacerbation of previously diagnosed PV 
(median disease duration of 2 vs. 18 months); 21 healthy individuals served as controls. Anti-Dsc 
IgG was found in 26.9% (7/26) of PV sera and 9.5% (2/21) of control sera. While anti-Dsc3 IgG was 
found in 15.8% of newly diagnosed PV patients and 28.6% of previously diagnosed patients, anti-
Dsc2 IgG was found in 26.3% of new onset PV, but in none of the previously diagnosed patients. 
Newly diagnosed patients with anti-Dsc IgG had a median disease duration of 4 months (IQR: 2-5.5) 
suggesting that the presence of anti-Dsc IgG is not restricted to a prolonged disease course and does 
not result from epitope spreading. In our limited PV cohort, patients with either anti-Dsc3 (which 
is pathogenic in PV) or anti-Dsc2 IgG (which has so far not been associated with PV pathogenesis) 
had younger age at disease onset, higher rates of cutaneous disease, better response to oral corti-
costeroids alone, and lower re-hospitalization rate. Anti-Dsc2 IgG was significantly associated with 
lesser need for immunosuppressive adjuvant treatment (p<0.05). Clinical phenotype was milder 
and hospitalization shorter in new patients with anti-Dsc2 IgG. The present data suggest that anti-
Dsc2 IgG may also be associated with PV and may serve as a clinically useful prognostic marker.   
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Characterization of lipoprotein composition and function in pediatric psoriasis reveals a 
more atherogenic profile
W Tom,1 LF Eichenfield,1 M Playford,2 S Admani,1 B Natarajan2 and NN Mehta2 1 Pediatrics 
& Medicine (Dermatology), University of California and Rady Children’s Hospital, San Diego, 
CA and 2 Cardiology Branch, NIH/NHLBI, Bethesda, MD
Psoriasis is associated with increased metabolic and cardiovascular disease (CVD) risk in adults, but 
the risk profile of affected children remains to be defined. The current study used advanced assays to 
test for adverse modulation of lipid and lipoprotein composition and function in pediatric psoriasis 
patients. We prospectively enrolled a consecutive sample of patients aged 0-18 years with psoriasis 
(n=50) and compared their risk factors with healthy age- and sex-matched controls (n=50). Fasting 
traditional lipid concentrations were obtained, lipoprotein particle size and number measured by 
nuclear magnetic resonance spectroscopy, and HDL cholesterol efflux capacity quantified using a 
validated ex vivo system involving the incubation of macrophages with apolipoprotein B-depleted 
serum from subjects. Multivariable linear regression adjusting for cardiometabolic risk factors was 
performed using STATA 10 software. The average age was 13.2 years and the population was 
ethnically diverse. Children with psoriasis had higher waist-hip ratios (0.85 vs 0.81; p<0.005) and 
higher insulin resistance measures (HOMA-IR 2.7 vs 1.96; p=0.04). Despite having normal lipid 
values by traditional measurements, they demonstrated significantly higher atherogenic apolipo-
protein B concentrations (74 vs 66; p=0.04), decreased beneficial large HDL particles (5.3 vs 6.6; 
p=0.02), and reduced HDL efflux capacity after adjusting for age, sex, fasting glucose, systolic blood 
pressure, body mass index, apolipoprotein A, and HDL concentration (beta -0.2, p=0.03). We note 
that young patients with psoriasis have an adverse cardiometabolic risk profile, with evidence of 
insulin resistance and lipoprotein dysfunction by particle size, number, and function measures. 
These findings may provide a basis for the observed link later in life between psoriasis and CVD and 
support the need to screen and educate young affected patients to minimize later complications.   
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The change in serum concentration of S100A7 correlated to the change in PASI score during 
the treatment with adalimumab
A Adachi, M Komine, N Maki, M Karakawa, S Murata and M Ohtsuki Dermatology, Jichi 
Medical University, Shimotsuke, Japan
Psoriasis is one of the inflammatory skin diseases with systemic inflammation. Many serum inflam-
matory molecules have been reported to correlate with disease severity. However, most of the 
investigation has been done in a group of patients at one time point, or at least before and after 
treatment, and there have been few reports on the chronological fluctuation of such molecules, 
and the relation to the changes in PASI score. In order to clarify which molecule reflect the best the 
chronological changes in PASI score, we evaluated the serum concentrations of several inflammatory 
molecules already reported to correlate with disease severity of psoriasis at several time points in 
each of 22 patients before and during treatment. Serum concentrations of soluble tumor necrosis 
factor receptor 1 (sTNFR1), interleukin (IL)-22, IL-6, vascular endothelial growth factor (VEGF), 
S100A7 protein and S100A12 protein were evaluated with enzyme-linked immunosorbent assay 
(ELISA) in 22 psoriasis patients before and several time points during the treatment with adalim-
umab. Serum concentrations of S100A7, IL-22, and IL-6 correlated to PASI score. However, serum 
concentrations of sTNFR1, VEGF or S100A12 did not correlate to PASI score. Serum S100A12 level 
showed correlation to the number of circulating neutrophils. The change in serum S100A7 levels 
correlated well to the change in PASI scores during the treatment, while the change in other serum 
molecules investigated did not show correlation to the change in PASI score during the treatment. 
S100A7 is overexpressed in the skin of psoriasis patients, and epidermal keratinocytes are the main 
source of S100A7. PASI score is the severity scale of skin eruption, and may be reflected the best by 
the changes in serum S100A7 levels, which is produced mainly by epidermal keratinocytes. Our 
results suggest that S100A7 would be the good marker for following acute chronological change 
in severity of skin eruption of psoriasis patients during the treatment.    
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Predominance of inflammatory and immune regulatory proteins in lesional skin – Insights 
into hidradenitis suppurativa pathology
M Devalaraja,1 H Sanganee,1 S Price,1 S Eketjall,1 C Morehouse,2 C Ward,2 L Webber,1 
S Korolevich,2 B Higgs,2 K Lehmann,2 Z Berke1 and E Prens3 1 AstraZeneca, Alderley 
Park, United Kingdom, 2 MedImmune, Gaithersburg, MD and 3 Erasmus Medical Center, 
Rotterdam, Netherlands
Hidradenitis suppurativa (HS) is chronic skin disease of unknown aetiology characterized by painful 
nodules, abscesses and fistulae in inverse body areas. HS pathogenesis is poorly understood but 
thought to be a localized inflammatory process; an emerging hypothesis is that IL-1a originating 
from follicular infundibula and keratinocytes initiates a sterile inflammatory cascade leading initially 
to a neutrophil-predominant influx and consequent damage. To gain molecular and mechanistic 
insights into HS pathology, cytokine, protein and gene expression analysis was conducted from 
plasma and lesional skin from 23 moderate to severe HS subjects and matching samples from10 
healthy donors. Consistent with the IL-1/neutrophil pathway hypothesis, IL-1a, IL-1b, IL-8, IL-17A 
and IL-17F were found to be elevated in HS lesional skin homogenates compared to controls. 
Immunohistochemistry further confirmed elevated lesional IL-1a. The minimal changes seen in 
circulating cytokines support a localized inflammation hypothesis. Interestingly, HS lesional gene 
expression data exhibited predominance of genes related to plasma cells, B and T lymphocytes, 
suggesting the possibility of an immune mediated response involved in pathogenesis of HS. Effort 
is underway to build network maps to understand the potential mechanisms of pathogenesis. The 
current study is the first to understand the molecular signatures present in HS and shed light on 
possible pathogenic mechanisms and new potential therapeutic targets.    
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Utility of T-cell receptor Vβ chain restriction and consideration for changes in B1 staging in 
the assessment of blood involvement in CTCL
JF Gibson, J Huang, K Liu, K Carlson, J Choi, R Edelson and M Girardi Dermatology, Yale 
School of Medicine, New Haven, CT
We studied the utility of TCR-Vβ testing for detection and monitoring of blood involvement in 
CTCL while exploring alternative criteria for B0 and B1 staging that are not based on Sézary cell 
(SC) enumeration. A survey study was initiated to members of the USCLC to characterize current 
clinical practices for analyzing peripheral blood in CTCL. Concurrently, a retrospective analysis of 
161 patients at the Yale Cutaneous Lymphoma Center (2011-2014) was conducted to compare the 
sensitivity, specificity, PPV, and NPV of the individual parameters for ISCL B2 staging (CD4/CD8 
ratio ≥10, %CD4+/CD26- ≥ 30%, %CD4+/CD7- ≥ 40%, TCR gene rearrangement via PCR). Patients 
were also assessed for TCR-Vβ usage in a gated atypical population, e.g. based on abnormal CD4, 
CD3, and/or CD7 expression. In an effort to improve detection of early blood involvement, we 
proposed and assessed the following modified B1 criteria: CD4/CD8 ratio ≥5, %CD4
+/CD26- ≥ 20%, 
%CD4+/CD7- ≥ 20% with evidence of clonality (by PCR or TCR-Vβ expansion). There was significant 
heterogeneity in clinical practices among institutions and 55% assessed for blood involvement 
using SC enumeration. Only 40% of respondents indicated that they assessed CD26 and only 
15% of respondents tested for TCR-Vβ restriction. We found current B1 criteria to be insufficient in 
evaluating intermediate blood involvement as these criteria identified two individuals with stable 
T1 disease and did not capture five individuals with clear flow cytometric abnormalities who later 
had disease progression. We propose the further study of modified B1 criteria—CD4/CD8 ratio ≥5, 
%CD4+/CD26- ≥ 20%, %CD4+/CD7- ≥ 20%. We found Vβ testing to have superior specificity as 
compared to PCR, and there appears to be a role for TCR-Vβ testing in patients who meet B2 or 
modified B1 criteria in order to detect clonality and possibly upstage patients. Further, in patients 
where a TCR-Vβ clone is detectable, it may be useful to continue to monitor tumor burden based 
on TCR-Vβ expression.    
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Photodynamic therapy for benign neurofibromas
EB Olasz,1 AM Schock,1 N Duncan,1 Z Lazarova,1 S Kumar,2 B Quirk3 and H Whelan3 
1 Dermatology, Medical College of Wisconsin, Milwaukee, WI, 2 Pathology, Children’s 
Hospital of Wisconsin, Milwaukee, WI and 3 Neurology, Children’s Hospital of Wisconsin, 
Milwaukee, WI
Neurofibromatosis type 1 (NF1) is among the most prevalent autosomal dominant diseases. Most 
common findings are multiple benign neurofibromas (NF), representing localized overgrowth of 
neural-crest-derived tissue. Treatment is surgical while medical treatment is not available. Prior 
studies using a mouse xenograft NF model showed that systemic administration of porfimer sodium 
and subsequent irradiation with 677nm red light resulted in reduction of subcutaneous NFs. The 
goal of this pilot study was to assess the safety and efficacy of photodynamic therapy (PDT) using 
5-aminolevulinic acid (ALA) and 630 nm red light (RL) for the treatment of benign dermal NFs in 
NF1 patients. The primary outcome measure was tolerability, secondary outcome assessed efficacy. 
Frozen sections obtained 24 hours after microneedling (MN) and ALA treatment of NFs (n=3) 
showed protoporphyrin IX (PpIX) fluorescence within the tumor but not in the surrounding tissue 
demonstrating that ALA was converted into PpIX within the tumors. RL treatment at a radiant flux of 
100 mW/cm2 and at a dose of 50 J/cm2 of ALA (n= 38) but not vehicle (n=34) treated tumors in 7 
subjects resulted in marked erythema and edema of the ALA but not the vehicle treated tumors. There 
was no blister formation, erosion or crusting observed. RL treatment of ALA but not vehicle treated 
tumors induced marked pain and discomfort and in one case prompted cessation of treatment due 
to pain. Light microscopy studies of ALA but not vehicle treated tumors biopsied 48 hours after PDT 
treatment showed mixed infiltrate consisting of lymphocytes and neutrophils. TUNEL assay showed 
increase in number of apoptotic cells per optical field in ALA treated tumor samples (42.5±8.9) as 
compared to control (1.13±0.64). Measurement of the tumors at 0, 14, 30 and 90 days after ALA 
treatment did not show significant size reduction. In conclusion, PDT using ALA and 630 nm RL 
may be a promising new treatment modality for benign dermal neurofibromas.    
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Relationship of the sun protection factor and the active ingredients in commercial sunscreens
M Gutiérrez,3 E Arenas,1 N Vázquez,2 B Moncada,1 G Toriz2 and J González3 1 Dermatología, 
Hospital Central “Dr. Ignacio Morones Prieto”, San Luis Potosí, Mexico, 2 Centro Universitario 
de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara, Mexico and 3 
Ciacyt, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico
Introduction: The ultraviolet (UV) radiation from the sun is the main factor of diseases on the skin 
in humans. To avoid these adverse effects, the use of sunscreens is extremely essential. Objective: 
To evaluate sun protection factor (SPF) of different commercial sunscreens of in vitro form and 
compare results with those shown on the label of the product. Methodology: Spectra of transmission 
71 different commercial sunscreens in Mexico were obtained to quantify your SPF in vitro using 
a system of spectrophotometry and quartz substrates. Results: The results show that around 70% 
of the commercial products do not offer protection announced on its label, which recommended 
that it should be regulated by any institution or clinical department. From the methodology carried 
out we can determine the SPF of any sunscreen only measure its transmission spectrum and obtain 
highly reliable results.    
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TCR sequencing provides superior diagnosis, staging and clinical assessment of patients with 
cutaneous T cell lymphoma
JT OMalley,1 I Kirsch,4 R Watanabe,1 D Williamson,4 L Campbell,1 C Elco,2 JE Teague,1 
A Gehad,1 E Lowry,1 JG Krueger,3 H Robins,4 TS Kupper1 and R Clark1 1 Dermatology, 
Brigham and Women’s Hospital and DF/BWH Cancer Center, Boston, MA, 2 Pathology, 
Brigham and Women’s Hospital, Boston, MA, 3 Dermatology, Rockefeller Institute, New 
York, NY and 4 Adaptive Biotechnologies, Seattle, WA
Cutaneous T-cell lymphomas (CTCL) are lymphomas arising from skin tropic T cells. Early diagnosis 
of skin-limited CTCL is difficult, in part because clonal T cells make up a small proportion of T 
cells in skin lesions and the clinical and histopathologic appearance of CTCL can resemble that of 
benign inflammatory skin diseases. Detecting a malignant T cell clone can be critical in diagnosing 
CTCL, but currently available TCRg PCR analyses detect clones in only a subset of CTCL patients. 
We report here that high-throughput TCR sequencing (HTS) detected T cell clones in 46/46 CTCL 
patients tested, was more sensitive and specific than TCRg PCR, and successfully discriminated CTCL 
from psoriasis, eczematous dermatitis and healthy skin. HTS also discriminated CTCL recurrences 
from benign inflammation, provided an accurate assessment of responses to therapy and facilitated 
early diagnosis of disease recurrence in both the skin and blood of CTCL patients. In patients with 
skin limited disease and no clinical involvement of peripheral blood by flow cytometry, HTS was 
able to demonstrate hematogenous spread of small numbers of malignant T cells. Lastly, HTS was 
a powerful research tool that provided comprehensive information about the diversity of benign T 
cells, identified the TCR Vβ usage of the clone, and allowed selective immunostaining and study 
of clonal malignant T cells. In summary, HTS is a powerful technique that accurately diagnosed 
CTCL in all stages of disease, discriminated CTCL from benign inflammatory skin diseases, facilitated 
clinical follow up and, as a research tool, has the capacity to provide unprecedented insights into 
the biology of CTCL.    
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Evaluation of diagnostic agreement among United States board-certified dermatologists 
viewing images transmitted from Tanzania using a smartphone-based store-and-forward 
teledermatology service
RD Granstein and SJ Coates Weill Cornell Medical College, New York, NY
Telemedicine is the use of telecommunications technology to transmit clinical information in order 
to serve patients across a distance. Dermatology is well suited to telemedicine because of its visual 
nature. Smartphones are a convenient modality for image transmission, particularly in the develop-
ing world where 3G data networks are more reliable and more available than wired networks. The 
purpose of this observational study was to assess the diagnostic reliability of an international mobile 
store-and-forward teledermatology link connecting dermatologists at the Weill Cornell Medical 
College in New York to physicians at the Bugando Medical Center in Mwanza, Tanzania. Three 
board-certified dermatologists independently evaluated 46 unselected cases submitted for evalua-
tion, listing three possible diagnoses in descending order of likelihood. Diagnostic reliability was 
measured as the percentage of cases in which agreement was observed. All three subjects rendered 
at least one diagnosis in common in 60.1% of cases. In 26.1% of cases, all subjects listed the same 
single most likely diagnosis. In three cases (6.5%), all three subjects listed two diagnoses in common. 
At least two of three subjects listed a single common diagnosis in 87% of cases. In 30.4% of cases, 
at least two of three subjects listed two common diagnoses. These data suggest that smartphones 
are reliable tools for delivering diagnostic opinions to resource-poor settings.    
227
Neutrophil and lymphocyte-mediated skin disease despite profound leukopenia
SJ Divito,3 GA Romar,1 LA Compton2 and TS Kupper3 1 Harvard Medical School, Boston, MA, 
2 Pathology, Brigham and Women’s Hospital, Boston, MA and 3 Dermatology, Brigham and 
Women’s Hospital, Boston, MA
Rashes following chemotherapy or conditioning regimens are a common finding in patients 
with hematologic malignancy, and are often attributed to chemotherapeutic effect or infection. 
Immune-mediated dermatitis is less commonly considered given patient’s leukopenia, however 
anecdotally, dermatologists not infrequently observe immune-mediated dermatitis in these patients. 
We performed a retrospective analysis of adult inpatients at Brigham and Women’s Hospital/Dana 
Farber Cancer Institute, for whom the dermatology consultant performed a skin biopsy. Patients 
whose peripheral WBC count was ≤ 1 x 103 cells / ml on the date of skin biopsy were selected for 
analysis. Fifty five patients (57 biopsies) were collected over a 17 month period fitting this profile. 
There were 33 males and 22 females, with age range 24 – 74 years-old (median 56 years-old). The 
majority of patients in our study population had acute myelogenous leukemia (n=35), although a 
number of other benign and malignant hematologic disorders were represented. Of the skin histo-
logic diagnoses, eight were positive for infection including seven fungal infections and 1 herpetic 
infection. The majority of remaining diagnoses were inflammatory (hypersensitivity, eczema, neu-
trophilic dermatoses, urticarial dermatoses, graft versus host disease, and vasculitis). Six patients had 
neutrophilic dermatoses on skin biopsy, despite absolute neutrophil counts ranging undetectable to 
maximum 620 neutrophils /mL blood on day of skin biopsy. Sixteen pathology reports specifically 
noted lymphocyte infiltration in the skin biopsy. Of these patients, absolute lymphocyte count 
ranged from undetectable to maximum 468 lymphocytes / mL of blood, at the time skin biopsy 
was taken. This data indicate that host immune/inflammatory-mediated skin disease can occur in 
the context of severe leukopenia.    
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Validation of the Epidermolysis Bullosa Disease Activity and Scarring Index: Characterising 
disease severity and responsiveness to clinical change in epidermolysis bullosa
SV Jain1, 2, AG Harris1, 2, CC Loh1, 2, J Kim,1 JS Su,3 D Orchard,3 LJ Warren,4 H McManus5 
and DF Murrell1, 2 1 Dermatology, St George Hospital, Sydney, NSW, Australia, 2 Faculty 
of Medicine, University of New South Wales, Sydney, NSW, Australia, 3 Dermatology, 
The Royal Children’s Hospital, Melbourne, VIC, Australia, 4 Dermatology, Women’s and 
Children’s Hospital, Adelaide, SA, Australia and 5 Kirby Institute, University of New South 
Wales, Sydney, NSW, Australia
The lack of longitudinally validated outcome measures for epidermolysis bullosa (EB) presents a 
barrier to evaluating the efficacy of therapies for this disease. This prospective cohort study assessed 
the responsiveness of the Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI), a 
recently developed disease-specific scoring system which separates disease activity from damage, 
in classifying patients according to disease severity and clinical response. 48 outpatients with EB 
were evaluated at two specialised EB clinics. At each visit, the physician at each site completed 
the EBDASI and global assessments of disease severity and change. EBDASI score ranges were 
determined for patients with mild, moderate and severe disease. Responsiveness of the EBDASI 
activity subscale was assessed within patients who were classified as stable, improved or deterio-
rated. Minimal clinically important differences were calculated and compared with the standard 
error of measurement. Receiver operating characteristic (ROC) curves were used to determine score 
cut-offs. An EBDASI score cut-off of 42 differentiated mild from moderate disease and a cut-off of 
104 differentiated severe from moderate disease. Reduction in EBDASI activity scores of greater 
than 9 indicated clinically significant improvement and an increase of 3 in the activity score indi-
cated clinical deterioration. All cut-offs correctly classified over 75% of patients. The EBDASI is 
a responsive tool and may be useful in charting the disease severity in EB in future clinical trials.   
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A cost-effective combinational and antioxidant therapy in veteran psoriasis patients
CN Young2, 1, G Messenger,1 C Duggan,2 T Abbas,1 W Nasir,1 C Hatzis1 and L Savoy2 1 
Dermatology, Wayne State University, Detroit, MI and 2 Dermatology, John D Dingell VA 
Medical Center, Detroit, MI
Psoriasis is a chronic inflammatory skin disease that affects nearly 3.2% of the world population (1). 
40-50% of patients are not satisfied with their current psoriasis regimen, signifying a need for more 
effective treatments to alleviate symptoms (2). Furthermore, the cost of psoriasis is an increasing 
economic burden on both patients and the health care system. A recent study found that in 2013 
the annual cost of psoriasis in the US was $112 billion dollars. In their lifetime, psoriasis patients 
would pay about $11,498 dollars to alleviate physical symptoms and emotional health (3). At the 
John D. Dingell VA Medical Center in Detroit, Michigan, a novel research clinical trial was con-
ducted on a cohort of 150 to 500 psoriasis patients that utilized the anti-inflammatory properties 
of supplemental antioxidant pills and topical antioxidant cream. In addition, patients were trained 
to engage an anti-inflammatory diets and healthy lifestyle. The new treatment modality has seen 
as high as a 95% reduction of psoriasis and many patients have gone into complete remission. 
After observing successful results in the treatment for majority patients, we were interested in the 
economic and health care value of this study and performed a cost-saving of psoriasis treatments 
before and after study enrollment from the perspective of the VA Medical Center. The results of 
this analysis revealed that the Detroit VA Medical would save approximately $200,000 per year to 
treat every 100 patients in this psoriasis research study. In summary, the combinational treatment 
of antioxidant therapy and modification of patient’s lifestyle has demonstrated to be cost effective 
and shield a light for a breakthrough improvement in psoriasis as well as reduction of economic 
burden on both patients and the health care system.    
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Laboratory work up for primary thrombophilia should be extensive
B Moncada,2 GJ Ruiz-Arguelles,1 C Martinez2 and E Arenas2 1 Hematology, Clinica Ruiz, 
Puebla, Mexico and 2 Dermatology, University of San Luis Potosi, San Luis Potosi, Mexico
Primary thrombophilia can be due to a heterogeneous group of abnormalities that make patients 
prone to have abnormal coagulation in different part of the body. A complete search for the possi-
ble elements involved, should be wide because when only a few test are performed and they are 
negative, a false sensation de normality may arise. Complete panel consists of 22 tests. Suspicion 
for primary thrombophilia may come into sight when a young person has a thrombotic event, 
unexplained fetal loses, thrombosis in presence of anticoagulation therapy etc. A 40 year old 
housewife otherwise healthy had a venous thrombosis of the left leg and was properly treated with 
warfarin for three months. Five months later after the anticoagulant drug was stopped, she developed 
another venous thrombosis in the other leg. Then warfarin was re started and one year later while 
she was still on the drug, she developed livedoid vasculopaty (atrophy blanch). The biopsy showed 
dermal arteriole occlusion without vasculitis. Extensive laboratory work up showed the presence of 
antiphospholipid antibodies 92.35 (Normal: less than 12) and anti beta2 glycoprotein 648 (normal 
:less than 20) But she also had abnormal platelets adhesivity, fact that constitute the sticky platelets 
syndrome. SPS. Then it can be assumed that the patient was protected from abnormal coagulation 
with warfarin regarding the presence of antiphospholipid antibodies, but not against the presence 
of the SPS, that requires drugs to fight excessive platelet adhesion i.e. aspirin.    
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Chronologic aging in African-American skin: A reliable photonumeric scale reveals age and 
body mass index as contributory factors
AL Chien, J Qi, R Grandhi, T Harris-Tryon, DM Kuhn, M Jang, N Kim, O Olowoyeye, 
S Leung, J Esandrio, B Rainer, F Poon, N Cheng, GA Hinds and S Kang Department of 
Dermatology, Johns Hopkins University, Baltimore, MD
While features of photoaging are well-characterized in the literature, less is known about chrono-
logic skin aging. A standardized grading scale on fine wrinkling was recently developed for chrono-
logic aging in Caucasians, but no such scale exists for African-Americans. In this cross-sectional 
study, standardized upper inner arm photographs of 75 subjects were taken (19 males, 56 females, 
age range 18-96). Five participants’ photographs were chosen as standards to develop a 9-point 
photonumeric scale for chronologic skin aging (0=none, 8=most severe) in African-Americans. Three 
dermatologists used the scale to independently grade the participants’ photographs on two occa-
sions, separated by 2 weeks. Using the intraclass correlation coefficient (ICC) method, the interrater 
agreements were 0.768 (95% CI: 0.671-0.834) for trial 1 and 0.725 (0.608-0.794) for trial 2. The 
intrarater agreements were 0.757 (0.596-0.875), 0.850 (0.771-0.903), and 0.790 (0.686-0.855) for 
the 3 graders. Conventionally, ICC agreement between 0.7 and 0.8 indicates strong agreement, while 
ICC > 0.8 indicates almost perfect agreement. Averaged chronologic aging scores were correlated 
with participants’ responses to a survey on lifestyle factors in univariate analyses, which yielded age 
as a significant predictor (r = 0.72, p<0.001). An optimal multiple regression model was developed 
to predict chronological aging (adjusted R2 = 0.537) which included the following variables: age 
(b1 = 0.084, p<0.001), BMI (b2 = 0.043, p=0.094), and gender (b3 =-0.635, p=0.123). This study 
created the first reliable photonumeric scale for chronologic aging in African-Americans and found 
increased age and greater BMI as contributors to intrinsic skin aging phenotype in this population.   
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Identifying risk factors for digital ulcers in patients with systemic sclerosis: A retrospective, 
case-control study in a tertiary care academic medical center
S Kam, J Besen, C Lam and M Lichtman Dermatology, Boston University, Boston, MA
Digital ulcers (DU) are a common complication of systemic sclerosis. Studies estimate up to 50% of 
patients with either limited or diffuse disease are affected by digital ulcers during their lifetime. While 
the exact etiology of these ulcers is unclear, it is thought that digital ischemia from microvascular 
damage may play a role. In light of this, some have argued for the use of aspirin in these patients. 
We performed a retrospective, case-control study of patients 18 years and older with systemic 
sclerosis (ICD-9 code 710.1) seen at Boston Medical Center between 2004 and 2014 to identify 
risk factors that may affect the development of digital ulcers in patients with systemic sclerosis. 
We identified 2008 patients seen in this time frame, and, after excluding patients with morphea, 
performed a preliminary analysis of 200 randomly selected patients (100 patients with digital ulcers, 
100 patients without digital ulcers). The average age of the population and sex distribution were the 
same in both groups (52.8 years and 83%, respectively). Using Chi-square analysis, we investigated 
the association between digital ulcers and gastrointestinal dysmotility, prednisone treatment, and 
aspirin use. Gastrointestinal dysmotility was significantly associated with the development of digital 
ulcers (OR 2.66, P=0.001). Interestingly, aspirin use and prednisone treatment were both negatively 
associated with the risk of developing digital ulcers (OR of 0.68 (P=0.187) and 0.57 (P=0.072), 
respectively), though these findings did not reach statistical significance. Our findings are consistent 
with other studies reporting a correlation between gastrointestinal dysmotility and digital ulcers in 
patients with systemic sclerosis. Prednisone and aspirin use may also be negatively associated with 
the development of digital ulcers. Additional studies with larger sample sizes are needed to further 
investigate these associations, as this may help identify which patients with systemic sclerosis are 
most at risk for digital ulcers.    
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The utility of laser thermometry in the evaluation of plaque psoriasis
V Pascoe, JM Donigan and AB Kimball Dermatology, Massachusetts General Hospital, 
Boston, MA
Characteristics of psoriatic plaques including scale, transepidermal water loss, inflammation, 
increased blood vessel formation, and vasodilation may affect thermoregulation and the tempera-
ture of psoriatic lesions. This study aimed to assess the utility of laser thermometry in evaluating 
the severity of psoriatic plaques to determine whether it could provide a non-invasive quantitative 
assessment. Twenty-five patients with plaque psoriasis were examined with a Milwaukee Laser 
Temp-GunTM Thermometer. Measurements were taken from 18 inches away to measure the tem-
perature of a 0.5 inch area. All determinations were made with the ambient temperature in the 
68-82° F range and were performed on psoriatic plaques (areas with and without scale), adjacent 
normal-appearing skin, and normal-appearing skin on the contralateral side of the body with at 
least one inch between each measurement. The severity of disease was evaluated using the Psoriasis 
Area and Severity Index (PASI), and Overall Target Plaque Severity Score (OTPSS). The majority of 
participants had Fitzpatrick II skin type with an average PASI of 7.3 and OTPSS of 3.2. Eighty-one 
percent of plaques were cooler than adjacent skin, and 83% were cooler than contralateral skin. 
Scaly regions of psoriatic plaques were, on average, 1.6° F cooler than non-scaled regions, 0.3° 
F cooler than adjacent skin, and 0.9° F cooler than contralateral skin. Non-scaled plaque regions 
were 0.5° F cooler than both adjacent and contralateral skin, on average. None of these temperature 
differences were statistically significant. There was not a strong correlation between the average 
plaque temperature and PASI regional erythema (r=0.21) or OTPSS (r=0.19). Laser thermometry with 
the device in this study was not particularly useful in evaluating psoriasis plaque severity; however, 
as temperature trends were observed, studies with more sensitive temperature instruments and a 
larger sample size may be warranted.    
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Geographically adjusted tool to estimate self-reported cumulative ultraviolet exposure and 
associated skin cancer risk
I Raber, G Zhu, S Li, S Sakshuwong, A Li, CZ Tan and AS Chang Stanford University School 
of Medicine, Redwood City, CA
A straightforward method to assess accurately an individual’s cumulative ultraviolet (UV) exposure is 
not available to identify individuals at increased risk for skin cancer. Following Institutional Review 
Board approval, a web-based survey tool that generates a Cumulative Lifetime UV exposure (CLUE) 
score that numerically estimates a person’s lifetime UV dose based on exposure and geographical 
location was tested in 1,118 volunteers. The age-matched CLUE scores were compared between 
those with a history of skin cancer (CLUE=242,074) and those without a history of skin cancer 
(CLUE=205,379), with scores significantly different in the two groups (p=0.003) at age of diagnosis 
of first skin cancer. Intra-rater reliability for the CLUE score was high (k=0.94) in individuals who 
took the survey tool two weeks after the initial assessment. In addition, the average CLUE score 
decreased in participants after diagnosis of skin cancer (average CLUE[before]=5320 versus average 
CLUE[after]=3842, p<0.0001), consistent with increased sun-protective behaviors. This phenome-
non has been reported in other studies in the medical literature. While the limitations of this study 
include recall bias, this tool is a first step to generate a quantifiable skin cancer risk metric that is 
clinically useful for screening individuals at increased risk for skin cancer. It may also be used to 
monitor ultraviolet exposure and sun-protective behaviors over time. The tool can also be used to 
more precisely assess UV exposure for research purposes.    
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Clinical characteristics, disease associations, and treatment of subacute cutaneous lupus 
erythematosus
A Gutierrez1 and DA Wetter2 1 Dermatology, Mayo Clinic, Scottsdale, AZ and 2 
Dermatology, Mayo Clinic, Rochester, MN
Subacute cutaneous lupus erythematosus (SCLE) is a specific disease entity that comprises part 
of the spectrum of cutaneous lupus erythematosus. We aimed to characterize our institution’s 
experience with SCLE with regards to clinical presentation, disease associations, treatments and 
patient outcomes, so as to augment our knowledge of this clinical condition. This study was a 
retrospective review of patients with SCLE seen at our institution between 1996 and 2011. Of 90 
patients with SCLE the mean age at diagnosis was 61 years; 64 (71%) were women and 11 (12%) 
were suspected of being drug-induced. Of patients with documented smoking histories, 17 of 59 
(29%) were current smokers at the time of diagnosis. SCLE lesions involved sun-exposed areas in 75 
patients (83%); while the most common lesion morphology was papulosquamous, occurring in 52 
patients (57%). Serologic testing was notable for anti-Ro/SSA positivity in 84 of 85 (99%) patients 
tested, while anti-La/SSB was positive in 32 of 85 (38%) patients tested. Rheumatoid factor and/or 
anti-CCP were positive in 19 of 49 (39%) patients tested. SCLE patients were diagnosed with asso-
ciated autoimmune connective tissue disorders (CTD) including Sjogren’s syndrome (13/90, 14%), 
systemic lupus erythematosus (6/90, 6%), rheumatoid arthritis (3/90, 3%), overlap CTD (3/90, 3%), 
and vasculitis (2/90, 2%). The most common drug therapy was hydroxychloroquine given in 50 of 
80 (63%) patients. Hydroxychloroquine-treated patients had a complete response in 34 of 46 (74%) 
patients. Other common drug therapies included prednisone (n=21, 26%), mycophenolate mofetil 
(n=6, 8%), methotrexate (n=4, 5%) and azathioprine (n=3, 4%). Of these therapies all induced 
either a complete or partial response, except for mycophenolate mofetil in one patient. Our study 
represents a large single-center case series of SCLE patients. Nearly one-quarter of the patients were 
diagnosed with an associated autoimmune CTD. Most patients responded to first-line therapies, but 
for difficult to manage cases there were number of effective therapies.    
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The efficacy of meditation for treatment of chronic pruritus: A pilot trial
SC Chen and M Jhaveri Dermatology, Emory University, Atlanta, GA
Our goal was to evaluate the feasibility of meditation as an adjunctive therapy for chronic pruritus. 
Chronic pruritus leads to increased activity of the anterior posterior cingulate cortex, in addition 
to activation of other neuronal and inflammatory markers similar to pain and stress. Meditation 
has been shown to de-activate the anterior cingulate cortex and decrease neuroendocrine and 
inflammatory markers. We hypothesize that meditation may help decrease the severity of chronic 
pruritus, via these mechanisms and thus decrease the impact of chronic pruritus on the quality of 
life. We recruited 10 adult (>18 years) patients with chronic pruritus for greater than 6 months, 
who were fluent in English and had not used meditation in the previous year. Although we suc-
cessfully recruited 10, only 7 patients formally consented due to unpredicted increases in work 
or flare of other medical conditions preventing attendance of the evening course. The meditation 
teachers defined completion if the participants attended >75% of the classes. Of the 7 patients who 
consented, 5 (71%) completed the course. Only one participant was limited by a flare of her skin 
condition. Self-reported itch severity (VAS) worsened on average when comparing the final VAS 
to that of the baseline (-0.6), but the quality of life impact as measured by ItchyQoL improved (0.5 
points). Improvement in ItchyQoL was significantly correlated with completion of at least 75% of 
classes (r=0.83, p=0.04). There was a statistically significant and high correlation between the total 
hours of practice and classes attended (r=0.82, p=0.02). We conclude that patients with chronic 
pruritus are able to fully participate in a meditation course without the sensation of itch interfering 
with their ability to complete the course. Qualitative exit interview data suggest that meditation also 
improved factors, such as sleep quality and relationships with close contacts, which decreased the 
impact of pruritus on the quality of life. We propose that a larger study needs to be conducted to 
further investigate the impact of meditation on itch severity and quality of life.    
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Characterizing subsequent malignancies after mycosis fungoides
KJ Martires, R Ho and J Latkowski Dermatology, New York University School of Medicine, 
New York, NY
Purpose: Mycosis fungoides (MF) is the most common cutaneous lymphoma. The chronicity of 
MF and immunosuppression induced by it places patients at risk for the development of second 
primary cancers. We sought to comprehensively examine this risk. Methods: We conducted a popu-
lation-based study using the Surveillance, Epidemiology, and End Results Program from 1973-2011 
to determine what cancers MF patients are at risk for using observed over expected values (O/E) 
with 95% confidence intervals (CI). We used logistic regression analyses to determine risk factors for 
development of subsequent cancers after MF. Survival was examined using Cox proportional haz-
ards modeling. Results: There were 3651 MF patients, and 585 (16.0%) with a subsequent cancer. 
We observed higher than expected incidences of subsequent cancers overall (O/E=1.16, 95% CI: 
1.07,1.24). Cancers with significantly elevated odds of developing after MF included melanoma (O/
E= 2.35, CI 1.25,1.87), rare skin cancers (merkel cell carcinoma and malignant fibrohistiocytoma) 
(O/E=5.65, CI: 1.93, 6.27), B-cell lymphomas (O/E=3.17, CI: 2.40,3.41), chronic lymphocytic leu-
kemia (O/E=2.35, CI: 1.50, 2.88), and lung cancer (O/E=1.16, CI: 1.07, 1.24). Patients with MF who 
developed second cancers were age ≥ 60 (p<0.01), more often male (p<0.01), and were more likely 
to have received radiation (p<0.01). In the multivariable analysis, only age ≥ 60 (p=0.01) placed 
patients at risk for subsequent cancers. MF patients with a subsequent cancer had worse overall 
survival in a multivariable analysis (p=0.02). This was particularly true for early-stage MF patients 
(p<0.01). Other factors predicting worse survival in MF patients were older age (p<0.01), higher stage 
(p<0.01), and history of radiation (p=0.01). Gender and race did not influence survival. Conclusion: 
Patients with MF, especially older men who received radiation treatment, should be monitored for 
the development of skin cancers, B-cell hematologic malignancies, and lung cancer. Patients with 
MF and a subsequent cancer have worse survival than patients with MF only.    
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Subcutaneous abatacept in the treatment of moderate to severe alopecia areata
J Mackay-Wiggan,1 NM Nguyen,1 C Clark,1 A Jabbari,1 G Ulerio,1 M Furniss,1 R Clynes1 and 
A Christiano1, 2 1 Dermatology, Columbia University, New York, NY and 2 Genetics and 
Development, Columbia University, New York, NY
Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%. Current treat-
ments including corticosteroids and other immunomodulators are not FDA-approved for AA and 
have demonstrated variable efficacy. In 2010, we published the first genome wide association 
study in AA, which revealed several susceptibility loci shared with other autoimmune diseases and 
in key pathways that regulate adaptive and innate immunity. This evidence, in conjunction with 
gene expression profiling, supported a critical role for the costimulatory pathway in AA. Pre-clin-
ical studies have shown disease can be induced in normal mice of the C3H/HeJ mouse model by 
transfer of T cells from affected mice or humans, suggesting a primary role of autoimmune T cells. 
Proof-of-concept has been done for CTLA4-Ig as a treatment of AA in the C3H/HeJ alopecic mouse 
model. CTLA4-Ig prevented alopecia in graft recipients whereas alopecia developed in untreated 
graft recipients. Here, we initiated an open label, proof-of-concept clinical trial for the treatment of 
moderate to severe AA in humans, using a fixed dose of subcutaneous abatacept 125mg weekly. 
We enrolled 15 patients for 6 months of treatment followed by 6 months of follow up off drug. All 
patients presented with moderate to severe, stable AA (>30% - 100% scalp hair loss). One of fifteen 
patients demonstrated a significant response to treatment with 98% hair regrowth compared to base-
line. Two patients demonstrated less significant response with up to 23% hair regrowth compared 
to baseline. Safety parameters including complete blood count and differential, basic metabolic 
panel, and liver function tests have remained within normal limits and no serious adverse effects 
have been reported. Genetic susceptibility at the CTLA4 locus was compared to treatment response 
to determine if correlation was present. These results suggest that abatacept may be efficacious in 
the treatment of a subset of patients with alopecia areata.    
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Treatment of angiolymphoid hyperplasia with eosinophilia: A systematic review
B Adler,1 A Krausz,1 J Silverberg2 and H Lev-Tov1 1 Division of Dermatology, Department of 
Medicine, Albert Einstein College of Medicine, Bronx, NY and 2 Dermatology, Northwestern 
University Feinberg School of Medicine, Chicago, IL
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a rare benign vasoproliferative disorder of 
unknown etiology. The biomedical literature contains multiple case series and case reports describ-
ing treatments for ALHE. However, there are no evidence-based reviews of treatment efficacy and 
predictors of disease recurrence after treatment. We conducted a systematic review of MEDLINE, 
EMBASE, Cochrane Library, and Google Scholar according to PRISMA guidelines, discovering 
over 500 cases of treatment for ALHE. The most commonly reported treatments were excision 
(43%), intralesional steroids (12%), topical steroids (9%), cryotherapy (7%), and systemic steroids 
(6%). Excision was associated with lower rates of recurrence (39.9%) compared to intralesional 
(74.6%), topical (100%), or systemic steroids (86.7%), or cryotherapy (76.5%). Other treatment 
modalities were associated with variable rates of recurrence, though never less than those of exci-
sion. Earlier age of onset (P=0.048), longer duration of disease (P=0.01), and presence of multiple 
lesions rather than a single lesion (P<0.0001) were all associated with higher rates of recurrence 
after excision. Recurrence rates were not associated with sex (P=0.47), race/ethnicity (P=0.31), 
maximum dimension of a lesion (P=0.66), or left-right laterality of lesions (P=0.07). These results, 
representing the largest aggregation of treated cases of ALHE to date, indicate that, while subop-
timal, surgical excision was the most effective treatment modality, whereas corticosteroids were 
ineffective treatments for ALHE. This study sheds light on treatment response patterns, highlights 
the overall need for better treatments, and will hopefully guide evidence-based clinical decision 
making for the management of ALHE.    
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Patients with sorafenib induced drug eruptions can be successfully re-challenged
D Pichard,1 A Cardones,2 E Chu3 and HH Kong1 1 Dermatology Branch, CCR, NCI, NIH, 
Bethesda, MD, 2 Dermatology, Duke University, Durham, NC and 3 Dermatology, University 
of Pennsylvania, Philadelphia, PA
Sorafenib is a small molecular inhibitor of several tyrosine protein kinases (vascular endothelial 
growth factor receptors/VEGFR, platelet-derived growth factor receptors/PDGFR, rearranged during 
transfection/RET, FMS-like tyrosine kinase 3/FLT3, and c-kit) and Raf kinases (C- & B-Raf). This drug 
is FDA approved for advanced renal cell carcinoma, unresectable hepatocellular carcinoma and 
locally recurrent or metastatic, progressive differentiated thyroid carcinoma refractory to radio-
active iodine treatment. Cutaneous side effects of this drug are common, affecting up to 91% of 
patients. Common reactions include hand-foot skin reaction and nonspecific rash, which can be 
dose-limiting. A less common reaction is generalized dermatitis that may be papular, morbilliform, 
or erythema multiforme-like. In the 10 previously reported cases in the English language literature, 
sorafenib was discontinued. We report 5 patients who developed cutaneous lesions while being 
treated with sorafenib. Cutaneous lesions consisted of a) targetoid dusky papules and plaques 
distributed on the trunk and extremities in some patients and b) widely distributed erythematous 
papules in other patients. No patients had mucosal findings. Skin biopsies demonstrated perivascular 
lymphohistiocytic or mixed infiltrate and spongiosis with rare, if any, necrotic keratinocytes. All 
patients had resolution of their skin lesions with discontinuation of sorafenib. Sorafenib was restarted 
at a decreased dose and was tolerated without a recurrence of the rash in all cases. Drug-induced 
eruptions can be severe and potentially life-threatening and have been reported to be a side effect 
of sorafenib. This series demonstrates that clinicopathologic correlation is important to examine 
histology to distinguish true cases of erythema multiforme and to consider restarting sorafenib, a 
potentially life-saving antineoplastic therapy, in patients who develop a drug-induced eruption.   
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Blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as 
Merkel cell carcinoma biomarkers
MR Gaiser,2 K Daily1 and I Brownell1 1 Dermatology Branch, National Cancer Institute, NIH, 
Bethesda, MD and 2 Department of Dermatology, University of Heidelberg, Heidelberg, 
Germany
Merkel cell carcinoma (MCC) is a rare but aggressive neuroendocrine skin cancer. Serial imaging 
studies are typically used to follow MCC treatment responses and to monitor for disease progression 
during aftercare. To evaluate additional modalities for monitoring disease status, we investigated 
the use of neuron-specific enolase (NSE) and chromogranin A (ChrA) blood levels, as well as 
EpCAM-positive circulating tumor cell (CTC) counts as biomarkers for MCC. A total of 60 patients 
with MCC were retrospectively analyzed for NSE and ChrA blood levels measured during routine 
care; 30 of these patients were additionally screened for CTCs using the maintrac method. Despite 
routine use by some physicians, NSE and ChrA blood levels did not correlate with progression free 
survival, disease specific survival, MCC treatment response, or MCC recurrence. We found CTCs 
in 97% of all tested MCC patients. CTC counts were significantly elevated in patients with active 
disease (p<0.05), suggesting their potential use in monitoring disease burden. Our findings indicate 
that real-world usage of NSE and ChrA blood levels failed to be effective as prognostic tests or in 
detecting disease progression during aftercare of MCC patients. In contrast, longitudinal monitoring 
of CTC shows promise as a novel biomarker for MCC disease behavior.    
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Progressive necrobiosis lipoidica of the bilateral breasts successfully treated with systemic 
corticosteroids, methotrexate, and pentoxifylline
NA Wright,1 DR Mazori,2 M Patel,1 VE Nambudiri,1 AN Femia2 and R Vleugels1 1 
Dermatology, Brigham and Women’s, Boston, MA and 2 Ronald O. Perelman Department of 
Dermatology, NYU School of Medicine, New York, NY
Necrobiosis lipoidica (NL) is a granulomatous disorder that typically presents on the shins, however, 
it may develop in uncommon sites including the face, upper extremities, and trunk. Only 2% of NL 
patients have no involvement of the legs. A variety of therapeutic modalities have been reported 
to be useful in the treatment of NL, but randomized controlled trials are lacking. We present a 43 
year-old woman with extensive, confluent plaques on the bilateral breasts that developed over the 
course of one year. Her lesions began unilaterally on the left breast and then rapidly progressed 
into coalescing plaques over both breasts. She had no additional lesions, including on the legs. 
The plaques failed to respond to topical corticosteroids and calcineurin inhibitors. Her examination 
revealed yellow and red-brown plaques with erythema and telangiectasias overlying the peripheral 
raised borders. The patient had no history of diabetes mellitus, and laboratory evaluation revealed 
no evidence of glucose intolerance or monoclonal gammopathy. Biopsy revealed a pandermal 
palisaded granulomatous dermatitis with plasma cells consistent with NL. Given the patient’s rap-
idly evolving course and risk for ulceration, she was placed on a three month prednisone taper 
in combination with methotrexate 25 mg weekly and pentoxifylline 400 mg three times daily. At 
four months, her eruption had largely resolved with residual yellow-brown hyperpigmentation in 
the affected areas, with no evidence of a raised peripheral border. Our case demonstrates a highly 
atypical location that clinicians should consider when diagnosing NL and represents the first reported 
case of breast NL treated with systemic therapy. In addition, it demonstrates that combination 
therapy with systemic corticosteroids, methotrexate, and pentoxifylline can be effective in patients 
with rapidly evolving disease.    
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Should granuloma faciale and erythema elevatum diutinum be classified in the IgG4-related 
disease spectrum? Histopathologic and immunophenotypic appraisal of 32 cases
S Kavand,1 J Lehman2 and L Gibson2 1 Medicine, SFH, University of Illinois, Evanston, IL and 
2 Dermatology, Mayo Clinic, Rochester, MN
IgG4-related disease (IgG4-RD) is a fibroinflammatory condition with poorly defined skin manifes-
tations. Unequivocal cases of IgG4-related skin disease typically present with pseudolymphomatous 
violaceous papules and nodules. Consistent microscopic features include increased density of 
IgG4+ plasma cells and IgG4+/IgG+ plasma cell ratio, storiform fibrosis, and obliterative phlebitis. 
We sought to evaluate microscopic features and IgG4+ plasma cell density and distribution in 
granuloma faciale (GF) and erythema elevatum diutinum (EED), two related dermatoses that share 
some microscopic features with IgG4-RD. With IRB approval, all cases of GF/EED diagnosed at our 
institution from 1992-2014 were evaluated based on the clinical and microscopic features and IgG4 
and IgG stain results. Cases with incompatible clinical or microscopic features, or with insufficient 
tissue for staining, were excluded. Thirty-two patients (GF, n=25; EED, n=7) met inclusion criteria, 
with male/female ratio of 2.2/1. No patient was known to have IgG4-RD involving another organ. 
Obliterative phlebitis, dermal fibrosis, and dermal plasma cell infiltrates were uniformly present, 
and eosinophilic inflammation was frequent. Average IgG4+ plasma cell density was 13.5 cells/
high powered field (hpf; range: 0- 95 cells/hpf), and mean IgG4/IgG ratio was 0.15 (range: 0- 0.5). 
50% of cases had < 5 IgG4+ cells/hpf. 18% of cases had at least one field with an IgG4/IgG ratio of 
>40%. Besides increased plasma cells on routine microscopy, no clinical or microscopic features 
were predictive of an elevated IgG4+ plasma cell density or IgG4/IgG ratio. This study is limited by 
small size and its retrospective nature, with both being related to the rarity of these disorders. Our 
results indicate that although some microscopic and immunophenotypic features of GF/EED may 
resemble those of IgG4-RD, the majority of cases do not meet microscopic criteria. Future studies 
may delineate the optimal classification of these disorders.    
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Assessment of the genetic basis of rosacea by genome-wide association study
AS Chang,1 I Raber,1 J Xu,1 R Li,1 R Spitale,2 J Chen,1 A Kiefer,3 C Tian,3 N Eriksson,3 D Hinds3 
and J Tung3 1 Dermatology, Stanford University School of Medicine, Redwood City, CA, 2 
University of California at Irvine, Irvine, CA and 3 23andme, Mountainview, CA
Rosacea is a common, chronic skin disease that is currently incurable. Although environmental 
factors influence rosacea, the genetic basis of rosacea is not established. In this genome-wide associ-
ation study, a discovery group of 22,952 individuals (2,618 rosacea cases and 20,334 controls) was 
analyzed, leading to identification of two significant single nucleotide polymorphisms (SNPs) asso-
ciated with rosacea, one of which replicated in a new group of 29,481 individuals (3,205 rosacea 
cases and 26,262 controls). The confirmed SNP, rs763035 (p=8.0x10-11 discovery group; p=0.00031 
replication group), is inter-genic between HLA-DRA and BTNL2. Exploratory immunohistochemical 
analysis of HLA-DRA and BTNL2 expression in papulopustular rosacea lesions from six individu-
als, including one with the rs763035 variant, revealed staining in the peri-follicular inflammatory 
infiltrate of rosacea for both proteins. In addition, three HLA alleles, all MHC class II proteins, were 
significantly associated with rosacea in the discovery group and confirmed in the replication group: 
HLA-DRB1*03:01 (p=1.0x10-8 discovery group; p=4.4x10-6 replication group), HLA-DQB1*02:01 
(p=1.3x10-8 discovery group; p=7.2x10-6 replication group), and HLA-DQA1*05:01 (p=1.4x10-8 
discovery group; p=7.6x10-6 replication group). Collectively, the gene variants identified in this 
study support the concept of a genetic component for rosacea, and provide novel candidate targets 
for future studies to better understand and treat rosacea.    
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Characteristics of ocular melanoma at University Hospitals Case Medical Center: 1996-2013
R Vyas,2 E Gotow,2 A Gerstenblith,1 K Honda2, 3, KD Cooper2, 3 and MR Gerstenblith2, 3 1 
Ophthalmology, Mid-Atlantic Retina Specialists, Hagerstown, MD, 2 Dermatology, University 
Hospitals Case Medical Center, Cleveland Heights, OH and 3 Case Western Reserve 
University, Cleveland, OH
Five percent of all primary melanomas are ocular in origin, with an age-adjusted incidence rate 
of 6 per million in the United States. Recent advances have established ocular melanoma as a 
distinct subtype with unique molecular profiles and biological behavior. We sought to determine 
the characteristics of ocular melanoma at our institution. After obtaining institutional review board 
approval, we searched our pathology database for all cases of ocular melanoma that occurred from 
January 1996 to March 2014. There were 51 primary ocular melanomas diagnosed by histology 
over the last seventeen years at our institution. The median age was 66 years, most were Caucasian, 
and 53% occurred in men. Thirty-one cases (61%) were uveal with the choroid being the most 
common site of origin. The most common histological type was mixed spindled and epithelioid, 
followed by unspecified, spindled, and epithelioid. Enucleation was the most common initial treat-
ment. Eight individuals required further treatment for primary tumor clearance. Eleven individuals 
recurred locally, and seven developed metastatic disease. Limited follow-up data were available 
for 22 patients (43%) and median follow-up duration was 3.5 years. We likely underestimated 
the incidence of ocular melanoma at our institution since ocular melanoma may be accurately 
diagnosed with clinical exam and ultrasonography and we used our pathology database to identify 
cases. The proportions of uveal to conjunctival melanoma at our institution, however, are consistent 
with previously published U.S.data.    
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Quality of life is equivalent between atopic dermatitis patients managed through a direct-ac-
cess online model compared to in-office care: A randomized controlled trial
AW Armstrong,2 M Johnson,2 S Lin,2 C Clark,1 AG Florek1 and F Liu2 1 University of 
Colorado, Aurora, CO and 2 University of California, Sacramento, CA
Many patients with chronic skin diseases, such as atopic dermatitis, lack regular access to specialist 
care. We aimed to compare quality of life between a direct-access online model for delivering care 
to patients with atopic dermatitis with in-person care in a randomized controlled equivalency trial. 
A total of 156 children and adults with atopic dermatitis were randomized to either direct-access 
online care or in-person care over 12 months. In the direct-access group, patients captured and 
transmitted digital images of skin lesions and history and received care online asynchronously; 
the dermatologists provided online evaluation, recommendations, and prescription. At the end 
of one year, clinically meaningful improvements in DLQI and CDLQI were observed in both the 
direct-access online and the in-person groups (all mean improvements >5). Specifically, among 
adults with atopic dermatitis, average Dermatology Life Quality Index (DLQI) score in the online 
group decreased from 11.6 SD 5.5 to 5.6 SD 3.4, with mean change of 6.0. In the in-office group, 
DLQI decreased from 12.0 SD 5.6 to 6.7 SD 3.6 with mean change of 5.3. Children in the online 
group experienced a decrease in CDLQI scores from 9.3 SD 5.5 to 4.1 SD 2.3, with a mean change of 
5.2. Children in the in-office group experienced a change in CDLQI score from 9.1 SD 4.9 to 3.7 SD 
2.7, with mean change of 5.4. In-between group differences in both DLQI and CDLQI were within 
the a priori determined equivalence margins. In adults, the Physical and Mental Health Composite 
Scale scores of SF-12 were within pre-specified equivalence margins between the in-person and 
online groups. Quality of life is equivalent between atopic dermatitis patients managed through a 
direct-access online model compared to those managed in office.    
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Ultraviolet light (UVB) alteration of epidermal nerve fibers (ENFs) and neuropeptides: A 
possible mechanism for the efficacy of light therapy in pruritic patients
AT Follansbee,1 IG Panoutsopoulou,1 G Wendelschafer-Crabb,2 WR Kennedy,2 E Hurliman,1 
M Hordinsky,1 GL Wilcox3, 1 and E Benlhabib1 1 Dermatology, University of Minnesota, 
Minneapolis, MN, 2 Neurology, University of Minnesota, Minneapolis, MN and 3 
Neuroscience, University of Minnesota, Minneapolis, MN
Phototherapy is commonly used to treat pruritus, but how light therapy decreases the symptom of 
pruritus is not known. Is the effect of light on nerves, neuropeptides or yet other cells in the skin? 
In this pilot study, one day before UVB treatment of forearm skin, volunteers were tested for their 
minimal erythema dose (MED, ~50 mJ/cm2) on the lower back using a Handisol broadband UVB 
lamp. Then using the MED dose of each volunteer, we obtained 2-mm skin biopsy specimens from 
the anterior forearm of each of four healthy Caucasian volunteers at 0h (baseline), 2h, 7h, and 24h 
post-UVB irradiation. These sixteen biopsy specimens were sectioned and triple-immunostained 
using a series of antibodies to PGP 9.5 (pan-neuronal marker), tryptase (mast cell marker), type IV 
collagen, and the neuropeptides calcitonin gene-related peptide (CGRP) and substance P (SP). Neu-
rolucida 5.05.4 tracing software was used to analyze confocal images for ENF density, and mast cell 
density and degranulation. CGRP and SP density was studied using epifluorescent microscopy. Skin 
erythema was maximal at the 7-hour time point, as was mast cell degranulation and CGRP expres-
sion. The 7-hour time point coincided with a nadir in the density of PGP-stained ENFs; a decrease 
of 4.0 ENFs per mm from 0-hour (p-value=0.1362). SP expression peaked at the 2-hour time point, 
preceding maximal erythema. Mast cell density remained stable throughout the four time points. 
We conclude that application of a MED of UVB light to normal skin is associated with a decrease 
in identifiable ENFs and an increase in SP- and CGRP-stained nerves, particularly at 7 hours. We 
postulate that these phenomena in normal skin also occur in pruritic patients who are successfully 
treated with UVB light and may explain the benefit such patients receive from phototherapy.    
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TRAF3IP2 D10N limits IL-17-induced expression of TNFAIP3 and NFKBIZ in psoriasis: Reg-
ulating the regulators?
S Lambert,1 SW Stoll,1 LC Tsoi,2 RP Nair1 and JT Elder1 1 University of Michigan, Ann Arbor, 
MI and 2 Biostatistics, University of Michigan, Ann Arbor, MI
TRAF3IP2 encodes Act1, a ubiquitin ligase that interacts with IL17R and members of the TRAF 
and IKK families. We and others identified a SNP (rs33980500 C>T) specifying Act1p.D10N as a 
psoriasis susceptibility locus. We have also shown that NFKBIZ and TNFAIP3, encoding transcrip-
tional regulator IkBz and deubiquitinase A20 respectively, map to psoriasis susceptibility regions. 
Because NFKBIZ and TNFAIP3 are known to be inducible by IL17, we used N/TERT KC expressing 
a Tet-inducible shRNA targeting TRAF3IP2 to assess the effects of TRAF3IP2 silencing on expression 
of NFKBIZ and TNFAIP3. Silencing inhibited induction of NFKBIZ and TNFAIP3 (4.1-fold and 
16.5-fold, p=0.0064 and 0.015 by qPCR, respectively; 200 ng/ml IL-17 for 1-2 hr, n=3), and the 
same effect was found for IkBz by Western blotting. We next investigated the effects of Act1D10N 
on NFKBIZ and TNFAIP3 expression, using cultured skin KC and FB from individuals homozygous 
for either allele (Act1DD and NN, respectively). IL17 induced expression of NFKBIZ (11.3-fold, 
p=6.42e-5) and TNFAIP3 (4.8-fold, p=0.002) in Act1DD KC. Induction was significantly less in 
Act1NN KC (1.58-fold, p=0.032 for NFKBIZ and 4.8-fold, p=0.001 for TNFAIP3 in NN vs. DD). FB 
yielded similar results (1.97-fold, p=0.006 for NFKBIZ and 2.1-fold, p=0.013 for TNFAIP3 in NN 
vs. DD). In contrast, Th17 counts were significantly increased in NN vs. DD PBMC (p=0.04), as 
was expression of several proinflammatory cytokines in psoriatic lesions (CXCL1, IFI6, IL8, IL12B, 
IL17A, OAS1, MX1, all FC >1.5, p<0.05 by RNA-seq). Given observations that IkBz and A20 act 
as negative feedback regulators of inflammation, our results suggest that Act1D10N is a loss-of-
function variant that reduces negative inflammatory feedback by limiting induction of NFKBIZ and 
TNFAIP3 by IL17, resulting in increased inflammation and psoriasis risk. As agents targeting IL17 
signaling are highly effective in psoriasis, our results also link three robust psoriasis genetic signals 
to a clinically-relevant functional network.    
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Thermal transport characteristics of human skin measured in vivo using ultrathin conformal 
arrays of thermal sensors and actuators
R Webb,1 R Pielak,2 P Bastien,3 J Nittynen,4 J Kurniawan,1 M Manco,5 A Lin,1 NH Cho,1 
V Malyrchuk,1 G Balooch2 and J Rogers1 1 Frederick Seitz Materials Research Laboratory, 
Department of Materials Science and Engineering, University of Illinois at Urbana-
Champaign, Urbana, IL, 2 California Research Center, L’Oréal, San Francisco, CA, 3 
Research and Innovation, L’Oreal, Aulnay sous Bois, France, 4 Department of Electronics 
and Communication Engineering, Tampere University of Technology, Tampere, Finland and 
5 Early Clinical, L’Oréal, Clark, NJ
Measurements of skin thermal properties can reveal changes in skin physical states and potentially 
provide clinically relevant information about different aspects of human physiology. Traditional 
methods for skin thermography use either sophisticated infrared digital cameras that require body 
parts stabilization or simple, paste-on temperature sensors for single-point measurements. These 
and other related technologies have value in certain contexts, but have limited application for the 
investigation of the skin as part of a complicated, living biological systems. Here a system of ultrathin 
arrays of heating elements that laminate onto the skin are used in clinical study to provide high 
resolution, in vivo skin thermal properties measurements. We perform a comprehensive analysis 
of the in vivo skin thermal properties on 6 different body locations of 25 human subjects. These 
transient heating measurements are then correlated with measurements of epidermis (EP) and stratum 
corneum (SC) thickness by optical coherence tomography (OCT), and electrical impedance based 
measurements of water content. The data demonstrate that thermal transport correlates negatively 
with SC and EP thickness and positively with water content, with a strength of correlation that varies 
from region to region, e.g. stronger in the palmar than in the follicular regions.    
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Likelihood of undergoing routine skin checks and use of skin cancer information are influ-
enced by family history of skin cancer but not other risk factors for skin cancer
DM Kuhn, S Alessi Cesar, R Grandhi, T Wang, S Kang and AL Chien Dermatology, Johns 
Hopkins University, Baltimore, MD
Routine skin exams and skin cancer education are important for the early detection and prevention 
of skin cancers. However, factors that contribute to an individual’s decision to undergo skin checks 
and acquisition of skin cancer knowledge are unclear. We conducted a cross-sectional analysis 
of 100 patients who received regular skin checks (at least 1 dermatology visit per year) and 100 
patients who did not. Surveys exploring factors influencing skin checks and skin cancer education 
were administered. We performed unconditional logistic regression and calculated 95% confi-
dence intervals while controlling for age, race, gender, level of general education, and region of 
residence. We found that subjects with a family history of skin cancer were more likely to receive 
regular skin checks than patients without skin cancers in the family (OR=3.21; 95%CI=2.31-4.11; 
p<.01). Surprisingly, other skin cancer risk factors (light eyes, light hair, tanning bed use, history 
of blistering sunburns) did not contribute significantly to an increased propensity to undergo a 
skin check. In regards to factors related to skin cancer education, we found a highly significant 
relationship between a positive family history of skin cancer and an increase in the number of skin 
cancer educational sources used (OR=2.68; 95%CI=2.38-2.98; p<.0001). Similar to the findings for 
skin exam, we found that other risk factors for skin cancer (light eyes, light hair, tanning bed use, 
history of blistering sunburns) did not contribute to the use of skin cancer educational resources. 
Our findings suggest while it is reassuring that a family history of skin cancer increases the likelihood 
of regular skin checks and increased use of skin cancer education, it is concerning that other risk 
factors for skin cancer are not significant contributors. The findings highlight the need for broader 
education regarding the importance of skin checks and skin cancer education.    
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Novel imaging techniques for quantifying cutaneous sclerosis
A Cardones1, 2, S Lee,3 J Hooten,1 L Banez,4 A Agarwal,4 RP Hall1, 2, K Sullivan5 and 
M Palmeri3 1 Dermatology, Duke University, Durham, NC, 2 Dermatology, Durham VA 
Medical Center, Durham, NC, 3 Biomedical Engineering, Duke University, Durham, NC, 4 
Duke University School of Medicine, Durham, NC and 5 Cellular Therapy, Duke University, 
Durham, NC
Objective, reproducible means for quantifying cutaneous sclerosis are lacking. Acoustic radiation 
force impulse (ARFI) and Shear Wave Elasticity (SWEI) imaging are novel technologies that utilize 
high energy sound waves and measure tissue displacement and shear wave speed (SWS). These have 
not been previously adapted for a superficial and thin organ such as skin. Our aim was to develop 
a novel method of shear wave generation and tracking, as well as a computational algorithm that 
would allow us utilize ARFI and SWEI to quantify skin stiffness. We further aimed to test the clinical 
utility of these modifications in a pilot study. We prospectively utilized ARFI and SWEI to measure 
tissue displacement and shear wave speed in 1) sclerotic and contralateral normal skin (n=20 pairs) 
and 2) paired normal right and left sites (n=150 pairs) among patients with morphea, sclerotic 
GVHD and healthy volunteers. Skin thickness was also measured using normal, B mode ultrasound. 
Median tissue displacement using ARFI was 1.82 times more in normal compared to sclerotic 
skin (p=<0.0001). Inversely, SWS was 1.33 times faster across sclerotic skin compared to normal 
(p=0.0001). Mean displacement (ARFI: -2.53 microns; p=0.001), SWS (SWEI: 1.52 m/s; p=0.0015), 
and thickness (BMode: -0.60 mm; p=0.0134) were significantly different between lesional and 
normal skin. Divergence of measurements between lesional and normal skin did not differ between 
SWEI and BMode (p=0.50) but was significantly greater for ARFI compared to either SWEI (p=0.004) 
or BMode (p=0.01). Measurements in normal skin also differed across anatomical locations for 
ARFI (p=0.001) and SWEI (p=0.001). In conslusion, ARFI and SWEI effectively and consistently 
discriminate between sclerosed and normal skin, but ARFI discriminates more effectively compared 
to SWEI and regular ultrasound. Larger prospective studies with clinical correlation are under way.   
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Identifying the allergic march related proteins in post-adolescent allergic march patients 
using proteomic analysis
J Shin, J Noh, S KIM, S Jin, H Lee, J Lee, C Park, H Chu, J Lee and KH Lee Department of 
Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University 
College of Medicine, Seoul, Korea (the Republic of)
Generally, early onset of childhood eczema, more severe eczema in childhood, and family history 
of atopic diseases are considered as factors contributing to the development of allergic march. 
In childhood, barrier defect and immune dysregulation involving thymic stromal lymphopoietin 
(TSLP) is regarded as a contributor in the pathogenesis of allergic march development. However, 
the characterization of allergic march patients who retain AD beyond childhood was never fully 
explored. Thus we aimed to compare the serum and T cells of atopic dermatitis patients who 
developed allergic march and who did not. In order to discover allergic march-regulated proteins, 
we performed 2-dimensional Difference Gel Electrophoresis (2D-DIGE) analysis for serum proteins 
and TMT labeled quantitative proteomics for T cells. In serum proteome analysis, 11 proteins 
including exophilin 5 and Zinc finger protein 443 were up-regulated and 17 proteins including Zinc 
alpha 2-glycoprotein were down-regulated in allergic march developed atopic dermatitis patients. 
Among the Gaussian fit 95% over proteins, 8 proteins were down-regulated and 64 proteins were 
up-regulated in T cell of allergic march developed atopic dermatitis patients. Among up-regulated 
proteins, 12 proteins including vacuolar protein sorting associated protein 4A, Ras GTPase-activating 
protein 1, ADP/ATP translocase 3, protein THEM6, Alpha-2-HS-glycoprotein were more increased 
in allergic march developed atopic dermatitis patients than atopic deramtiits only patients. Since 
the biomarker to predict allergic march has not been established yet, these proteins could be the 
candidates of novel allergic march biomarkers.    
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The percentage of dermal elastin protein correlates with age and Fitzpatrick skin type rather 
than skin elasticity
TC Florence,1 H Pham,1 B Reece,2 D Gan,1 G Kalahasti1 and MD Hines1 1 Skin & Clinical 
Research, Mary Kay, Inc, Dallas, TX and 2 RCTS, Inc., Irving, TX
Skin elasticity is attributed to multiple extra cellular matrix proteins in the dermis. However, elastin 
is thought to be a key protein critical for this function in the skin. Age and extrinsic factors such 
as UV exposure are known reduce skin elasticity over time. In a previous study, skin elasticity 
was measured on a cohort of panelists of varying age and Fitzpatrick skin type. Not surprisingly, 
elasticity negatively correlated with age. However, elasticity also correlated with Fitzpatrick skin 
type, regardless of age. Volunteers in highest age range (60-69) with Fitzpatrick skin type (V-VI) had 
better skin elasticity than volunteers in the mid age range (46-59) with Fitzpatrick skin type (I-II). 
Using biopsies generated from 21 panelists, the percent of total elastin protein in the dermis was 
analyzed and found no significant correlation between the percent of elastin in the skin and mea-
sured elasticity. However, the percentage of elastin did correlate with Fitzpatrick skin type. Higher 
skin types (IV-VI) contained a lower percentage of elastin, while lower skin types (II-III) contained 
more. In addition, the total percentage of elastin negatively correlated with panelist age, suggesting 
that the increased elastin protein in these samples was dysfunctional. These data demonstrate that 
the preservation of elastin protein, either through age or the innate photo protection associated with 
darker skin types, is important for skin elasticity. The increased elastin observed here might indicate 
dysfunction due to UV damage, but increased elastin due to other technology may yield functional 
elastin. Stimulation of functional elastin in the skin is an important target in evaluation of skin aging 
which could prove useful in the development of future anti-aging treatments.    
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Disruption and disorganization of type I collagen fibrils in early striae gravidarum
F Wang,1 K Calderone,1 TR Johnson,2 GJ Fisher1 and JJ Voorhees1 1 Dermatology, University 
of Michigan, Ann Arbor, MI and 2 Obstetrics & Gynecology, University of Michigan, Ann 
Arbor, MI
Striae gravidarum (SG), or stretch marks of pregnancy, affect 50-90% of women and are per-
manent. As the pathogenesis of SG remains unclear, we investigated the organization of type I 
collagen (COL) fibrils in early abdominal lesions of 27 pregnant women. Using second harmonic 
generation (SHG) microscopy, we found that dermal COL fibrils in control (hip) and stretched 
perilesional abdominal skin appeared as thick, densely packed bundles (n=19). In SG, especially 
in the reticular dermis, COL bundles were markedly separated. Between separated bundles, there 
were clumps of thin, disorganized COL strands, which persisted into the postpartum period without 
forming thick, densely packed bundles. Enmeshed within these strands were many fibroblasts with 
intense immunofluorescent staining of type I procollagen, as observed by multiphoton plus SHG 
microscopy. Three-dimensional images revealed that these synthetically active fibroblasts were 
intimately associated with disorganized COL strands, suggesting that the strands are newly synthe-
sized. Supporting this possibility, immunostaining of type I procollagen revealed minimal staining in 
the dermis of control or perilesional skin, whereas staining in SG was increased 14-fold (p<.05 vs. 
control, n=11) and localized to numerous fibroblasts throughout the dermis. Immunostaining of heat 
shock protein (HSP) 47, a chaperone needed for procollagen synthesis, was similar and increased 
30-fold in SG (p<.05 vs. control, n=11). Additionally, SG displayed increased gene expression 
of type I procollagen, HSP47 and prolyl-4-hydroxylase (4.5-, 2.8- and 3.0-fold, respectively; all 
p<.05 vs. control, n=12), but no significant changes in COL-degrading matrix metalloproteinase 
(MMP)-1 or -3. Thus, early SG display marked separation of COL bundles, accompanied by the 
emergence of persistent, disorganized COL strands. These data support the hypothesis that intense 
skin stretching stimulates COL production, but prevents formation of normal COL bundles, which 
translates clinically to atrophy.    
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Epicutaneous sensitization to peanuts and other food allergens by patch testing promotes 
Th2 polarization with increased IL-33
B Ungar1, 2, T Czarnowicki,2 JM Corrêa da Rosa,2 JG Krueger2 and E Guttman-Yassky1, 2 1 
Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY and 2 Laboratory for 
Investigative Dermatology, The Rockefeller University, New York, NY
Food allergy has increasing prevalence and often coincides with other atopic disorders. While 
past studies focused on immediate hypersensitivity reactions, with treatment mostly reliant on oral 
immunotherapies, recent data show possible advantage to alternative epicutaneous immunotherapy 
based on delayed hypersensitivity (DTH). However, the molecular basis for DTH reactions has not 
been evaluated. We sought to perform a molecular (gene arrays and RT-PCR) and cellular (immu-
nohistochemistry) characterization of patch-tested skin with different food allergens (e.g peanuts, 
codfish, beef) compared with control skin from 12 patients with known food allergy. These data were 
also compared to biopsies from 25 positive patch-tests with common contact allergens (e.g nickel). 
Criteria of fold change/FCH>2.0 and FDR<0.05 were used to define differentially expressed genes 
(DEGs) compared with control skin. Weaker genomic responses were elicited by food compared to 
contact allergens (only 158 DEGs vs. 1937 DEGs, respectively), and only five genes were uniquely 
modulated by foods (including the neutrophil chemoattractant LTB4R). Despite the weaker reactions 
with foods, higher expression of the Th2 cytokine IL-33 was detected in food compared to stronger 
allergens such as nickel (6 FCHs for peanuts; p=0.07 for all foods). Food responses were largely 
Th2 and Th22 polarized, with smaller Th1 and Th17 components. Among food allergens, beef and 
codfish showed the highest cellular infiltrates and strongest modulation of inflammatory and Treg 
pathways, while peanuts showed the highest expression of IL-33 and innate (IL-8, IL-1β) genes. In 
sum, epicutaneous sensitization with food allergens induces innate cytokine responses and drives a 
Th2/Th22 polarization with increased IL-33. Given the increasing role of IL-33 in food sensitization 
and Th2 priming, this molecule might be an attractive therapeutic target for peanut allergic patients.   
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Detection of the Merkel cell polyomavirus in human Merkel cell carcinomas and the clinical 
implications of tumor viral status
R Doumani,1 AS Moshiri,1 L Yelistratova,1 O Chang2, 1, M Delaney,2 M Huang,3 S McArdle,3 
P Nghiem1 and A Blom1 1 Department of Medicine, University of Washington, Seattle, WA, 
2 Department of Pathology, University of Washington, Seattle, WA and 3 Department of 
Laboratory Medicine, University of Washington, Seattle, WA
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer associated with the 
Merkel cell polyomavirus (MCPyV). Previous studies have reached conflicting conclusions regarding 
the proportion of MCCs that do not contain the virus and the clinical impact of tumor viral status. 
We used three separate methods to detect MCPyV in 229 unique MCC tumors. Immunohistochem-
istry (IHC) with two monoclonal antibodies (CM2B4 and Ab3) specific for different portions of the 
large T antigen was performed. Antibody staining was scored using the Allred system (score ≤2 
was negative). We also employed quantitative TaqMan PCR on each sample using primers specific 
for the large T region of MCPyV and considered <1 copy of viral DNA/100 cells to be negative. A 
sample was ultimately deemed virus-negative if 2 or 3 of the diagnostic criteria listed above were 
negative, and 35 of 229 (15%) unique patient tumors in our cohort were virus-negative by these cri-
teria. Survival analysis showed virus negative patients have significantly decreased progression-free 
survival relative to patients with virus positive tumors when controlled for sex, immune status, 
and stage (p=0.023). While there does not appear to be an ideal method for detecting MCPyV in 
MCC patients, immunohistochemistry analysis with CM2B4 appears to be the most accurate test 
of tumor viral status (sensitivity = 0.90, specificity = 0.97). We confirm that a subset of MCCs do 
not contain detectable MCPyV, and virus negative MCCs may represent a more aggressive subtype 
that warrants closer clinical follow-up.    
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Unique cutaneous reaction to second- and third-generation tyrosine kinase inhibitors for 
chronic myeloid leukemia
A Patel,1 A Solomon,2 M Mauro3 and BD Ehst2 1 Dermatology, UT MD Anderson Cancer 
Center, Houston, TX, 2 Dermatology, Oregon Health & Science University, Portland, OR and 
3 Medicine, Division Hematology, Memorial Sloan-Kettering Cancer Center, New York, NY
Recently developed tyrosine kinase inhibitors (TKIs) offer first-line alternatives or rescue options 
to patients with chronic myeloid leukemia (CML) who previously had only imatinib as a targeted 
therapeutic choice. While these medications are generally well-tolerated, cutaneous reactions 
occur frequently and can present a management challenge. We describe our experience with a 
newly recognized, yet under-reported and appreciated, skin reaction to the second-generation TKIs 
dasatinib and nilotinib, and extend it to the newer third-generation agent ponatinib. Nine patients 
developed varying degrees of a clinically and histopathologically lichenoid exanthem comprised of 
erythematous, predominately follicular papules with scale and alopecia. The pattern is reminiscent 
of the scarring and non-scarring alopecia of follicular lichen planus/lichen planopilaris (LPP) with 
keratosis pilaris (KP)-like-LPP, the rare Graham-Little-Piccardi-Lassueur syndrome. Several patients 
developed the eruption on more than one TKI while others resolved when switched to a different 
drug. Importantly, the accompanying pruritus can be severe enough to result in discontinuation of 
what is potentially life-saving therapy. Clinicians should be aware of this unusual eruption to the 
newer TKIs used to treat CML and the potential challenges it presents for treatment. Understanding 
these eruptions resulting from targeted therapeutics may also suggest potential mechanisms in the 
idiopathic forms of follicular lichen planus.    
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Ustekinumab treatment of psoriatics infected with hepatitis B and/or hepatitis C virus
S Siegel, S Naugler, K Winthrop and BD Ehst Oregon Health & Science University, Portland, 
OR
Exacerbation or reactivation of chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) in infected 
psoriatics during treatment with biologics is a well-known risk with use of TNF inhibitors. Very little 
is known, however, about these risks in relation to ustekinumab therapy as less than 30 cases are 
reported despite its wide-spread use over the past six years. We retrospectively reviewed our own 
large cohort of psoriatics treated with ustekinumab in the setting of HBV and/or HCV infection. 
Eighteen adults (13 men, five women; age 23-60) with psoriasis (17 plaque-type, one palmar/plan-
tar; nine with concurrent psoriatic arthritis) were identified, all having received at least two doses 
of ustekinumab. Seven patients had HBV infection alone, including four sAg+ chronic hepatitis B 
patients (one eAg+, viral load >170,000,000 IU/ml), and three received concurrent antiviral treat-
ment. Three patients were co-infected with HBV and HCV including one with chronic HBV (sAg+, 
eAg-), all three with detectable HCV viremia; two received concurrent antivirals for HBV. Eight 
patients were infected with HCV alone, four viremic at start of therapy. Four of the HCV+ patients 
had biopsy-proven cirrhosis at the start of therapy. Average treatment time with ustekinumab was 
10 (HBV), 16 (HBV/HCV) and 15 (HCV) months respectively. Serum transaminases and viral DNA/
RNA levels were followed serially in all patients, and there was no evidence of viral reactivation 
or significant elevations in liver enzymes. Fourteen patients remain on ustekinumab currently, 
while four individuals discontinued due to unsatisfactory efficacy. With careful patient selection 
and monitoring, ustekinumab may offer another viable treatment option for psoriatics dealing with 
chronic viral hepatitis.    
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Clinical features of PRP from patient and provider perspectives: An epidemiologic cross-sec-
tional study of 100 PRP cases
NA Ross, H Chung, MS Keller, J Andrews, Q Li and J Uitto Dermatology and Cutaneous 
Biology, Sidney Kimmel Medical College, Philadelphia, PA
Pityriasis Rubra Pilaris (PRP) is a papulosquamous disorder with limited epidemiologic and clini-
copathologic data. To evaluate objective and subjective disease experience metrics, we surveyed 
100 patients reporting PRP diagnosis. Two dermatologists examined clinical, photographic and 
histopathologic information and confirmed definitive diagnosis of classic PRP in 50 patients. Females 
represented 56%. The average age at symptom onset was 57 yrs (range, 25 to 80; median, 60) in 
adults, and 7 yrs (range, 2 to 13; median, 4) in children. Onset peaks occurred in the 1st as well 
as 6th and 7th decades of life. Average age at diagnosis was 58 yrs (range, 29 to 80; median, 60) 
in adults, and 16 yrs (range, 2 to 37; median, 4) in children. Only 26% of patients were correctly 
diagnosed at initial presentation. This was delayed, on average, by 29 months (range, 0.25 to 288; 
median, 2) with most (54%) having undergone ≥2 biopsies. Nearly all (98%) elected for some form 
of therapy. Topical emollients, corticosteroids and urea as well as oral retinoids, methotrexate and 
TNF-α inhibitors were the 3 most common topical and systemic treatments, respectively. However, 
topical corticosteroids and urea as well as oral retinoids, corticosteroids and TNF-α inhibitors were 
perceived by the patients to be the most helpful. Symptoms persisted in 72% for 58 months (range, 
1 to 300; median 30) on average. The 28% who entered remission had symptoms for 84 months 
(range, 4 to 516; median, 44). Only one juvenile entered remission (5 year course); those still afflicted 
have had symptoms, on average, for 124 months (range, 12 to 348; median, 96). Comorbidities were 
reported in 62%, most commonly hypothyroidism (20%), dyslipidemias (18%) and other cutaneous 
diseases (14%). Depression secondary to their PRP was reported in most patients (76%). None 
reported a family history of PRP; 18% reported a family history of psoriasis. Study data reconfirm 
that PRP remains a challenging diagnosis without established treatment.    
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Hashimoto’s thyroiditis associated with psoriasis: A cross-sectional study 
T Kiguradze,1 F Bruins,1 T Bhattacharya,1 A Rademaker,2 A Posligua,1 AS Amin,1 
AE Laumann,1 SM Belknap1, 3, DP West1 and B Nardone1 1 Department of Dermatology, 
Northwestern University, Chicago, IL, 2 Department of Preventive Medicine, Northwestern 
University, Chicago, IL and 3 Department of Medicine, Division of General Internal Medicine 
and Geriatrics, Northwestern University, Chicago, IL
Psoriasis is increasingly being explored as a metabolic syndrome disorder with systemic manifesta-
tions. Moreover, previous reports show associations between psoriasis and autoimmune diseases. 
For Hashimoto’s thyroiditis, a chronic, autoimmune disorder, there are scarce reports exploring such 
an association that remains to be elucidated. We sought to determine if we could detect an associ-
ation between psoriasis and Hashimoto’s thyroiditis in a large, urban academic patient population 
through advanced data-mining of an electronic medical record (EMR) database. In our EMR database 
(> 2.5 million individuals; January 2001 through December 2013), we selected subjects by ICD-9 
codes (psoriasis: 696.0; 696.1; Hashimoto’s thyroiditis: 245.2). An odds ratio (OR) was obtained for 
association between psoriasis and Hashimoto’s thyroiditis. Of a total of 856,615 individuals, 9,654 
had a diagnosis of psoriasis, while 1,745 had a diagnosis of Hashimoto’s thyroiditis. Of these, 41 
subjects were diagnosed with both diseases. A highly significant association between psoriasis and 
Hashimoto’s thyroiditis was detected in this population after adjusting for confounding variables 
such as sex, age, psoriatic arthropathy and systemic anti-psoriatic agents, however PUVA was not 
included as a confounding variable (OR=2.49; 95%CI 1.79 -3.48; p <0.0001). These findings show 
that Hashimoto’s thyroiditis is strongly associated with psoriasis in our study population. With these 
new findings, further investigation regarding the association between psoriasis and Hashimoto’s thy-
roiditis is warranted. Since these findings have broad clinical impact in dermatology and medicine, 
this association deserves prioritized attention in both patient care and clinical research, including 
developmental therapeutics.    
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Forward-looking infrared imaging predicts ultimate burn depth in a porcine vertical injury 
progression model
JA Miccio,1 S Parikh,3 X Marinaro,2 A Prasad,3 C Qian,3 S McClain,5 A Singer5 and 
RA Clark3, 4 1 School of Medicine, Stony Brook University, Stony Brook, NY, 2 Department 
of Bioengineering, Cornell University, Ithaca, NY, 3 Department of Biomedical Engineering, 
Stony Brook University, Stony Brook, NY, 4 Department of Dermatology, Stony Brook 
University, Stony Brook, NY and 5 Department of Emergency Medicine, Stony Brook 
University, Stony Brook, NY
Current methods of assessing burn depth are inadequate and are primarily based on visual assess-
ments. This technique has been shown to have only 60% accuracy and thus a more precise method 
is needed. Forward-Looking Infrared (FLIR) thermography is a simple and noninvasive tool with the 
potential to rapidly assess burn depth. We evaluated if early measurements of burn temperature 
with FLIR imaging can be used as a predictor of burn depth as assessed by vertical scarring 28 days 
post-injury. Same size burns of different intensities were created on the backs and flanks of female 
Yorkshire Pigs. The burns were imaged with FLIR and analyzed with FLIR ExaminIR® software and 
Matlab. The temperature minima and a parabolic area encompassing a line of 100 temperature 
points across the mid-burn to the temperature minima (temperature half area) were used to correlate 
with scar depth. Four image parameters were found to be predictive of scar depth: temperature 
minima at day 2, temperature half area at day 2, and change in these variables from day 1 to day 
2. Temperature half area values 2 days post-burn had higher correlations with scar depth than did 
the minimum temperatures (r2 0.67 vs. 0.59). However, when data were analyzed for sensitivity 
and specificity of predicting >3mm scar depth, indicative of a full thickness burn, temperature 
minima at 2 days post-burn had a sensitivity of 97% and a specificity of 100%. In summary, FLIR 
imaging is a fast and simple tool that we show can predict burn wound outcome in a porcine 
vertical injury progression model. Although these results must be validated in clinical studies, FLIR 
imaging has the potential to aid clinicians in assessing burn severity and thereby assisting in burn 
wound management.    
262
Host T cells survive conditioning in skin and are present during acute GVHD
SJ Divito,1 C Elco,1 TS Kupper1 and Z Yan2 1 Dermatology, Brigham & Women’s Hospital, 
Boston, MA and 2 Harvard Medical School, Boston, MA
Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative in some patients with 
hematologic malignancies, but its full potential has been limited due to transplant-related compli-
cations, including graft vs host disease (GvHD). It is currently hypothesized that in GvHD, donor 
T cells target and destroy host barrier tissues (skin, gut, liver and lung). A role for host T cells has 
not previously been explored, as it is presumed that host T cells in peripheral tissues are eliminated 
by conditioning regimens, along with host T cells in lymphoid organs and blood. However, it has 
recently been appreciated that large numbers of memory T cells reside long-term (TRM) in barrier 
organ epithelial tissues, which are the organs most affected by GvHD. To test the hypothesis 
that skin T cells may survive conditioning regimens and contribute to acute GvHD, we obtained 
formalin-fixed paraffin embedded sections from skin biopsies taken from patients with acute skin 
GvHD who had undergone myeloablative or non-myeloablative conditioning and allo-HSCT with 
sex-mismatched donor cells. Tissue was stained by immunofluorescence for the T cell marker CD3, 
then stained by fluorescent in situ hybridization for X and Y chromosomes. Nuclei were counter-
stained with DAPI. High power images were taken with fluorescent microscopy (Isis Fluorescence 
Imaging Software). Overlay images were used to identify whether skin infiltrating T cells were of 
donor or host origin. All patients studied demonstrated persistence of significant numbers of host T 
cells in skin during acute GvHD, concomitantly with infiltrating donor T cells. Host T cell nuclei 
appeared viable, including in an acute GvHD skin biopsy taken 74 days post-transplantation. This 
data demonstrate that host T cells can survive both myeloablative and non-myeloablative condi-
tioning in skin, and are present during acute skin GvHD. Further research is necessary to determine 
what role, if any, these host T cells play in GvHD. However, their observation in acute GvHD skin 
opens a novel avenue of research in GvHD pathobiology.    
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Shared inflammatory signatures between atherosclerotic plaques and psoriasis skin
WR Swindell,1 A Johnston,1 S Ganesh,2 K Gallagher,3 NL Ward,4 X Xing,1 MK Sarkar,1 
RP Nair,1 JT Elder1 and JE Gudjonsson1 1 Dermatology, Univ of Michigan, Ann Arbor, MI, 2 
Int Med, Univ of Michigan, Ann Arbor, MI, 3 Surg, Univ of Michigan, Ann Arbor, MI and 4 
Dermatology, Case Western Reserve Univ, Cleveland, OH
Increased risk for and accelerated progression of atherosclerosis is a prominent co-morbidity of 
psoriasis. The biologic basis of this association is unclear but does not appear to be due to shared 
genetic predisposition. Using a systems biology approach, we analyzed global transcriptome data-
sets of psoriasis skin (n=163) and post-mortem samples of carotid atherosclerotic plaque (n=13 early 
stage; n=16 advanced stage). We identified increased expression of 438 genes (FC>2; FDR<0.05) 
and decreased expression of 196 genes (FC<0.5; FDR<0.05) in psoriasis lesions. 77% of the psori-
asis-increased genes were also increased in atherosclerotic plaques (P=1.71×10-35). Likewise, 60% 
of the psoriasis-decreased genes were also decreased (P=0.008). Genes increased in both psoriatic 
and atherosclerotic plaque were enriched with respect to 66 Gene Ontology terms (P<0.001), the 
majority of which were related to processes, such as inflammatory response, response to IFN-γ, 
and regulation of T cell activation. These responses were significantly enriched for signature genes 
expressed by macrophages, monocytes and dendritic cells (FDR≤1.11×10-6). This common psoriasis/
atherosclerosis gene set had a strong overrepresentation of genes induced by IFN-γ (FDR=1.47×10-11) 
and TNF (FDR<0.01), including the chemokines CCL18, CCL19, ADAMDEC1, and IFN-response 
genes IFI30 and IRF8 (P<0.001, all). We demonstrate that both IFN-γ and TNF-α are elevated in the 
serum of patients with active psoriasis (2.4 and 31-fold changes, respectively, p<0.002) and that 
receptor systems for both cytokines are present in atherosclerotic plaques. These results identify key 
common cellular and cytokine responses between atherosclerosis and psoriasis, provide testable 
mechanisms by which cutaneous inflammation may feed into and accelerate atherosclerosis in 
psoriasis patients, and may provide guidance for prioritization of therapeutic development.    
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Characterization of gene expression biomarker signatures in cross-sectional and longitudinal 
studies for use as an Alopecia Areata Disease Activity Index (ALADIN)
JE Cerise,1 A Jabbari,1 M Duvic,2 M Hordinsky,3 D Norris,4 VH Price,5 J Mackay-Wiggan,1 
R Clynes1 and A Christiano1, 6 1 Dermatology, Columbia University, New York, NY, 2 
Dermatology, MD Anderson Cancer Center, Houston, TX, 3 Dermatology, Univ of Minnesota, 
Minneapolis, MN, 4 Dermatology, Univ of Colorado, Denver, CO, 5 Dermatology, UCSF, 
San Francisco, CA and 6 Genetics & Development, Columbia University, New York, NY
Alopecia Areata (AA) is a highly prevalent autoimmune disease in which the hair follicle is attacked 
by cytotoxic T lymphocytes. The accessibility of the target organ within skin biopsies has provided 
the opportunity to develop a novel disease activity score based on quantitative composite gene 
expression signatures. Using both Affymetrix microarrays and RNA-Seq data analyzed using Inge-
nuity Systems IPA, we previously identified three striking gene expression signatures in total skin 
from both human AA and the C3H-HeJ mouse, namely, an IFN-γ response (IFN) signature, a cyto-
toxic T cell (CTL) signature, and a hair keratin (KER) signature. To generate a functional biomarker 
from the AA transcriptome, we developed the Alopecia Areata Disease Activity Index (ALADIN), 
a three-dimensional quantitative composite score. ALADIN was derived from expression levels of 
representative genes from the IFN, CTL and KER signatures to generate a measure of the distance 
of AA transcriptional levels from a baseline obtained from the scalp skin of healthy individuals. In 
our studies of mouse AA, we demonstrated that ALADIN scores provide a quantitative measure of 
pharmacologic prevention and treatment of disease. Here, we refine ALADIN and demonstrate its 
potential utility in human AA using Affymetrix microarray data from a multi-center cross-sectional 
study, as well from a longitudinal study in which we tracked patients enrolled in an interventional 
clinical study of AA. Our findings indicate that ALADIN will be useful as a dynamic functional 
biomarker to stratify and longitudinally track patients enrolled in observational and interventional 
clinical studies of AA.    
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Hyaluronan synthase 2 antisense transcript level associates with human skin youthfulness as 
identified by transcriptome sequencing
J Xu,1 RA Flynn,1 R Spitale,2 E Torre,1 R Li,1 DG Kern,3 H Knaggs,3 H Chang1 and AS Chang1 
1 Dermatology, Stanford University School of Medicine, Stanford, CA, 2 Pharmaceutical 
Science, University of California at Irvine, Irvine, CA and 3 NuSkin, Provo, UT
Intrinsic pathways protecting against aging in humans are not well known. The main objective of 
this study was to identify gene expression profiles of older women with visibly youthful skin. After 
Stanford IRB approval, 120 healthy females of European descent, aged 18-93 years, and Fitzpatrick 
Skin Type I/II consented to punch biopsies of skin on sun-protected arm and sun-exposed cheek skin. 
Individuals using anti-aging medications or have undergone cosmetic procedures were excluded. 
Covariates considered included cumulative sun exposure and smoking history. 91 skin samples 
were subjected to 3’-end sequencing for expression quantification (“3-seq”) and the gene expression 
profiles were analyzed between skin youthfulness (SY) and non-SY samples. Results were verified by 
quantitative RT-PCR. Unbiased clustering revealed gene expression signatures characteristic of older 
women with youthful appearing skin distinct from older women without this phenotype. Expression 
of the HAS2-AS1 noncoding RNA, transcribed antisense to HAS2, was significantly decreased in 
patients SY. The expression of HAS2 showed a positive correlation to HAS2-AS1 in 3’seq samples. 
Interestingly, HAS2 has been associated with anti-aging and anti-carcinogenic properties in animal 
models of aging such as the naked mole rat. Altered HAS2-AS1 expression and additional global 
gene expression changes identified as associated with SY provide new targets for further study of 
healthy aging in humans.    
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Aberrant fibroblast differentiation towards cartilage and bone underlies human keloids
JB Fuentes-Duculan,1 KM Bonifacio,1 MH Tirgan,2 M Suarez-Farinas1 and JG Krueger1 1 
Investigative Dermatology, The Rockefeller University, New York, NY and 2 Mount Sinai St. 
Luke’s Roosevelt Hospital, New York, NY
Keloids are common, benign fibroproliferative tumors that occur more frequently among African 
Americans (incidence rate 4-16%). To date, the etiopathogenesis of keloid is not fully understood. 
To investigate the pathogenesis of keloids, we performed transcriptional profiling of biopsies from 
extensive keloid lesion (L), adjacent nonlesional (NL) skin and newly formed keloid of African 
American patients(n=3). Using Affymetrix HGU133 2.0 plus arrays, we identified 1,202 up-regulated 
and 961 down-regulated differentially expressed genes (DEG) between L keloid and NL skin. There 
were 1,819 up- and 1,867 down-regulated DEGs between newly formed keloid and NL skin, while 
492 up- and 775 down-regulated DEGs were identified between L skin and newly formed keloids 
(Fold change >2, False discovery rate <0.05). Most of the top upregulated DEGs between L and 
NL skin are involved in bone/cartilage formation, which includes FBN2 (Fibrillin 2), COL10A1 
(Collagen type X alpha1), ASPN (Asporin), CILP2 (Cartilage intermediate layer protein 2), CDH11 
(Cadherin 11, type 2, osteoblast cadherin), BMP1 (Bone morphogenic protein 1), and BMPR1B (Bone 
morphogenic protein receptor, type 1B). Many upregulated DEGs from the comparison between 
newly formed keloid lesion and NL skin are also related to cartilage or bone, i.e. COL10A1, SPP1 
(Secreted phosphoprotein 1), FBN 2, ASPN, CDH11, RUNX2(runt-related transcription factor 2), 
BMP1; and nerve, i.e. NRP2 (Neuropilin 2), NEFH (Neurofilament). We performed immunohisto-
chemistry staining on selected genes (COL10, FBN2, ASPN, CDH11, BMP1, SPP1, RUNX2) and 
found increased protein expression on L skin and new keloid lesion compared to NL skin. We 
hypothesize that keloids represent a dysplasia of connective tissue towards immature cartilage/
bone differentiation. The phenotype is potentially regulated by overexpression of RUNX2 or other 
transcription factors. This knowledge may give insights to guide the development of better treatment 
for keloids in the future.    
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The impact of chocolate consumption on acne vulgaris 
GR Delost,2 JR Lloyd,1 J Selph,1 ME Delost3 and RJ Pohle-Krauza4 1 Dermatology, University 
Hospitals Case Medical Center, Cleveland, OH, 2 Dermatology, Lake Erie College of 
Osteopathic Medicine, Erie, PA, 3 Health Related Sciences, Youngstown State University, 
Youngstown, OH and 4 Department of Human Ecology, Youngstown State University, 
Youngstown, OH
The effect of individual foods on physiological functioning, including effects on development of 
disease has received renewed attention in recent years. The implication of chocolate in acne 
vulgaris pathogenesis has been historically refuted and this notion has largely been replaced by 
the suggestion that any food with a high glycemic index may indeed contribute to acne vulgaris. 
The goal of this study was to assess the development of new acne lesions following ingestion of 
chocolate as compared to ingestion of a non-chocolate candy with a similar glycemic index. In a 
randomized clinical trial, 54 college students were assigned to either the chocolate or non-chocolate 
group; acne changes were accessed after 48 hours. As an added control, one month later, the groups 
were reversed and acne changes were again noted. Photography was blindly reviewed to assess the 
number of acne lesions. Results revealed that following chocolate consumption, the acne increased 
by an average of 4.8 lesions per student. Following non-chocolate candy consumption with a 
similar glycemic index, the acne decreased by an average of 0.6 lesions per student. Statistically 
significance was noted between the two groups using the paired sample t- test (p<.05, df = 53). 
These results suggest that chocolate consumption is involved with worsening acne, while glycemic 
index variations in diet may not be implicated in acne pathogenesis.    
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Genital metastasis from a primary colorectal cancer: Case report
KI Martínez-Rosales and B Moncada University of San Luis Potosi, San Luis Potosi, Mexico
A 52-year old male patient presented with a history of 1-month with painful ulcers on the penis. 
The patient was diagnosed with colorectal cancer a year before and received radiotherapy, chemo-
therapy and underwent radical surgery achieving complete remission. A year later, an increased in 
carcinoembryonic antigen was reported; therefore imaging studies and Tc-99m bone scintigraphy 
were performed and revealed pulmonary and bone metastases. The patient was treated with a 
second cycle of radiotherapy and chemotherapy and was responding favorably; however a month 
after the last radiotherapy session presented two well-circumscribed and painful ulcers located on 
the glans of penis. Skin biopsy was performed and a moderately differentiated adenocarcinoma 
was found. The diagnosis of cutaneous metastasis from the primary colorectal cancer was made. 
Surgical treatment was discarded and the patient continued with chemotherapy. At this time the 
clinical condition of the patient is stable; however the prognosis of a favorable outcome is poor. 
Colorectal carcinoma is the 3rd most common cancer in the United States. Skin metastasis represent 
the spread of neoplastic cells from a primary malignancy to the skin; the malignant cells can come 
from an internal malignancy or from a primary cancer from the skin. The incidence of skin metastasis 
related to visceral carcinomas is 9%; incidence of skin metastasis from colorectal cancer is 19% in 
men and 9% in women. Skin metastasis from a primary colorectal cancer is uncommon; most are 
diagnosed once the primary malignancy is documented. Metastases from colorectal cancer to the 
skin are located on the abdomen and pelvis. Skin metastases present as rapidly growing solitary 
or multiple subcutaneous nodules; however in the case of primary gastrointestinal carcinomas 
clinical presentation is variable; therefore papules, papillomatous, inflammatory or telangiectatic 
lesions can be found. The histopathological study along with an appropriate clinical assesment are 
needed for the diagnosis; immune markers and ultrastructural studies are helpful to determine the 
origin of the primary tumor.    
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Neural contribution to augmented protease-dependent pruritus in seborrheic dermatitis 
scalp skin
S Goummih,1 T Du,1 T Conniff,1 A Bar-Hen,2 J Langer,3 O Jammayrac,4 R Jourdain,4 L Breton4 
and D Wolpowitz1 1 Dermatology, Boston University, Boston, MA, 2 UFR de Mathématiques 
et Informatique, Université Paris Descartes, Paris, France, 3 L’OREAL Research & Innovation, 
Clark, NJ and 4 L’OREAL Research & Innovation, Aulnay sous Bois, France
Pruritus is a cardinal feature of seborrheic dermatitis (SD) but its pathogenesis is not well-under-
stood. In 14 SD subjects and 16 controls, we tested their normal forearms and pruritic SD scalps 
(SDS) (median VAS-itch, 55/100) and non-pruritic control scalps (CS) (median VAS-itch, 0/100) for 
hyperknesis (pin-prick pain felt as itch) and then measured cowhage-induced (CI) itch. Cowhage, 
a legume, has bean-pod spicules that when inserted in skin, elicit itch mediated by the protease 
mucunain. We biopsied the sensory-characterized scalp tissues and performed multi-label immu-
nohistochemistry for markers of cutaneous innervation. We correlated nerve and CI-sensations. 
SDS lacked hyperknesis but had augmented CI-area under the curve for itch (AUC-itch) vs. CS 
(median, 25%-75%: 4079, 1029-8319 vs 1114, 232-3499; p=0.03) not seen in SD vs control 
forearms (p>0.05). Intraepidermal (IE) nerve fiber density (IENF) was not changed in SDS vs CS 
(p=0.78). IE nerves transmit pain to the spinal cord, where pain input can inhibit itch. IENF did not 
correlate significantly with CI-AUC-itch in CS (p>0.05) but did in SDS (0.44, p<0.05). For %papillary 
dermal (PD) nerves expressing putative itch markers, SDS had significantly more %PD-substance 
P (SP)+/gastrin-releasing peptide (GRP)(-) nerves vs CS (19, 3-38 vs 7, 0-23; p=0.05). CI-AUC-itch 
correlated significantly with %PD-SP+/GRP+ nerves in CS (0.56, p<0.001) but only significantly 
with %PD-total SP+ nerves in SDS (0.35, p<0.05). Our data suggest PD-SP+ nerves contribute to 
protease-mediated itch signaling (P-MIS) in CS and SDS and that augmented P-MIS contributes to 
SD scalp itch, peripherally by sensitization of SP+/GRP(-) nerves and centrally by altered spinal 
cord processing of IE nerve signals, such as loss of itch inhibition by pain. These findings indicate 
protease-inhibitors and NK1-receptor antagonists may treat SD scalp pruritus.    
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University tort liability for allowing college debit card purchasing of indoor UV tanning
K Grigoryan,1 A Best3 and R Dellavalle2 1 University of Cincinnati College of Medicine, 
Cincinnati, OH, 2 Denver VAMC, University of Colorado Denver, Denver, CO and 3 Sturm 
College of Law, University of Denver, Denver, CO
Over forty percent of US college students use indoor UV tanning, almost half of colleges have 
indoor tanning on campus or in student housing, and many colleges list UV tanning salons as 
merchants accepting college debit cards for purchases. The 2014 US Surgeon General’s Call to 
Action to Prevent Skin Cancer recommends that colleges discontinue affiliations with indoor UV 
tanning merchants. We reviewed potential tort liability for universities with such affiliations should 
students be injured by UV tanning either immediately by burning or subsequently by developing skin 
cancer. Negligent misrepresentation might be established with proof that a university unreasonably 
gave false information to the student resulting in the harm. “Information” might be an endorsement 
of indoor tanning safety inferred by the student from the university’s inclusion of tanning services 
among those that can be purchased through the university’s payment system. Negligent performance 
of a voluntary undertaking might be established with proof that a university undertook to render 
services to the student that the university should have realized would be necessary for the student’s 
protection, and the university failed to exercise reasonable care in carrying out the undertaking. Neg-
ligent facilitation of harm might be established with proof that a university unreasonably provided an 
authoritative endorsement of a dangerous activity. Violation of a state consumer protection statute 
might be a basis for relief based on a university’s deceptive endorsement. Legal risk management 
dictates that universities cease business relationships with tanning salons to both limit their financial 
liability and to promote student health.    
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Successful treatment of palmoplantar pustulosis with adalimumab
RE Schopf and E Beis Dermatology, Johannes Gutenberg Univ., Mainz, Germany
Palmoplantar pustulosis (PPP), a neutrophilic skin disease, is difficult to treat. Adalimumab, a fully 
human anti-TNF-alpha monoclonal antibody, has been described to be effective in generalized 
pustular psoriasis. The effects of adalimumab monotherapy on PPP have not been examined system-
atically. We investigated the clinical and immunohistological effects of adalimumab in 8 patients 
with chronic PPP. Our results indicate that neutrophils, lymphocytes and dendritic cells are affected 
by adalimumab treatment. Methods: 8 patients were treated with Adalimumab. No other treatment 
except for emollients was allowed. At week 0 a loading dose 80 mg Adalimumab was administered 
followed by 40 mg at weeks 1 to 11 every other week. End of observation was at week 12. Skin 
biopsies of lesional skin were taken at weeks 0 & 12. Histological sections were stained with: 
hematoxylin & eosin, specific antibodies for neutrophil marker neutrophilic elastase, dendritic cell 
markers CD83, HLA-DR, CD11c, CD1a, lymphocyte markers CD3, CD4, CD8, Langerhans cells 
marker langerin, differentiation markers cytokeratin 16, filaggrin, involucrin, proliferation marker 
MIB-1, all visualized by peroxidase. Results: Clinical: Adalimumab treatment cleared PPP in 6 out 
of 8 patients. 1 patient showed a moderate improvement, 1 patient developed generalized pustular 
skin lesions and discontinued at week 4. Histological results: After Adalimumab treatment intraepi-
dermal pustules disappeared and inflammation was reduced. Neutrophil invasion was completely 
inhibited. CD3+, CD4+, CD8+, CD45-Ro+ T-cells were partially inhibited, activated HLA-DR+ and 
CD83+ DCs were partially inhibited, native CD1a+, S-100+ DCs remained unchanged Langerhans 
cells increased, epidermal cell differentiation increased and cell proliferation remained steady. 
Discussion: Anti-TNF-alpha treatment with adalimumab in PPP leads to a complete inhibition of 
neutrophils, a partial inhibition of activated DCs and T-cells, an increase of Langerhans cells and 
of epidermal cell differentiation. We conclude that adalimumab may be of value in the treatment 
of palmoplantar pustulosis.    
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Oral ruxolitinib induces hair regrowth in moderate to severe alopecia areata
J Mackay-Wiggan,1 NM Nguyen,1 C Clark,1 A Jabbari,1 G Ulerio,1 M Furniss,1 R Clynes1 and 
A Christiano1, 2 1 Dermatology, Columbia University, New York, NY and 2 Genetics and 
Development, Columbia University, New York, NY
Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%. Current treat-
ments including corticosteroids and other immunomodulators are not FDA-approved for AA and 
have demonstrated variable efficacy. In 2010, we published the first GWAS in AA, which revealed 
several susceptibility loci shared with other autoimmune diseases and in key pathways that regu-
late adaptive and innate immunity. This evidence, in conjunction with gene expression profiling, 
supported a critical role for the interferon-gamma (IFN γ) pathway, whose expression levels are 
markedly upregulated in AA. Since the IFNγ pathway is regulated in part by Janus kinases (JAKs), 
we first conducted pre-clinical studies to ask whether immunosuppression with JAK inhibitors could 
induce hair regrowth in the C3H/HeJ graft mouse model of AA. We found that both systemic as well 
as topical treatment with ruxolitinib (JAK1/2 inhibitor) reversed established disease. This response 
persisted for up to 3 months in 100% of mice treated. Here, we initiated an open label, proof-of-
concept clinical trial for the treatment of moderate to severe AA in humans, using oral ruxolitinib 
20mg BID. We enrolled 12 patients for 3-6 months of treatment followed by 3 months follow up 
off drug. All patients presented with moderate to severe, stable AA (>30% - 100% scalp hair loss). 
Nine of twelve patients demonstrated a remarkable response to treatment. Of those 9 patients, 7 had 
over 95% hair regrowth, 1 had over 85% hair regrowth, and 1 had over 55% hair regrowth. Eight of 
those nine patients had at least 50% and up to 88% hair regrowth by week 12 of treatment. Gene 
expression profiling was used on scalp biopsy mRNA to monitor the response to treatment. With 
rare exceptions, safety parameters including complete blood count and differential, liver function 
and lipids remained within normal limits and no serious adverse effects have been reported. These 
results indicate the potential benefit of JAK inhibitors in the treatment of alopecia areata.    
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A meta-analysis of laboratory monitoring during treatment with isotretinoin
TP Scharnitz,1 J Kirby2 and YS Lee2 1 College of Medicine, Penn State Hershey Medical 
Center, Hershey, PA and 2 Dermatology, Penn State Hershey Medical Center, Hershey, PA
Severe nodulocystic acne is often treated with isotretinoin. Though effective, isotretinoin has been 
reported to be associated with several adverse effects including teratogenicity, hyperlipidemia/
pancreatitis, leukopenia, thrombocytopenia, and hepatotoxicity. However, laboratory monitoring 
is not standardized and much variability exists in the type and frequency of monitoring. This study 
aims to compile laboratory monitoring data from existing trials and cohort studies in order to support 
clinical practice. We conducted a search to identify studies of oral isotretinoin for acne vulgaris. 
The search included MEDLINE (1960–August 2013), EMBASE (1988– August 2013), Cochrane 
Library (August 2013), gray literature, and the reference lists of included papers. Two reviewers 
independently assessed each study for eligibility; disagreements were resolved by a third party. 
Inclusion was limited to studies of oral isotretinoin (sustained release or lipid-enhanced products 
excluded), with dose regimens of at least 40mg or 0.5mg/kg daily, for a duration of at least 4 weeks, 
for young adults (12-30 years old) with acne vulgaris. Studies with a cohort or comparison design 
and case series of 10 or more were eligible. Outcomes of interest were complete blood count, liver 
function tests, and/or lipid panel. Results: Initial analysis of the data show that following a small 
initial treatment effect, mean values do not exhibit significant change for the duration of follow-up. 
Precise data is currently being analyzed and should be available at the time of presentation at the 
SID. Limitations: The data lack detailed information on individual dosing and medical histories. 
Thus, correlations between individuals and laboratory abnormalities were not made. The study is 
subject to reporting bias since we have only included studies that contain published data. Conclu-
sions: Changes in laboratory values during isotretinoin therapy appear to occur early in the course, 
and the need for long-term monitoring during therapy appears to be lacking.    
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Detection of PTCH1 in human vulvar basal cell carcinomas via in-situ hybridization: Impli-
cations for targeted molecular therapy
H Yang, G Cho, S Kang and JM Taube Johns Hopkins School of Medicine, Baltimore, MD
Vulvar malignancies are the fourth most common type of gynecologic malignancy and account for 
approximately 5% of all malignancies of the female genital tract. Basal cell carcinoma (BCC) is a 
basaloid-appearing tumor that can occur on the vulva. BCC, while a common neoplasm elsewhere, 
rarely occurs on the vulva and accounts for 3-5% of all vulvar malignancies. While rare, vulvar 
BCCs are often diagnosed late and in advanced stages, and current treatment options are largely 
limited to surgical excision and/or radiation. Cutaneous BCC is associated with significant UV 
exposure, and it has been well established that aberrant Hedghog (HH) signaling activation is the 
key driver of BCC development and maintenance. Vismodegib, Smoothened receptor inhibitor, has 
shown promising results for non-surgical treatment of cutaneous BCCs. However, the pathogenesis 
of vulvar BCC in sun protected skin is not well understood. Here we report that HH pathway is 
constitutively activated in 4 vulvar BCC cases, as assessed by human PTCH1 in situ hybridization. 
Similarly, HH pathway was activated in cutaneous BCCs, in keeping with previous published data. 
Furthermore, vulvar BCCs exhibited similarly increased rates of proliferation as cutaneous BCCs, as 
assessed by Ki67 immunostaining. Previous studies have shown canonical Wnt pathway activation 
in HH-driven cutaneous BCCs. Cytoplasmic and nuclear beta-catenin localization was observed 
in vulvar BCCs, suggesting concurrent canonical Wnt pathway activation in these sun protected 
tumors. While additional investigation is necessary and on-going, preliminary findings from this 
project may suggest a new insight into hitherto unknown molecular mechanism in vulvar BCC 
development, and may identify novel targets for pharmacological intervention.    
275
Atopic dermatitis in children: Relationship with phosphocalcic metabolism, weight and lipids
P Agón,1 R Sanmartín,2 A Hernández-Martin,3 R Alijarde,4 C Pardos,4 J Puzo,5 A García-
Malinis6 and Y Gilaberte6 1 Pediatrics, Jaca Hospital, Jaca, Spain, 2 061 Emergency, Huesca, 
Spain, 3 Dermatology, Niño Jesús Hospital, Madrid, Spain, 4 Pediatrics, Perpetuo Socorro, 
Primary Care, Huesca, Spain, 5 Biochemistry, Miguel Servet Hospital, Zaragoza, Spain and 6 
Dermatology, San Jorge Hospital, Huesca, Spain
Some studies relate atopic dermatitis (AD) to vitamin D (VD) deficiency and overweight, however, 
there are few studies about other parameters such as lipids or phosphocalcic metabolism. Our aim 
was to investigate the relationship between AD and its severity with weight, lipids and phosphocalcic 
metabolism in a pediatric population. A prospective case and control study was performed in a 
sample of children diagnosed with AD in San Jorge Hospital, Huesca, and Niño Jesús Hospital, 
Madrid, and a group of healthy controls, during 2012 and 2013. Variables of age, sex, anthropo-
metric data, phototype, and serum VD, parathyroid hormone (PTH), calcium (Ca), phosphorus (P), 
total cholesterol (TC), LDL, HDL and triglycerides (TGC) were gathered. AD severity was determined 
according to SCORAD index. 239 subjects under 14 years of age were included, 134 with AD and 
105 controls. Mean VD in the total sample was 26.7ng/ml, decreasing with AD severity 32.5ng/
ml mild (n=21), 28.2ng/ml moderate (n=89) and 26.2ng/ml severe (n=24) (p>0.05), whereas PTH 
levels significantly increase with it (p=0.008). P diminished also severity of AD (p=0.046). Weight 
was significantly lower in controls (10.6kg) than in atopic children (9.0kg) (p=0.016) under 2 years 
(n=47), whereas the opposite happened in those older than 12 years (n=26) (53.3kg vs 73.1kg 
respectively, p=0.007). Mean weight increased with AD severity. Serum levels of PTH, TC, LDL and 
TGC were higher in atopic children than in controls, and increased with severity. By contrast, HDL 
was higher in children with mild disease. No association was found between VD serum levels and 
Ca, P, TC, LDL, HDL and TGC. In conclusion, AD, especially most severe cases, may be associated 
with obesity, hyperlipidemia and alteration of phosphocalcic metabolism.    
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Underrepresented minorities (URMs) and perspectives on successful matching to derma-
tology residency
R Vasquez,1 S Jeong2 and A Pandya1 1 Dermatology, University of Texas Southwestern Med 
Ctr, Dallas, TX and 2 University of Texas Southwestern Med Ctr, Dallas, TX
Underrepresented minorities (URMs), including African Americans, Hispanics, and Native Amer-
icans, comprise 30% of Americans but less than 15% of U.S. physicians. Additionally, recent 
reports show strikingly low numbers of URMs in subspecialty fields like dermatology, radiology 
and otolaryngology compared to primary care. The reasons for this disparity are unclear. Cohort 
group interviews (consisting of 15 questions) were conducted with residency applicants who applied 
through standardized electronic application to the dermatology residency program at the University 
of Texas Southwestern Medical Center. The cohort group interviews were conducted in 2014 and 
analyzed using grounded theory. Fourteen residency applicants were interviewed, including four 
who were identified as URMs. Of the 14 applicants interviewed, 85% (n=12) successfully matched 
to a dermatology residency program (including 2 underrepresented minority applicants). Major 
barriers to becoming a successful URM dermatology applicant cited by participants included lack 
of mentorship, financial constraints, lack of familial support, and cultural differences in the value of 
education. Applicants agree that increasing the number of URMs would enhance patient-physician 
relationships. The need for increased and equal representation in all fields of medicine is significant, 
as multiple reports have shown that minority physicians increasingly provide care for the poor 
and underserved communities. Programs that promote early mentorship as well as provide and/
or identify means to alleviate financial constraints (in the form of scholarships) may help alleviate 
barriers URM’s face in successfully matching to a dermatology residency program.    
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Lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) expression is similar in normal 
human parietal and occipital scalp
B Hanson,1 M Weber-Sanders,1 J Hodges,2 H Bemmels,1 M Hordinsky1 and M Ericson1 
1 Dermatology, University of Minnesota, Minneapolis, MN and 2 Biostatistical Design 
and Analysis Center, Clinical and Translational Science Institute, University of Minnesota, 
Minneapolis, MN
LYVE-1 is expressed in the endothelium of lymphatic capillaries and functions in hyaluronan-medi-
ated leukocyte adhesion and hyaluronan clearance. In a mouse model system, LYVE-1 expression 
has also been found to be down-regulated by the pro-inflammatory cytokines tumor necrosis alpha 
(TNF-alpha) and TNF-beta. This is a potentially important observation when taken in conjunction 
with our finding of a significant reduction in the number of lymphatic vessels in the upper- and 
mid-dermis of 2 scalp biopsy specimens taken from alopecia areata (AA) patients as compared to a 
control subject. Whether this is unique to the two AA patients studied or reflects a process similar 
to that seen with miniaturization of the vascular system in AA and in androgenetic alopecia is not 
currently known. The goals of this study were (1) to examine LYVE-1 expression in 4-mm scalp 
biopsy specimens taken from the parietal and occipital scalp of 5 healthy subjects (2M, 3F) between 
20 to 48 years and (2) to quantify the lymphatic vasculature density to rule out regional differences. 
This was accomplished using single photon confocal microscopy on sections immunolabeled with 
antibody to LYVE-1 and histomorphometric counting methodologies. To ensure a healthy scalp, all 
subjects were asked to standardize scalp care prior to biopsy with the use of DHS-Zinc shampoo. 
We found no significant difference in dermal lymphatic density between the parietal (0.0386 + 
0.0212 normalized units) and occipital scalp (0.0312 + 0.0196 normalized units, p=0.34) in healthy 
scalp. Given the interaction between LYVE-1 and inflammatory cytokines such as TNF-alpha and 
TNF-beta, these data provide a quantitative foundation for further studies investigating the role of 
lymphatic vessels in inflammatory hair loss diseases such as alopecia areata.    
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Myeloid biomarkers and vascular PET-MRI during psoriasis treatments: Preliminary report
JB Golden,1 S Santilli,1 F Muakkassa,1 P Rajiah,2 JK O’Donnell,2 SG Groft,1 F Galimberti,1 
DC Soler,1 T McCormick1, 3, N Korman1, 3 and KD Cooper1, 3 1 Dermatology, University 
Hospitals Case Medical Center, Cleveland, OH, 2 Radiology, University Hospitals Case 
Medical Center, Cleveland, OH and 3 The Murdough Family Center for Psoriasis, Cleveland, 
OH
Cardiovascular disease (CVD) biomarkers linking psoriasis pathogenesis and treatment responsive-
ness that could be used as CVD outcome surrogates in large scale comparative effectiveness trials of 
psoriasis treatments are not yet established. We initiated a pilot study to examine the performance 
of serum, plasma, and monocyte markers of CVD risk in relation to PET-MRI quantitation of arterial 
inflammation and thickness during systemic psoriasis therapy. Patients eligible for enrollment were 
aged 18-65, with moderate to severe psoriasis for >1 yr (plaque affecting >10% of subject’s body 
surface area (BSA) and >PASI 10) and were initiating treatment with a standard systemic therapeutic. 
PET-MRI allows quantitation of soft tissue parameters of intimal lesions in 3D with simultaneous 
quantitation of FDG-glucose uptake by monocytes and macrophages without radiation exposure of 
CT scans. 18F-FDG-PET/MR imaging was performed on a combined current-generation time-of-flight 
PET and a 3T MR imaging system (Ingenuity TF PET/MR; Philips Healthcare). Mean and maximum 
standardized uptake value (SUV mean, max) and regions of interest (ROI) were measured. Prelimi-
nary analysis revealed elevated SUVs in the ascending and descending aorta by PET-MRI in 5/8 initial 
patients at baseline when compared to equivalent regions of the liver, consistent with inflammation. 
Elevated monocyte aggregates were present in 7/8 patients and rapidly decreased in 50% of patients 
by one month after initiation of treatment. Circulating Monocyte-Derived Suppressor Cells (MDSC) 
also decreased in 3/5 patients 1 month into therapy. Determining the sensitivity of monocyte 
biomarker responses with PET-MRI-confirmed arterial inflammation and thickening is intended 
to validate new surrogates of CVD risk that may be useful in evaluating psoriasis therapeutics.   
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Adult-onset linear morphea is associated with significant morbidity and methotrexate may 
reduce risk of disease reactivation
DR Mazori,1 NA Wright,2 M Patel,2 S Ramachandran,1 AG Franks,1 R Vleugels2 and 
AN Femia1 1 The Ronald O. Perelman Department of Dermatology, NYU School of 
Medicine, New York, NY and 2 Department of Dermatology, Brigham and Women’s 
Hospital, Boston, MA
Linear morphea (LM) is characterized by linear sclerotic plaques on the limbs or face and scalp, 
and can result in functional disability or permanent disfigurement. As the disease predominantly 
manifests in the pediatric population, little is known about the epidemiology of adult-onset LM. This 
retrospective cross-sectional study characterizes the clinical features and disease course of patients 
with adult-onset LM. Using 2 medical record systems with over 3 million patients, we queried the 
ICD-9 code 701.0 to identify LM patients at a large tertiary care center from 2011 to 2014 with 
disease onset at age 18 years or older. Of the 17 patients identified, 53% (n=9) had en coup de sabre 
(ECDS), 6% (n=1) hemifacial atrophy (HFA), and 41% (n=7) LM involving an extremity. Mean age 
of onset was 34.5 years; 94% were women. Eighteen percent had concomitant lupus erythematosus 
(n=2), Sjögren’s syndrome (n=1), Hashimoto’s thyroiditis (n=1), and/or antiphospholipid syndrome 
(n=1). Twenty-nine percent with limb involvement had functional limitations due to involvement 
over a joint; 40% with ECDS or HFA self-reported substantial psychological distress. Mean interval 
between LM onset and diagnosis was 34.3 months. Treatment regimens included methotrexate 
(MTX), ultraviolet B phototherapy, calcitriol, doxycycline, and topical agents, amongst others. 
Disease reactivation was 3.5 times less likely in patients treated with MTX than in those not treated 
with MTX (20% vs. 70%) during a mean follow-up of 39.5 months. In our study, adult-onset LM was 
associated with delayed diagnosis, functional and psychological sequelae, and other autoimmune 
conditions. Treatment with MTX, which is considered first-line for pediatric-onset LM, was asso-
ciated with a lower risk of disease reactivation. Additional study is needed to further characterize 
adult-onset LM and determine an appropriate treatment algorithm.    
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An integrated model of atopic dermatitis (AD) severity based on lesional, non lesional and 
systemic biomarkers
M Suarez-Farinas,1 JG Krueger,1 S Garcet,1 S Noda1 and E Guttman-Yassky2 1 Department 
of Investigative Dermatology, Rockefeller University, New York, NY and 2 Department of 
Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Current atopic dermatitis (AD) models link epidermal abnormalities in lesional (LS) skin to cytokine 
activation. However, there is evolving evidence of systemic immune activation and detectable 
abnormalities in non-lesional (NL) skin. Since some of the best single correlations with severity (by 
SCORAD) are not only detected in LS, but also in NL skin and blood, a more complex biomarker 
model of AD is needed. We thus performed extensive biomarker measures in these compartments 
using univariate (Spearman) and multivariate (muScores) approaches to correlate disease biomark-
ers with SCORAD and with a combined hyperplasia score (thickness + K16 mRNA) at baseline 
and after cyclosporine treatment in 21 severe AD patients. In univariate analyses, SCORAD was 
correlated with immune (IL-13, IL-22) and epidermal (thickness, K16) markers, and negatively with 
FLG, in LS but also in NL skin (r>0.4 or -0.4 for all, P<0.05). Significant correlations were also 
found with serum cytokines (IL-22, IL-13). Using multivariate U-statistics, a biomarkers set from 
all tissues {(thickness, CD11+ cell counts, IL-13 (NL), S100A12 (LS), CCL11 (serum)} improved 
the SCORAD correlation (r=0.75, p<0.0005). An even higher correlation (r=0.90; P<0.0005) was 
found between the combined hyperplasia score and a biomarker set {IL-22, IL-19, PI3, S100A12, 
IL-17A and filaggrin (negative correlation; all LS)}. Similar, a much better correlation with SCORAD 
improvement after treatment (r=0.79, p<0.0001) was obtained by a combined biomarker set {IL-22, 
IL-13, CD206 (LS) and IL-22 and CCL4 (serum)}. The highest therapeutic improvement muScore 
(r=0.95; p<0.0001) was obtained with hyperplasia reversal {(IL-19, IL-23A, PI3/elafin, S100A12, 
and negatively with filaggrin (LS)}. Overall, static and dynamic AD severity is best modeled by an 
integration of immune and epidermal barrier biomarkers in all compartments, with particularly 
impressive correlations with hyperplasia correlates.    
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Approaching zero— long-term blockade of IL-17RA with brodalumab substantially abates 
psoriasis “residual disease expression” signature
CB Russell,1 J Bigler,1 K Kerkof,1 JF Duculan,3 X Hu,1 T Marty,1 M Boedigheimer,1 
A Anderson,1 G Kricorian,2 P Klekotka,2 A Nirula2 and JG Krueger3 1 Medical Sciences, 
Amgen, Seattle, WA, 2 Inflammation, Amgen Inc., Thousand Oaks, CA and 3 Rockefeller 
Univ., New York, NY
Molecular and cellular signatures that differentiate lesional vs. non-lesional plaque psoriasis skin 
often demonstrate substantial but incomplete reductions after various treatments. Even in responding 
patients, residual evidence of inflammation can remain, including cellular infiltrates (defined as 
greater-than non-lesional cell counts) and psoriasis-related gene expression (traditionally defined as 
mRNA transcripts with expression changes <75% of the baseline lesional vs. non-lesional differential 
expression). As IL-17 signaling pathway blockade has demonstrated greater degrees of molecular 
effects than previous treatments, we conducted molecular and cellular analyses of skin and subcu-
taneous fat biopsies from a Phase 3 randomized placebo-controlled study of brodalumab, a human 
anti-IL17RA therapeutic antibody (NCT01708590). Lesional skin biopsies indicated substantial 
decreases in all inflammatory cell types and mRNAs, beginning ≤4 weeks of brodalumab initiation. 
Both pathological epidermal hyperplasia (as measured by keratinocyte proliferation [Ki67+]), and 
inflammatory expression of IL12B, IL23A, and IL17C mRNAs rapidly reversed. After 12 weeks 
of brodalumab (n=31), IL-17 signature gene expression in the subcutaneous fat was suppressed, 
and previously identified residual psoriasis skin gene expression was consistently reduced >75%. 
However, some pathways and cell types, including interferon pathway, IL17A, and IL17F mRNAs, 
still displayed numerically elevated levels at Week 12. Under continued IL-17RA blockade, these 
minimal residual gene signatures and inflammatory cell infiltrates continued to resolve during 
4052 weeks of treatment (n=21), reaching non-lesional levels. These data support the existence of 
an innate inflammatory memory that can be maintained through 12 weeks of inflammatory cycle 
blockade, but continues to resolve in the absence of ongoing IL-17 pathway activation.    
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Using RNA-seq in the transcriptome analysis of the Koebner phenomenon in psoriasis
K Chun, S Chen, A Two, T Hata and RL Gallo University of California, San Diego, La Jolla, CA
The Koebner phenomenon is a well-described event that occurs in psoriasis when psoriatic plaques 
develop in nonlesional areas that have sustained trauma. However, the pathogenesis is unknown. 
To better elucidate the mechanism of the Koebner phenomenon, RNA sequencing (RNA-seq) was 
used to identify differentially expressed genes (DEGs) after wounding in nonlesional skin of pso-
riasis as compared to normal healthy skin. One psoriasis subject underwent a single 2mm punch 
biopsy to their lesional and nonlesional skin, and one control had a single 2 mm punch biopsy of 
healthy skin. Four days later, these subjects had 4mm post-wounding punch biopsies, which were 
centered directly over the initial biopsy sites. RNA-seq identified DEGs in the transcriptomes of 
lesional psoriatic and normal skin, which were consistent with previously identified DEGs in a recent 
large-scale study by Li et al., 2014. Additionally, we examined DEGs established by Li et al. in the 
“cytokine-cytokine receptor” pathway and compared fold changes observed between pre-wounding 
and post-wounding biopsies in nonlesional and normal control patients. Interestingly, CXCL5 and 
CXCL6 showed the largest fold change between nonlesional biopsies after wounding as compared 
to normal skin after wounding. CXCL5 demonstrated a 2353-fold increase in nonlesional skin after 
wounding, as compared to a 164-fold increase observed in control skin after wounding. There 
was a 62-fold increase observed in CXCL6 for nonlesional skin after wounding, as compared to an 
8-fold increase observed in control skin after wounding. As there were large overall fold changes 
after wounding in nonlesional psoriatic skin versus normal skin for CXCL5 and CXCL6 (14.3 and 
7.8-fold, respectively), we conclude that these chemokines were disproportionately upregulated 
in nonlesional psoriatic skin after trauma and may play an active role in the pathogenesis of the 
Koebner phenomenon. Further studies with larger sample sizes and qRT-PCR should be done in 
order to confirm these novel findings.    
   
